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Abstract 
Lipid-based (LB) formulations are versatile systems that can solubilise poorly water-soluble drugs, but also work as dispersing 
medium for hydrophilic formulation components. Dispersed particles can consist of more complex structures. Interesting is 
the dispersion of water-based microgels in LB systems to create hydrophilic compartments within a non-aqueous medium, 
suitable for direct capsule filling. Such systems represent a suitable milieu for protein microencapsulation to ensure protection 
from degradation of these macromolecules. In fact, while oral macromolecule delivery is a thriving topic in modern 
pharmaceutics, the first challenge is to achieve a stable drug product throughout manufacturing. Owing to the structured and 
complex nature of such system, a thorough characterisation is needed to gain adequate understanding of the system. 
Identification of critical material attributes and process parameters is key in the framework of the Quality-by-Design (QbD) 
initiative. The purpose of this thesis is to formulate novel LB systems suitable for capsule filling that allow oral delivery of 
proteins and small molecules. 
The present thesis consists of four studies. The first two introduce new manufacturing approaches for protein 
microencapsulation using LB systems as carrying medium for oral delivery. The third and fourth studies address manufacturing 
criticalities of LB systems using macromolecules and small molecules as active ingredients, respectively. A special focus is kept 
on the development aspects of these systems by using statistical methods to design quality into the novel drugs delivery 
formulations. 
The first study focused on the feasibility of protein microencapsulation by prilling into a LB hardening bath. Here, prilling was 
applied by dropping a protein-containing polymeric solution into a LB hardening bath where cross-linking occurred. Bovine 
serum albumin (BSA) and a chitosan derivate were used as a model protein and a polyfunctional gel-forming polymer, 
respectively. The hardening bath was loaded with calcium ions to allow ionotropic gelling of the polymer. Particle morphology 
and size were dependent on the LB hardening bath used. The microgels had high protein encapsulation efficiency and were 
able to rapidly release their content during in vitro dissolution testing. Additionally, the model protein remained unscathed 
throughout the entire manufacturing process and during preliminary stability studies in the LB hardening baths. Overall this 
approach demonstrated the technical viability of LB systems to act as hardening bath for the prilling process and 
simultaneously as dispersing medium for the thereby formed microgels to achieve liquid capsule filling. 
The second study focused on improving the previously introduced LB drug delivery systems (DDS). The aim was to achieve a 
multi-compartmental system composed of protein-containing nanotubes embedded into the microgels obtained by prilling. To 
increase protein loading by better fitting the large model protein, i.e., BSA, the nanotubes’ lumen was chemically enlarged. The 
obtained Nanoparticles-in-Microsphere Oral System (NiMOS) showed hardening bath-dependent morphology and good 
protein entrapment efficiency. Protein stability during the process was confirmed. Furthermore, the proposed NiMOS 
demonstrated protection from enzymatic degradation after preliminary in vitro testing. Also, the multi-compartmental 
structure extended the protein release profile. This study showed the feasibility of this flexible multi-compartment system for 
oral protein delivery. 
The third study investigated systematically LB formulations as hardening baths for prilling using Design of Experiments (DoE). 
Over 880 formulations were screened with respect to miscibility, counter-ion solubility, and droplet gelling by using 60 ternary 
phase diagrams comprising two co-solvents, ten different glycerides, and three so-called complementary excipients. Soft and 
hard capsules were filled with 245 selected hardening bath formulations for a preliminary compatibility assessment. The 
ternary phase diagrams’ centre points were statistically evaluated to understand the formulation effect on microgel 
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morphology, protein encapsulation efficiency, and protein stability. The large datasets were analysed by means of partial least 
squares (PLS) regression to correlate the formulation and experimental factors with the chosen response variables. This work 
generated an improved understanding for this type of LB systems. 
Finally, a fourth study introduced novel tools within the QbD initiative to evaluate complex LB dispersions such as highly 
concentrated suspensions. The surface energy of the particles intended for suspension was profiled using inverse gas 
chromatography to understand the heterogeneity in energy distribution. This was correlated to different inter-batch 
rheological properties at higher solid fractions after LB suspension manufacturing. A mathematical model was then used to 
predict experimental viscosity values as a function of suspended solid fraction. The agglomeration patterns of the 
manufactured suspensions were interpreted using the fractal concept of flocculation. This concept as well as the surface energy 
profiling showed great potential for designing quality into concentrated pharmaceutical suspensions. 
This thesis introduced new complex LB systems suitable for oral delivery of proteins and small molecules. Novel formulations 
approaches have been investigated and developed within a QbD framework. A particular emphasis was on microgel dispersions 
in lipids for oral (local) protein delivery. The technical viability of this delivery approach was demonstrated on the level of 
manufacturing and in vitro release testing. Future research may include in vivo studies to understand and improve the 
biopharmaceutical performance of the proposed LB DDS, as well as a thorough mechanistic investigation for these complex LB 
formulations. 
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 Chapter 1 
Introduction 
1.1 Background 
Lipid-based (LB) systems have shown great potential in 
terms of drug delivery. While not a recent invention, LB 
formulations have become especially important in recent 
years because of a rising number of biopharmaceutically 
challenging drug candidates that are emerging from high 
throughput screenings [1]. For example, different LB 
products are available on the market, such as Juvela®, 
Duspatalin®, Sandimmune Neoral®, and Norvir®. The 
functionality of LB systems, however, is not limited to 
solubilise lipophilic compounds. LB formulations can also 
work as dispersing medium for simple drug powder, as well 
as for active pharmaceutical ingredients (API) loaded into 
more complex particulate systems. A solid dispersion or 
suspension has the advantage, compared to a solution, that 
the drug dosage per unit can be dramatically increased. 
When compared to a purely solid system, a dispersion has 
the particular advantage of exposing the active ingredient 
to the gastrointestinal milieu with a higher surface area, 
thus improving its dissolution in the biological fluids [2]. 
While LB dispersions find limited application as final 
dosage forms, these systems can be easily filled into 
capsules for oral administration. Lipids have also shown 
great potential for protein delivery [3]. In addition, the 
dispersed particulate systems could comprise a protein-
loaded complex system. LB dispersions may constitute 
platforms to form a stable drug product suitable for oral 
(local) protein delivery. A further biopharmaceutical 
rationale to employ LB systems is that many lipids are 
known to increase the oral bioavailability of API, e.g., by 
forming drug-loaded micellar dispersions during digestion 
in case of poorly water-soluble drugs [4,5]. The design of 
such complex LB systems for oral protein delivery is a 
particular focus of this thesis. 
Many therapeutically active macromolecular compounds, 
such as peptide, enzymes, and monoclonal antibodies, are 
nowadays either commercially available or taking part of 
clinical development programmes [6–10]. These large 
molecules generally possess complex three-dimensional 
structures. In proteins, for example, the overall structure is 
divided in four structural hierarchies that are named 
primary (amino acid sequence), secondary (localised three-
dimensional structures), tertiary (overall protein spatial 
configuration), and quaternary (arrangement of different 
protein monomers). The therapeutic activity of a protein is 
closely related to the integrity of each structure [11] 
Furthermore, proteins are strongly influenced by the 
surrounding medium and chemical, physical, and structural 
instabilities may occur even under relatively mild 
physicochemical or mechanical stress [12,13]. Instability 
during manufacturing is therefore a key hurdle in 
formulating oral protein delivery systems and mild 
conditions must be applied to the production process. 
Hence, the manufacturing of a stable drug product is a first 
formulation challenge. 
Protein formulation for oral delivery must also face a 
biopharmaceutical challenge to achieve adequate oral 
bioavailability [14]. Oral administration would be a desired 
way to achieve either systemic action or to treat local 
gastrointestinal diseases, which both may lead to increased 
patient compliance and reduced cost. However, proteins 
undergo extensive and thorough digestion in the 
gastrointestinal (GI) tract [15]. This begins in the stomach, 
where the proteins are cleaved and degraded by hydrolytic 
enzymes and by the acidic environment. Further digestion 
occurs in the small intestine through the action of 
pancreatic proteases and brush border enzymes, whereas 
enzymatic activity decreases only in the large intestine [15]. 
Furthermore, relevant enzymatic degradation may occur 
because of colonic bacteria for the macromolecules which 
escape digestion in the upper gut [16]. Another obstacle is 
given by the mucus layer, which can hinder protein 
absorption or action, according to the required site of action 
[17]. 
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Much effort has been invested in modern pharmaceutics to 
overcome the aforementioned issues [14]. Many 
approaches have been proposed to deliver proteins to the 
GI tract [18,19]. Protection of the macromolecular API from 
the GI milieu has been addressed with microencapsulation 
[20,21]. This formulation approach has shown potential to 
overcome especially enzymatic degradation. However, 
most research has been limited to designing the 
microencapsulation system and direct in vitro or in vivo 
testing. Many of these drug delivery systems (DDS) do not 
represent final dosage forms which can be directly 
administered orally. As earlier mentioned, further 
processing steps required to obtain a final dosage form may 
cause protein instabilities and foil the carefully designed 
systems. Hence, mild conditions must be applied during 
formulation. 
Microencapsulation is considered one of the most effective 
methods to formulate proteins with regards to protection 
from enzymatic degradation [20]. Several other 
formulation techniques are available in this sense, but not 
all can combine mild manufacturing conditions with 
effective encapsulation [22]. Prilling is a technique that uses 
the Plateau-Rayleigh instabilities to form equally sized 
droplets from a liquid stream extruded through a nozzle 
[23]. An external vibration is applied to induce and control 
this instability, thus the technique is also named vibrating 
nozzle method. To achieve drug encapsulation, the API and 
a polymer can be loaded in the prilled liquid. The droplets 
are collected in a hardening bath where ionotropic cross-
linking of the polymer occurs, which entraps an API into the 
forming microgel. By using concentric nozzles, this method 
can also produce microcapsules with separate core and 
shell compartments [24]. While this technique is devoid of 
potentially harmful conditions for protein 
microencapsulation, its application in macromolecule 
encapsulation has received only preliminary investigation 
[25,26]. Furthermore, the state-of-the-art application of 
this technique uses alginates as polymers and an aqueous 
hardening bath [27]. Polyfunctional polymers, such as 
chitosan derivates, have found only preliminary 
applications with this technique [23]. Moreover, aqueous 
hardening baths require removal to further process the 
formed microgels into a final dosage form, such as liquid 
capsule filling. The prilled microgels can be used as suitable 
containers for protein API [28]. 
In recent years, with the widespread use of 
nanotechnologies also in pharmaceutical development, DDS 
have attained new levels of sophistication. The research on 
multi-compartmental DDS is gaining momentum due to 
high flexibility and versatility ensured, and it is mostly 
focused on macromolecular delivery. These DDS exploit the 
different properties of each compartment to modify the API 
release or to increase its oral bioavailability. Several 
architectures and production technologies are available, for 
instance Nanoparticles-in-Microsphere Oral System 
(NiMOS) or Janus nanoparticles [29,30]. However, not all 
processes are suitable for scale-up, and some 
biopharmaceutically promising DDS may encounter issues 
in later pharmaceutical development if the complexity is 
excessive [31]. Such complex drug delivery systems can 
become a challenge for pharmaceutical development, 
particularly when a robust process quality is targeted in 
manufacturing. 
In recent years a great effort has been put by regulatory 
authorities to embed quality in all steps of the design and 
production of a drug product [32–34]. The Quality-by-
Design (QbD) initiative has been proposed by the Food and 
Drug Administration (FDA), where a thorough 
understanding of formulation and production processes 
with the different sources of variability is targeted [32]. 
Design of Experiments (DoE) has been typically employed 
in the framework of QbD to assess the critical properties of 
design, development, and manufacturing, as well as to 
optimise these steps [35]. Owing to their high complexity, 
structured dosage forms, such as highly concentrated LB 
suspensions and multi-compartmental DDS, require a 
systematic investigation to comply with modern 
pharmaceutical quality standards. 
1.2 Objectives 
The present thesis aims to formulate novel LB systems 
suitable for capsule filling that allow oral (local) delivery of 
proteins and small molecules. A QbD framework is applied 
to identify critical attributes and parameters of the 
proposed formulations and processes. A novel 
manufacturing approach is introduced to formulate 
proteins into LB dispersion medium, while ensuring 
adequate pharmaceutical quality. To achieve this goal, an 
innovative microencapsulation approach has been adapted 
for LB formulations to avoid stressful manufacturing 
conditions that are potentially harmful for an active protein. 
Such DDS are then further developed to improve protein 
stability after oral administration. The relevant quality 
aspects of these formulations are analysed using 
experimental design and statistically evaluated by partial 
least squares (PLS) regression. Furthermore, new tools for 
LB system characterisation are introduced for mechanistic 
process understanding and modelling. This thesis presents 
individual chapters that study the design of LB formulations 
and systematically investigate their properties for 
manufacturing. 
The second chapter aims to provide adequate theoretical 
background to the underlying the research conducted. The 
state-of-the-art pharmaceutical technology employed for 
complex LB dispersion design and development is 
described, as well as the background necessary to 
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understand the fundamentals of protein oral delivery. 
Focus is put on formulation and manufacturing of these 
structured systems, including relevant quality aspects for 
their implementation. 
The objective of the third chapter is to develop lipid-based 
systems for oral delivery of macromolecules. The chapter is 
divided in two sections. The purpose of the first section is 
to introduce prilling, a microencapsulation technique, as a 
suitable manufacturing approach to prepare protein-
loaded microgels into lipid medium for direct capsule 
filling. The microencapsulated system is evaluated in terms 
of particle morphology, encapsulation efficiency, and 
protein stability after manufacturing. 
The second part of the third chapter aims to form NiMOS-
based multi-compartmental DDS using the previously 
outlined prilling approach. A model protein is here loaded 
into natural nanotubes, which are then microencapsulated, 
to ensure further protection from enzymatic degradation 
after oral administration. The NiMOS system is 
characterised and protein stability is assessed after prilling 
and after preliminary enzymatic digestion.
The fourth chapter’s objective is to investigate understand 
the quality aspects in the design and manufacturing of 
complex lipid-based pharmaceutical dispersions. Two 
studies are presented in the fourth chapter. The first part’s 
purpose is to find suitable excipient combinations for the 
previously introduced prilling process and to investigate 
systematically diverse material and process factors. An 
experimental design is employed to identify correlate 
process parameters and LB formulation properties to 
microgel characteristics and protein stability. 
Finally, the second study of the fourth chapter aims to 
introduce new QbD tools to understand and predict the 
behaviour of complex lipid-based dispersions, such as 
highly concentrated suspension. Novel concepts with 
potential for designing quality into concentrated 
pharmaceutical suspensions are proposed to obtain 
mechanistic understanding of these LB systems’ 
instabilities. 
 Chapter 2 
Theoretical section 
2.1 Lipid-based (LB) dispersions 
2.1.1 Introduction to LB dispersions 
Lipids are a group of molecules which comprises several 
water insoluble organic compounds, such as acylglycerols, 
oils, waxes, sterols, and vitamins [36]. They have been used 
over centuries in pharmaceutical applications for their 
therapeutic action and as excipients. In fact, several lipids 
are well-known to exhibit an activity in the organism, for 
example vitamins, sterols, or polyunsaturated fats. The 
application of lipids in pharmaceutics is focusses on their 
use as carrying, dispersing, or dissolving medium mostly for 
poorly water-soluble drugs. Up to 70% new chemical 
entities (NCE) discovered and developed by pharmaceutical 
companies are poorly water-soluble [37]. According to the 
biopharmaceutics classification system (BCS), these 
compounds belong to class II (low solubility and high 
permeability) and IV (low solubility and low permeability) 
[38]. 
Several techniques are known to increase solubilisation and 
hence oral bioavailability of poorly soluble compounds, 
such as particle size reduction or salt formation. However, 
most techniques have practical limitations, such as the lack 
of ionisable groups on the molecule for salt formation. 
Other options to increase the bioavailability of these 
compounds are available, for instance solubilising the 
molecule in the formulation. A key formulation approach is 
to employ lipid-based (LB) formulations. Different 
mechanisms have been proposed to understand how such 
delivery systems are capable of increasing oral drug 
absorption of biopharmaceutically challenging drugs 
[39,40]. However, drug solubilisation is limited in the 
medium  
especially for compounds that are rather hydrophobic. LB 
formulations can also be biopharmaceutically meaningful 
as particulate dispersions of active pharmaceutical 
ingredients (API) [1], which is especially the case for 
compounds that are labile or that require permeation 
enhancement for an effective oral delivery. 
Pharmaceutical dispersions consist of a dispersing medium 
and a dispersed solid fraction [41]. This solid fraction is 
usually the API alone, but it may also be formulated in larger 
carrier particles to ensure proper dispersability. The typical 
particle size of dispersions may vary greatly, between 
100 nm and 100 μm, thus ranging from colloidal 
dispersions to coarse suspensions. In the present thesis, the 
words “suspension” and “dispersion” are used 
synonymously. When differentiation is needed, the wording 
“colloidal dispersion” and “coarse suspension” are 
employed. Generally, the increase in surface area of 
dispersed systems represents an advantage, especially 
compared to solid dosage forms. Thus, dispersed drugs 
exhibit typically increased dissolution rates in 
gastrointestinal fluids and absorption compared to classical 
solid dosage forms [2]. It has also been shown that 
pharmaceutical suspensions provide an edge in paediatric 
and geriatric populations who cannot easily swallow tablets 
or capsules [42]. Compared to other liquid systems, namely 
solutions or syrups, suspensions allow higher API content 
to meet the required therapeutic need. 
Dispersed systems often require the presence of surfactants 
to provide adequate dispersion of the solid fraction, avoid 
particle agglomeration, and prevent settling. Surfactants 
are amphiphilic molecules, i.e., they possess both a 
hydrophilic and a hydrophobic part, which migrate to the 
interface between two phases or adsorb according to 
affinity onto the surface of a particle. Different surfactant 
types exist, namely non-ionic, cationic, anionic, and 
zwitterionic. Non-ionic compounds act through steric 
interaction, whereas ionic surfactants interact 
predominantly by means of electrostatic forces. 
Suitable lipid media for suspensions are usually medium- 
(from 6 to 12 carbon atoms) and long chain (more than 12 
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carbon atoms) mono-, di-, and triglycerides as well as to 
some extent their corresponding free fatty acids (FFA) [43]. 
Longer chain FFAs and glycerides, however, tend to have 
high melting points, thus being solid at room temperature. 
Nevertheless, the presence of unsaturated bonds in the fatty 
acid chain decreases the melting point, and therefore these 
lipids can be liquid at room temperature. Most vegetable 
oils are employed as dispersing media. Many of these lipids 
are available as excipients on the market with various trade 
names in pure form, as well as in mixtures. Some lipids may 
be also modified by adding polymers, such as polyethylene 
glycol (PEG), or other moieties, such as propylene glycol to 
the glyceride structure. Similar modifications may also give 
surfactant properties to the excipients. Finally, 
phospholipids like phosphatidyl choline may also be 
formulated in the dispersing medium due to the specific 
zwitterionic nature and their functionality as suitable 
wetting agents. A list of the lipids commonly employed in 
pharmaceutical oral delivery is shown in Table 2.1. 
A specific type of LB dispersions is solid dispersions. In 
these systems, the API is dispersed in a solid excipient or 
matrix. This system may protect the API from the external 
environment, allows high drug loading, and typically 
enables rapid drug dissolution. The advantages of these 
systems and their limitations have been well reviewed, e.g., 
by Serajuddin [44]. Apart from lipid-based solid 
dispersions, there are other solid systems that make use of 
lipid excipients. Solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC) have been proposed as 
formulation principles for poorly soluble drugs [45,46]. The 
differences and properties of these formulation approaches 
have been adequately reviewed by Saupe and co-workers 
[47]. 
The different LB systems span from solutions to semisolids 
and solids, which all require further processing to achieve 
suitable patient compliance in a final dosage form. A 
common dosage form containing LB formulations is a 
capsule. Different encapsulation processes exist for LB 
systems that are further described in Section 2.2. Lipid-
based suspensions are available on the market, for instance 
Lamprene® capsules (clofazimine, from Alliance 
Pharmaceuticals), Juvela® N Soft capsules (tocopherol, 
from Eisai Co), and Duspatalin® capsules (mebeverine 
hydrochloride, from Abbot Laboratories). Lipid-based 
suspensions are typically filled into soft capsules and more 
recently also into two-piece hard capsules [48]. 
2.1.2 Theoretical aspects of dispersions for 
formulation and manufacturing 
Pharmaceutical suspensions are typically complex systems 
that are kinetically stabilised while they are still unstable 
from a thermodynamic viewpoint. Dispersions and 
suspensions are defined as lyophilic when the dispersed 
particles display affinity for the dispersing media, or 
lyophobic in the opposite case. Lyophilicity is useful to 
understand wetting of the particles’ surface by the 
suspending medium. A lyophilic dispersion can be easily 
wetted by the surrounding milieu, whereas a lyophobic 
system will require the use of surfactants to ensure 
stability. 
Several types of interactions and forces need to be taken 
into account to evaluate suspension instability. The first and 
foremost factor is the sedimentation of the suspended 
particles. Sedimentation is typical for suspension (or 
flotation depending on the density gradient) and the 
velocity is described by the well-known Stokes equation 
(Equation 2.1): 
TABLE 2.1 – Lipids commonly employed in oral pharmaceutical formulations. 
Glycerides Natural compounds Modified compounds 
Caprylic/capric triglyceride 
  (Labrafac™ Lipophile) 
Glyceryl monolinoleate 
  (Maisine™ 35-1) 
Glycerol monooleate 
  (Peceol™) 
Glyceryl monocaprylate 
  (Capmul® MCM-C10) 
Glyceryl tricaprylate 
  (Captex® 1000) 
Glyceryl trioleate 
  (Captex® GTO) 
Olive oil 
D-α-tocopherol 
Apricot kernel oil 
Peppermint oil 
Peanut oil 
Sesame oil 
Beeswax 
Corn oil 
Canola oil 
Linseed oil 
Coconut oil 
Propylene glycol monocaprylate 
  (Capryol™ 90) 
PEG-8 caprylic/capric glycerides 
  (Acconon® MC8-2) 
PEG-80 sorbitan monooleate 
  (Tween 80) 
D-α-tocopheryl PEG-1000 succinate 
  (TPGS) 
PEG-35 castor oil 
  (Kolliphor® EL) 
PEG-6 oleic glycerides 
  (Labrafil® M1944CS) 
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𝑣𝑠 =
(𝜌𝑝 − 𝜌𝑓)
18 𝜂
∙ 𝑔 ∙ 𝑑𝑝
2 2.1 
Where vs is the settling velocity, ρp is the particle density, ρf 
is the fluid density, η is the fluid viscosity, g is the 
gravitational acceleration, and dp is the particle diameter. 
Sedimentation alone can be considered only in dilute 
suspensions, whereas in concentrated suspensions other 
factors need to be taken into consideration [49]. Dilute 
suspension are intended as dispersed system where the 
particles’ Brownian motion is predominant over 
hydrodynamic interaction between particles [50]. Usually a 
solid volume fraction (Φ) of 0.01 is assumed as an upper 
threshold to define these diluted systems. An increase in 
solid fraction requires considering also interparticle 
interaction. Four different types of particle interactions can 
be distinguished and are described in Table 2.2. 
The combination of the electrostatic repulsion energy (Gr) 
and the van der Waals attraction energy (Ga) are the base 
for the Derjaguin, Landau, Verwey, Overbeek (DLVO) 
theory [51,52]. The simplified equations that describe Gr 
and Ga are shown in Equations 2.2 and 2.3, respectively 
[50]. 
 
𝐺𝑟 =
4𝜋 ∙ 𝜀0 ∙ 𝜀𝑟 ∙ 𝑟
2 ∙ 𝜓0
2
2𝑟 + ℎ
∙ 𝑒−𝜅ℎ 2.2 
 
𝐺𝑎 = −
𝐴 ∙ 𝑟
12ℎ
 2.3 
Where ε0 is the permittivity in vacuum, εr is the relative 
permittivity, r is the particle radius, ψ0 is the surface 
potential, κ is the reciprocal Debye length, h is the shortest 
distance between two particles, and A is the Hamaker 
constant. The negative sign in Equation 2.3 represents the 
attractive nature of this type of interaction, provided that A 
of the particles is higher than A of the medium. 
The sum of interaction energies (Gt) of Ga and Gr creates two 
distinct regions of attraction. The first one occurs at very 
close distance between the particles and causes strong and 
irreversible particle agglomeration, defined as primary Gt 
minimum. A second attraction region is present at higher 
interparticle distance, called secondary Gt minimum. This 
allows a reversible particle agglomeration, defined as 
flocculation. An accurate understanding of this instability is 
useful to define the final characteristics of a dispersion. 
Formulation scientists often use polymers or 
macromolecular surfactants as excipients for dispersions 
and therefore further stabilising factors must be 
considered. The theory underlying surfactant repulsion 
forces is defined by the steric hindrance of the surfactant 
chains. When two particles are close, the non-ionic 
surfactant (or polymeric) layers adsorbed on their surfaces 
begin to mix. The interpenetration of the two layers causes 
a localised increase in osmotic pressure, which creates an 
osmotic repulsion force [53]. Especially when two 
macromolecular surfactants are used, the free energy of 
mixing can be used to calculate this repulsion [54–56], as 
described in Equation 2.4 [50,57]. 
TABLE 2.2 – Interparticle interactions. 
Interaction Description 
Hard-sphere Particles behave as rigid spheres. When very small interparticle distance occurs 
(i.e., when centre-to-centre distance is smaller than twice the particle radius), 
suspension behaviour changes from liquid- to solid-like. 
Electrostatic Particles possess here surface charges or have ionic surfactants adsorbed, on 
which a counter-ion layer from the surrounding medium is formed. A further layer 
of co-ions covers this layer. Particles interact according to the overlaying of their 
respective double layers. 
Steric Particles have adsorbed non-ionic surfactants or polymers on their surface. When 
the adsorbed layers of different particles encounter and overlap and slightly 
compress. Repulsion occurs due to local increase of osmotic pressure and volume 
restriction. 
van der Waals Particles are attracted at short distances due to dipole-dipole interactions, dipole-
induced dipole interaction, and dispersion forces. 
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2
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2 ∙ (
1
2
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∙ (𝛿 −
ℎ
2
)
2
∙ (3𝑟 + 2𝛿 +
ℎ
2
) 
2.4 
Where Gmix is the polymer free mixing energy, kB is the 
Boltzmann constant, T is the absolute temperature, Vm,2 is 
the molar volume of the polymer or surfactant chain, Vm,1 is 
the molar volume of the dispersing medium, n2 is the 
number of polymer or surfactant chains per unit area, χ is 
the Flory-Huggins interaction parameter, and δ is the 
surfactant or polymer layer thickness. The sign of Gmix is 
positive (i.e., repulsion occurs) when a good solvent is 
employed as dispersing medium. Furthermore, the layer 
interpenetration causes a loss of configurational entropy of 
the surfactant chains, especially on larger molecules, as 
explained by the Hesselink, Vrij, Overbeek (HVO) theory 
[54]. This causes further repulsion (Gcon) between two 
surfactant-stabilised particles, according to Equation 2.5: 
 𝐺𝑐𝑜𝑛
𝑘𝐵 ∙ 𝑇
= 2𝑛2 ∙ ln
Ωℎ
Ω∞
 2.5 
Where Ωh represents the number of configurations the 
surfactant or polymeric chain can assume when another 
particle hinders it sterically; Ω∞ represents the 
configuration number when the surfactant or polymeric 
chains are free to rotate. The combination of Gmix and Gcon 
with the van der Waals attraction Ga form the Gt for 
surfactant-stabilised suspensions. While allowing 
reversible flocculation (Gmin), steric hindrance may prevent 
stronger instabilities by creating strong repulsion forces at 
close distances. LB dispersions are rarely administered as 
final dosage form and usually go through a further 
manufacturing step, namely encapsulation into soft and 
hard shell capsules. Here, poor dispersion stability could 
lead to poor content uniformity in an administered volume 
and therefore incorrect dosing may result. 
The aforementioned models are limited to the interaction 
between two spheres in the suspending medium. On a 
larger scale, these effects reflect on the bulk properties of 
the suspensions. In terms of manufacturing, the most 
important suspension bulk property is viscosity. This 
property exhibits often a strong influence on overall 
manufacturability of a suspension. Einstein first proposed a 
correlation between solid fraction and viscosity for diluted 
dispersions described in Equation 2.6 [58]: 
 𝜂𝑟 = 1 + 2.5Φ 2.6 
Where ηr is the relative viscosity. This equation is valid only 
for systems with Φ < 0.1 and for hard-sphere interactions. 
Batchelor later proposed a modification to Einstein’s 
equation to consider the hydrodynamic contribution due to 
interparticle interaction. The modified version, which is 
valid for 0.1 < Φ < 0.2, is shown in Equation 2.7 [59]: 
 𝜂𝑟 = 1 + 2.5Φ + 6.2Φ
2 + 𝜗 2.7 
Where the second order term accounts for the 
hydrodynamic interactions and the term ϑ for higher order 
interactions. To describe the behaviour of highly 
concentrated systems, different semi-empirical equations 
have been proposed. For example, Dougherty and Krieger 
developed the following equation (Equation 2.8) [60,61]: 
 
𝜂𝑟 = (1 −
Φ
Φ𝑚𝑎𝑥
)
−[𝜂]Φ𝑚𝑎𝑥
 2.8 
Where [η] is the intrinsic viscosity, and Φmax is the 
maximum packing fraction. Another semi-empirical model 
was proposed by Mooney, as described in Equation 2.9 [62]: 
 
𝜂𝑟 = 𝑒𝑥𝑝(
2.5 ∙ 𝛷
1 −
𝛷
𝛷𝑚𝑎𝑥
) 2.9 
This equation was found to be especially useful for 
predicting viscosity at highly elevated volume fractions. 
Recently, Brady and co-workers have proposed a 
mechanistic understanding of suspension bulk viscosity 
starting from the particles’ microscale interactions [63]. 
However, when surfactant-stabilised suspensions are used 
the volume fraction is usually substituted with the effective 
volume fraction (Φeff) that accounts for the adsorbed 
surfactant layer thickness (δ) on the particles surfaces, as 
defined in Equation 2.10 [50]: 
 
Φ𝑒𝑓𝑓 = Φ ∙ [1 + (
𝛿
𝑟
)]
3
 2.10 
Rheological properties become even more complex at high 
Φ, since shear thinning and shear thickening effects become 
more prominent [64,65]. The presence of a surfactant may 
decrease these phaenomena, although the addition of 
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surfactants increases the Φeff, thus increasing viscosity. 
Other viscosity prediction models have been proposed for 
the other different types of interparticle interaction, as well 
as for agglomerated and flocculated suspensions. For 
further information, the reader is referred to the works 
from Tadros [66] and Nutan [67]. Also, for flocculation in 
non-aqueous media and in LB dispersing systems, the 
scientific contributions by van Mil et al. and Lyklema et al. 
should be mentioned here [68–71]. 
Particle size and morphology are known to influence 
suspension properties such as stability and rheological 
properties. Intuitively, smaller particles have higher surface 
area and have decreased stability [72]. Ellipticity, for 
example, has been shown to augment viscosity in 
suspensions [73,74]. The decrease of particle sphericity 
also decreases Φmax, which in turn increases viscosity. 
However, effects such as shear thinning and thickening may 
be positively or negatively influenced by irregular particle 
shapes [67]. This brief summary of dispersion rheology 
indicates that, although over a century of research has been 
conducted, open research questions remain. Therefore, 
especially the fields of concentrated dispersions and 
mechanistic modelling give rise to much contemporary 
research in basic as well as applied rheology. 
2.1.3 Advantages and limitations of LB dispersions 
LB suspensions are promising yet challenging formulations. 
When considering oral administration, formulation of a LB 
system has a number of advantages, which are hereby 
summarised: 
 Versatility. LB suspensions are suitable for both 
hydrophilic and lipophilic compounds, and 
generally for all insoluble compounds. Low drug 
solubility in the dispersing medium is advised to 
avoid recrystallization that could alter the 
biopharmaceutical API behaviour. 
 High dosage. Compared to LB formulations with 
dissolved drug, suspensions have the advantage 
that higher drug loading is enabled. Thus, 
suspensions are suitable also for rather low 
potent drugs. 
 Dissolution. Reduction in particle size enhances 
dissolution rate by increasing the surface area of 
the suspended particles. There is no 
disintegration step need as compared to tablets 
and fast dissolution is often associated with higher 
availability of the drug at the site of action or 
absorption. 
 Absorption. According to the site of action, 
absorption through the intestinal epithelium may 
be required. The lipids presented in the LB 
dispersing medium are known to enhance 
permeation through the gut wall by acting on the 
tight junctions between the cells of the epithelial 
lining [75]. In addition, LB formulations increase 
permeability by improving enterocyte membrane 
fluidity [76,77] Moreover, lipid dispersions can 
have further biopharmaceutical advantages 
regarding expected intestinal solubilisation 
during lipolysis [78]. 
 Drug stability. An API may be prone to degradation 
in aqueous media, and the absence thereof 
increases dramatically the compound’s stability. 
Similarly, aqueous environments are a favourable 
milieu for microorganism proliferation, which 
may degrade the drug thus impairing its 
therapeutic activity. Furthermore, simple 
dispersion or suspension can avoid 
manufacturing processes stressful for the 
molecule, like compression forces in tabletting, 
shear forces in homogenisation, or temperature in 
spray-drying or hot melt extrusion. 
Still, LB suspensions possess some disadvantages that must 
be duly considered upon considering this formulation type. 
Hereby are listed some of the most challenging aspects of 
LB suspensions formulation for oral administration: 
 Biopharmaceutical limitations. Drug suspensions 
in lipids are often beneficial regarding dissolution 
and absorption compared to other standard 
dosage forms using crystalline drug, but there are 
typically clear biopharmaceutical limitation in 
comparison to LB formulations with dissolved 
drug. 
 Formulation instability. Most suspensions are 
thermodynamically unstable while retaining 
kinetic stability for different time spans. Different 
mechanisms of physical instability can occur 
ranging from aggregation to sedimentation (or 
flotation) as well as dissolution/recrystallization. 
 Final dosing. LB suspensions are often not suitable 
as final dosage forms regarding especially 
palatability. The dispersions are generally filled 
into soft or hard shell capsules. 
 Viscosity. While an increase in drug loading is 
positive for low potency drugs, it can harm the 
formulation’s machinability. Especially highly 
concentrated dispersions exhibit a rather too high 
viscosity, which is often accompanied with high 
variability.  
2.2 Encapsulation of LB dispersions 
While LB suspensions show interesting pharmaceutical 
properties for oral administration as earlier described, they 
have to be generally filled into capsules that constitute a 
Chapter 2. Theoretical section   9 
 
 
final dosage form. Different capsule materials exist and they 
come in several sizes and shell compositions [79]. Capsules 
may have benefits compared to other solid dosage forms in 
terms of patient compliance [80]. While capsules are 
suitable for liquid filling mostly of lipid systems, their shell 
material – usually gelatine – is incompatible with fillings 
containing water or high organic co-solvent percentage 
[81]. 
Capsules are classified as soft and hard depending on the 
shell type [82]. Hard capsules have a two-piece shell that is 
interlocked, and the shell production and capsule filling are 
two separate processes. This type of capsule offers great 
possibilities and flexibility in terms of formulation design, 
since powders, beads, granules, tablets, semi-solids, and 
liquids may be easily filled into these dosage forms. This 
versatility may be further exploited by loading modified 
release drug delivery systems into the capsule. 
Furthermore, hard capsules may be used not only for oral 
administration, but find application also in pulmonary 
delivery for loading of dry powders for inhalation [83,84]. A 
certain disadvantage on the side of machinability is a lower 
output of the filling machines in terms of capsules per hour 
compared to tableting equipment. Moreover, gelatine, the 
material usually employed to form the shell, can cause 
compatibility issues due to chemical cross-linking, as well 
as raise ethical and religious concerns due to its animal 
origin. 
Soft capsules are a single piece shells produced and filled in 
a single process. Soft shell capsules are usually composed of 
gelatine which has been further plasticised by addition of 
glycerol or sorbitol [79]. The shell water content is 
comparatively higher in soft capsules and they are 
practically exclusively used for filling of liquid formulations, 
which makes a difference to the more versatile hard 
capsules.  
2.2.1 Recent advancements in capsules as dosage 
forms 
The history of soft capsules starts with Mothes and 
DuBlanc’s first patent in 1834 [85], whereas that of hard 
capsules begins with Lehuby in 1846 [86]. Since these 
pioneer days of the prototype capsules, much has been 
achieved in terms of novel shell materials and production 
techniques for both types. 
While gelatine represents the state-of-the-art in terms of 
capsule shell material, the need for valid alternatives has 
increased due to multiple factors. Gelatine is an animal-
derived product, which entails an adequate quality 
screening to avoid microbiological contamination. 
Moreover, gelatine has shown several compatibility issues 
with hydrophilic fillings, e.g. low molecular weight PEGs, as 
well as cross-linking phaenomena in presence of aldehydes 
or at pH > 7.5 [79]. 
Several novel materials have been proposed, developed, 
and commercialised to overcome the technical issues of 
gelatine, as well as to circumvent religious or dietary 
concerns that are linked to the animal source of the shell 
material [79,87,88]. For hard capsules, the most 
widespread alternative shell material is hydroxypropyl 
methylcellulose (HPMC). This semisynthetic polymer is 
widely used in pharmaceutics for coating, granulation, and 
tableting. HPMC can be used as capsule shell material using 
the same dipping technology as two-piece hard gelatine 
capsules, although a gelling agent is needed in the 
composition to allow suitable manufacturing properties 
[89]. Among the commercially available products based on 
HPMC, Qualicaps® SA (Alcobendas, Spain) introduced 
Quali-V®, formed with carrageenan as gelling agent. 
Similarly, Capsugel® NV (Bornem, Belgium) has developed 
several HPMC capsules, such as VCaps® and DRcaps™, 
which both contain gellan gum as gelling agent. Recently, 
Capsugel® also introduced VCaps® Plus, which do not 
contain any gelling agent in the shell formulation. These 
novel shell materials have been found to closely mimic the 
behaviour of standard hard gelatine capsules, and their 
performance has been elsewhere reviewed [90–96]. Shell 
materials have been proposed for example by Capsugel, 
such as starch (Capill®) and pullulan (Plantcaps®) [97–
99]. These materials may become possible alternatives to 
gelatine, but further research and development is still 
needed to create competitive products compared to 
gelatine capsules. Other materials have been tested for 
suitable capsule shell formation [100,101], but a significant 
amount of research is still needed to bring such novel 
materials to the pharmaceutical market. As for non-gelatine 
soft capsules, several new products have already entered 
the market using starch as an alternative capsule material. 
For instance, Catalent Pharma Solutions (Somerset, NJ) has 
proposed Vegicaps® Soft Capsules, Aenova GmbH 
(Starnberg, Germany) has introduced VegaGels®, and 
Acsana AG (Cham, Switzerland) has developed Soft SANA 
Caps™. Although starch appeared to be the most 
investigated and commercially successful alternative to 
gelatine for soft capsules, synthetic polymer polyvinyl 
alcohol display also potential as a substitute capsule shell 
material [88,102]. 
2.2.2 Liquid capsule-filling technology 
Soft and hard capsules have different liquid filling 
technologies due to their diverse type of production. Soft 
capsules are produced, filled, and sealed within the same 
manufacturing process. While several techniques are 
known to form this kind of liquid-filled capsules, the two 
most widespread processes are the rotary die method 
(Scherer) and the bubble method (Globex). The rotary die 
method (Figure 2.1a), which was first invented by R. P. 
Scherer in 1931 [103,104], is the most known continuous 
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industrial process for soft capsule manufacturing. Briefly, 
after melting the capsule shell material, two films thereof 
are formed and casted on two separate die rolls. These rolls 
are set in parallel at close distance and are separated by an 
injection wedge, which will pump the liquid fill between the 
two casted films. The rolls have small symmetrical pockets 
that allow the shell material to swell during the forceful 
injection of the liquid filling. The convergent die roll 
rotation leads to the sealing of the die pockets, and 
subsequently to the cut out of the formed soft capsules. The 
bubble method (Figure 2.1b), which was first industrially 
applied on the Globex Mk II Encapsulator, forms seamless 
one-piece soft capsules. A concentric tube extrudes molten 
shell material from the outer annulus and the liquid fill from 
the internal tube. The droplets assume a spherical shape 
due to surface tension, and the molten shell material 
solidifies into a cooled oil column. The thereby formed 
capsules undergo a final drying step. Schematics of the 
rotary die method (a) and bubble method (b) for liquid 
capsule filling process, and of the capsule sealing 
techniques using banding (c) and LEMS™ (d). 
Unlike soft capsules, the filling of hard capsules is separated 
from the production step. The shell formation of the hard 
capsules is usually achieved by dipping metal pins into 
molten shell material or a solution thereof. Different pins 
are used for the two components of hard shells, namely cap 
and body, to ensure later the adequate interlocking of the 
two pieces. The pins are subsequently extracted to allow 
deposition of the material thereon and dried to form the 
shell [79]. The filling step of hard shell capsules follows 
general operations that are common to most equipment, 
namely rectification, capsule body and cap separation, 
dosing, rejoining, sealing, and ejection. In the first step, the 
empty capsules are automatically oriented in the same 
direction, i.e. cap upwards and body downwards. 
Afterwards, the cap and body are separated in order to 
allow the filling of the body compartment. The dosing or 
filling step is the most critical, and a variety of different 
instruments, both laboratory and industrial scale, are 
available on the market [105]. Since the liquid or semi-solid 
fill is dispensed in the capsule volumetrically, its 
physicochemical and especially its rheological properties 
are of critical importance. For example, apparent viscosity 
at the given shear rate in the nozzle plays a major role 
during the dosing into capsules [106,107]. Once the fill has 
been loaded, cap and body are rejoined and subsequently 
sealed to prevent liquid leakage from the capsules. Two 
industrial sealing methods are commonly used for this last 
step, i.e. banding and LEMS™ sealing (Figure 2.1c and 2.1d, 
respectively). Banding is the most known technique, in 
which band of shell material is applied on the overlap 
between capsule cap and body [108]. Instead, in the LEMS™ 
sealing process from Capsugel, a hydroalcoholic solution is 
sprayed on the gap between capsule cap and body 
[109,110]. This mixture is drawn further in the overlap 
between the two capsule halves by capillary forces and 
there the presence of moisture lowers the melting point of 
the shell material. The sealing is then finalised by the 
application of gentle heat in a machine drying tunnel. The 
most common liquid-filling and sealing techniques together 
with their equipment have been thoroughly reviewed by 
Cole [111]. 
2.3 Oral delivery of proteins 
Several different peptide and protein drugs are available for 
different therapeutic applications. Many pharmaceutical 
companies have also refocused their research and 
development from small molecules to therapeutically active 
macromolecules. Proteins and peptides, such as insulin, 
calcitonin, octreotide, glucagon-like peptide-1, and 
interferon α, are currently being developed by major 
pharmaceutical companies for oral administration [14]. 
Currently, however, nearly all macromolecular compounds 
are administered parenterally. Stepping towards oral 
administration could increase patient compliance. 
Furthermore, for local gastrointestinal (GI) delivery there 
may be the additional advantage of targeting directly the 
pharmacological site of action. However, the low oral 
bioavailability due to the characteristics of the GI tract itself 
poses several challenges to this administration route. 
Proteins and peptides are naturally metabolised as part of 
 
FIGURE 2.1 - Schematics of the rotary die method (a) 
and bubble method (b) for liquid capsule filling 
process, and of the capsule sealing techniques using 
banding (c) and LEMS™ (d). 
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the digestion process, which is certainly a hurdle to 
macromolecular oral delivery. In order to have a systemic 
action, the macromolecular APIs must cross a mucus layer, 
which covers most of the GI tract’s epithelium, and has to 
permeate the epithelium itself. However, if systemic action 
is not intended and only local GI activity is required, mainly 
intestinal degradation is targeted. Consequently, mucus or 
enterocyte permeation is optional given the specific mode 
of pharmacological action [112]. Therefore, oral peptide 
and protein administration appears to be a much more 
realistic goal to reach for local action as compared to an 
intended systemic therapy. This enables many novel 
therapeutic options for the treatment of intestinal ailments 
[113]. Regardless of the GI tract barriers, an adequate drug 
delivery system must also allow a technically feasible and 
competitive manufacturing process. To deliver its 
therapeutic effect, the macromolecular API must retain its 
structure and activity throughout compounding and 
processing to a final dosage form. The oral delivery of 
proteins, either systemic or local, represents a significant 
challenge for modern pharmaceutics. Many systems have 
been devised and preliminary tests have shown some 
potential to achieve the goals, but these efforts have so far 
not provided suitable drug delivery systems that are viable 
for the pharmaceutical market [114]. 
2.3.1 Gastrointestinal (GI) barriers and 
formulation strategies 
The stomach constitutes a particular hurdle to oral peptide 
and protein delivery because of the acidic environment and 
the enzymatic activity. Therefore, enteric coating is 
probably needed for any suitable oral drug delivery system 
using this type of active principles. The lower intestine may 
represent a better site of release for peptides and proteins 
and the formulation technique would have to address the 
barriers for this kind of APIs. Beside the acidic environment 
in the stomach, the GI tract possesses three major hurdles 
to be overcome for successful API action, namely enzymatic 
degradation (i), mucus penetration (ii), and absorption 
(Figure 2.2). The last step can be further divided into 
overcoming permeation into the enterocytes (iii) and 
avoiding efflux pumps (iv), surviving cellular metabolism 
(v), and, if paracellular absorption occurs, pass the tight 
junctions (vi). For systemic delivery of macromolecules all 
three barriers must be overcome, whereas according to the 
type of local action, only some of the hurdles may truly 
represent limiting steps to the therapeutic efficacy of the 
API. 
2.3.1.1 Enzymatic degradation 
The most relevant enzymes which could degrade a protein 
drug in the GI tract are listed in Table 2.3 (modified from 
Woodley [15]). While the stomach and the small intestine 
show high enzymatic activity, this is reduced in the large 
intestine. However, the enzymatic activity is here still 
comparatively high due to surviving enzymes from the 
small intestine. Additionally, the colonic bacteria also 
contribute to the metabolism of nutrients which escape 
digestion in the upper gut, including proteins [115,116]. 
The epithelial cells of the lumen also have a relatively high 
turnover (3-6 days), and after being sloughed off they may 
release further digestive enzymes in the GI tract, such as 
lysosomal cathepsins [15]. 
One of the most widespread formulation techniques to 
prevent enzymatic digestion is encasing or embedding the 
API within a nano- or microparticle. this creates a physical 
separation between the digestive enzymes and the loaded 
API. The method to obtain such drug loaded microparticles 
is commonly defined as microencapsulation and is 
discussed in depth in Paragraph 2.3.2.2.1. Enzymatic 
inhibitors have been extensively studied to overcome the 
enzymatic barrier step. These molecules can be added in the 
formulation to reduce enzymatic degradation. Several 
compounds are available and have shown different 
selectivity for digestive enzymes. In the formulation step, 
the addition of an enzymatic inhibitor requires the 
knowledge of the exact degradation mechanism of the 
intended protein API. Many enzymatic inhibitors 
demonstrated potential toxicity. Different classes of 
inhibitors are available, such as polypeptidic [117], peptidic 
 
FIGURE 2.2 - Gastrointestinal barriers to drug action 
and absorption. The drug is represented by blue 
circles and digestion enzymes are shown as red 
circles. Enzymatic degradation (i), mucus layer 
penetration (ii), enterocyte absorption (iii) and efflux 
pumps (iv), cellular metabolism (v), tight junction 
closure (vi). 
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[118], amino acidic [119], non-amino acidic [120]. 
Especially polypeptidic compounds have shown 
comparatively lower toxicity and high potency. 
Polypeptidic enzymatic inhibitors are divided into 
Bowman-Birk inhibitor and Kunitz trypsin inhibitor 
families. Size and sequence differences occur between these 
two families, but both are known to inhibit trypsin, 
chymotrypsin, and elastase [121]. Due to the molecular 
weight of these compounds, which is comparable to 
therapeutically active proteins, these inhibitors could be 
formulated directly with the macromolecular API and have 
similar release profiles if controlled release is required. For 
example, Kimura et al. showed that insulin formulated in gel 
spheres with aprotinin, a well-known Kunitz-type 
enzymatic inhibitor, could increase oral drug bioavailability 
in vivo and these compounds had a similar release rate 
[122]. However, all enzymatic inhibitors hinder negative 
feedback to further digestive enzyme secretion. This has 
been linked to pancreatic hypersecretion and potential 
pancreatic hyperplasia [123]. 
An effective approach is to chemically modify the desired 
macromolecular API to prevent its enzymatic digestion. 
This can be achieved by modifying the N and C terminus of 
the therapeutic protein [124], by PEGylating the protein 
[125], or by replacing labile amino acid bonds with more 
stable ones [126]. Several chemical residues have been 
covalently conjugated to proteins, for example PEG [127], 
D-amino acids [128], vitamin B12 [129], and fatty acids 
[130]. Such modifications, however, alter the chemical 
structure of the protein, thus requiring substantial safety 
and quality understanding due to their status of new 
biological entities (NBE). Non-covalent protein 
modifications, which would not require a NBE profiling, 
have been proposed and have proven successful in initial in 
vivo screening [131]. 
2.3.1.2 Mucus layer 
A valuable technique to increase oral bioavailability of APIs 
is to increase their residence time in the GI tract in 
proximity of the epithelial cells. Developing mucoadhesive 
TABLE 2.3 – Relevant enzymes of the gastrointestinal tract (GI) tract (modified from Woodley [15]). 
Stomach 
Small intestine 
Pancreatic juices a Brush border 
Endopeptidase Endopeptidase Endopeptidase 
  Pepsin   Trypsin   Endopeptidase 24.11 
   Chymotrypsin   Endopeptidase 24.18 
   Elastase   Enteropeptidase b 
 Exopeptidase Exopeptidase 
   Carboxypeptidase A   Aminopeptidase N 
   Carboxypeptidase B   Aminopeptidase A 
    Aminopeptidase P 
    Aminopeptidase W 
    γ-glutamyl transpeptidase 
    Dipeptidyl peptidase IV 
    Carboxypeptidase P 
    Carboxypeptidase M 
    Peptidyl dipeptidase A 
    γ-glutamyl 
  carboxypeptidase 
a the proteolytic enzymes secreted by the pancreas are in their zymogen form 
b enteropeptidase is a highly specific protease that activates trypsinogen, the zymogen of trypsin. After activation, trypsin 
activates the other pancreatic enzymes. 
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systems is a valuable approach to achieve this purpose. 
Mucus is mainly composed of water (95%) and mucin, a 
high molecular weight glycoprotein. Other components 
include electrolytes, lipids, lysozyme, IgA, and sloughed 
cells [132]. The mucus layer has different thicknesses in the 
GI tract, starting between 50-500 μm in the stomach and 
decreasing to 15-150 μm in the colon [133]. This 
glycoproteic layer also has a very short turnover time, 
entailing that although high adhesion may be achieved, the 
mucus is frequently sloughed off, thus removing the 
attached delivery system. The underlying mechanisms of 
the mucoadhesion process have been excellently reviewed 
by Smart [134] and by Khutoryanskiy [135], and are 
summarised in Table 2.4. 
Lamprecht and co-workers also showed the influence of 
particle size on the interaction with mucus [142]. 
Furthermore, particle size appeared to be critical not only 
to interact with the mucus, but also to penetrate and cross 
it [143]. Many polymers have suitable mucoadhesive 
properties, for example polylactic acid [144], polylactic-co-
glycolic acid [145], chitosan [146], and alginate [147]. The 
target protein API may then be embedded in a polymeric 
matrix, or a polymeric coating may be applied to the 
formulation. Mucoadhesion is especially useful for 
multiparticulate systems, whereas for single dosage units it 
could lead to localised dose dumping and differences in 
therapeutic response [148]. In addition, single dosage units 
have shorter transit time that could lead to lack of 
effectiveness [149]. 
2.3.1.3 Epithelial absorption 
The final step to overcome, especially when systemic action 
is required, is the absorption. The intestinal epithelium 
typically allows two types of transportation, namely 
transcellular and paracellular [150]. Extensive literature 
exists on the mechanistic aspects of each transportation 
type [151–155] also in regards of peptides and proteins 
[14,150,156,157]. Many in silico, in vitro, and ex vivo models 
have been proposed to adequately predict in vivo 
absorption of drugs, but much research is still needed 
[158,159]. 
Transcellular absorption may occur by passive diffusion, by 
transporter systems, or by pinocytosis. Preliminary reports 
have shown that bile salts potentially increase in vivo 
transcellular permeation of peptides and proteins by 
solubilising the membrane phospholipids [118,160]. 
Several transport systems take care of both influx and efflux 
through the cell membranes. Most of the influx pumps work 
with small molecules, whereas some others work 
selectively with oligopeptides [161]. Efflux pumps like the 
P-glycoprotein, however, may be inhibited to improve 
bioavailability with small molecules [162], PEGs and 
PEGylated compounds [163], and ionic polymers [164,165]. 
However, similarly to affecting influx pumps, this approach 
is useful mostly for smaller molecules such as peptides. A 
more protein-specific type of transcellular absorption is 
pinocytosis. This is a type of endocytosis, often mediated by 
clathrins, where the luminal cell membrane invaginates to 
sample some luminal fluid, and an apical early endosome is 
formed. The compound may then be recycled back into the 
lumen, undergo degradation in the cellular lysosomes, or 
cross the cell through the common endosome and be 
released on the basolateral side of the epithelium. 
Paracellular absorption occurs through the tight junction 
complexes, which interconnect epithelial cells. These 
structures comprise several types of proteins, which 
provide scaffolding and maintain the junction integrity 
[150]. Tight junctions, however, are dynamic structures 
that can be easily modulated. For instance, medium chain 
fatty acid salts, i.e., caprylates, caprates, and laureates, have 
shown to loosen the tight junctions and lead to increased 
paracellular absorption of peptides [5,166]. A similar effect 
on peptide paracellular absorption was also demonstrated 
for medium chain mono- and diglycerides [4]. Furthermore, 
other small molecular compounds can be used, for example 
nitric oxide donors [167]. Polymers have been proposed as 
permeation enhancers, and especially chitosan has shown 
encouraging results from the start [168]. Furthermore, two 
chitosan derivates, namely N,N,N-trimethyl chitosan (TMC) 
and mono-N-carboxymethyl chitosan (MCC), exhibit even 
TABLE 2.4 – Mucoadhesion theory. 
Mechanism Type of interaction 
Electronic 
theory 
Mucus and polymer have opposite 
charges and electrostatic interactions 
occur [136]. 
Adsorption 
theory 
Hydrogen bonds are formed and van 
der Waals forces act between mucus 
and polymer [137]. 
Wetting 
theory 
Correlated to the surface tension of 
polymers and mucus. Polymers with 
better ability to spread over the mucus 
layer have increased mucoadhesive 
properties [138]. 
Diffusion 
theory 
Mucin chains enter and diffuse slightly 
in the polymeric network, thus forming 
an interpenetration layer [139]. 
Fracture 
theory 
Concerns the strength needed to 
separate polymer and mucus after 
adhesion [140]. 
Mechanical 
theory 
Mucoadhesion is correlated to the 
roughness and the porosity of the 
polymeric structure [141]. 
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more potential for enhancement of peptide paracellular 
permeation enhancement [169]. The reader is referred to 
other excellent reviews on the topic of protein permeation 
and absorption enhancers [170–172], and for the use of LB 
DDS in these regards [3]. 
2.3.2 Protein formulation 
2.3.2.1 Protein stability 
Biotechnological products such as therapeutic proteins 
displayed a significant development in recent years. 
However, formulation for these compounds is still 
problematic due to their stability profile. Owing to their 
large size (> 5 kDa) [173] and highly complex polymeric 
nature, protein structure is usually divided into a primary, 
secondary, tertiary, and quaternary type of formation. The 
characteristics of each type of structure are listed in Table 
2.5. 
In order to maintain therapeutic effect, the protein 
structure must be preserved throughout the manufacturing 
steps of the drug products, during storage, and following 
administration. A major challenge for correct 
manufacturing is to prevent unwanted degradation. Two 
typical issues in protein physical stability are denaturation 
and aggregation. Denaturation is a spatial alteration of the 
protein’s three-dimensional structure. This structural 
unfolding can cause loss of activity, or alter the physical 
properties of the protein such as solubility, although it is not 
always an irreversible process [11]. 
The denaturation occurs according to a three state model, 
where the protein is in a native state, moves to an 
intermediate state, and finally the denatured species is 
formed [174]. The intermediate, which does not always 
occur, usually retains some secondary structure, and it can 
also lead to protein aggregation. Formulation and 
manufacturing can cause stress to the protein and lead to 
denaturation, although each protein behaves differently. 
Denaturation is triggered by several factors, such as pH, 
pressure, shear forces, temperature, and chemical 
denaturants [13]. During manufacturing, any shear stress 
involved may harm the protein structure [12]. Even 
formulation techniques that are usually employed with 
proteins may lead to denaturation [175]. Aggregation is 
caused by unfolded proteins’ response to external stimuli, 
e.g., variations in protein concentration or ionic strength. 
The interactions that take place between proteins may be 
covalent, such as disulphide bond formation, or non-
covalent, for instance by hydrophobic forces. Further 
interactions may occur that lead to precipitation of protein 
aggregates and formation of protein fibrils. 
Chemical instability must be taken in consideration when 
peptides and proteins are formulated. Each composing 
amino acid may respond to chemical stimuli which could 
lead to an overall conformational change and finally to 
protein degradation [176]. The pH certainly plays a major 
role with respect to chemical instability [177]. For instance, 
high pH may entail hydrolysis of aspartate-proline and 
aspartate-tyrosine peptidic bonds. Furthermore, at low pH, 
tryptophan, methionine, cysteine, tyrosine, and histidine 
groups may undergo oxidation. Photooxidation may also 
occur in presence of light, for example on phenylalanine 
groups. Reduction and oxidation of cysteine groups also can 
lead to denaturation [178]. 
2.3.2.2 Protein formulation for oral delivery 
To ensure adequate protein stability, different formulation 
approaches have been proposed. Due to protein instability 
and limited bioavailability by oral administration, most 
techniques are tailored for parenteral delivery. Direct 
protein solubilisation or lyophilisation are the most 
widespread methods and have been adequately reviewed 
[173,179,180]. As for oral delivery strategies, Hwang and 
Byun [181] have recently reviewed the currently available 
approaches. To increase oral bioavailability of 
macromolecules, the authors suggested the use of 
absorption enhancers (which were earlier outlined in this 
chapter), microencapsulation (which is discussed in 
Paragraph 2.3.2.2.1.) and chemical modifications (covalent 
and non-covalent) of the protein API (Paragraph 2.3.1.1). 
Further suggested reading on peptide and protein delivery 
is available from several different research groups [181–
185]. 
2.3.2.2.1  Microencapsulation for oral protein delivery 
Microencapsulation allows API loading into typically 
micron-sized particles, thus enabling protection from 
TABLE 2.5 – Structures of protein. 
Structure Characteristics 
Primary L-α-amino acid sequence. 
Secondary Local three-dimensional arrangement 
due to hydrogen bond formation. 
Typical structures are α-helices and β-
sheets.  
Tertiary Global three-dimensional arrangement 
of secondary structure and side chains. 
Structure maintained by hydrophobic 
and steric interactions, as well as 
disulphide bridges between cysteine 
residues. 
Quaternary Non-covalent assembly of protein 
monomers to form larger complexes. 
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digestive enzymes, and adhesion to the mucus layer. The 
nomenclature of the obtained drug delivery systems, 
however, is not entirely consistent within the scientific 
literature [186]. The terminology used is closely related to 
the particle’s size and architecture. Generally, 
“microparticle” represents an umbrella term which 
comprises all particles with a diameter between 1 and 1000 
μm. Microparticles are furthermore divided into 
“microcapsules” and “microspheres”, which are 
represented in Figure 2.3. Microcapsules are spherical 
microparticles where two different domains are present. 
The classical example of a microcapsule is a microparticle 
with an external shell and an internal core (Figure 2.3a), but 
the core structures may hold for a dispersion within the 
particle (Figure 2.3b). To ensure protection from the 
external environment, the API is usually loaded in the core 
compartments, whilst other adjuvants such as enzymatic 
inhibitors may be present in both domains. Microspheres, 
instead, are made of a matrix-like single compartment in 
which the API is finely and homogenously dispersed or 
dissolved (Figure 2.3c). A specific type of microspheres is 
microgels, defined by Bysell et al. as cross-linked gel 
particles whose structure responds to environmental 
stimuli [187]. Microgels exhibit the advantage of the 
specific characteristics of the polymeric type that composes 
the network, and form a suitable environment for a 
macromolecular API, while protecting it from the GI milieu 
[187]. Furthermore, some polymers such as alginates and 
chitosans have shown mucoadhesive and permeation 
enhancing properties [188–190]. 
Chitosan and its derivates have especially shown feasibility 
for oral delivery of proteins and peptides [191–196]. 
Several different methods are known for 
microencapsulation, such as solvent evaporation [197], 
spontaneous emulsification and solvent diffusion [198], 
supercritical fluids [199], and ionic gelling, and have 
elsewhere been reviewed [20,21,200–202]. 
Microencapsulation methods, however, must take into 
consideration the protein structure, which can be easily 
harmed in presence of elevated temperatures, denaturing 
agents, or high shear forces [12,173]. There are preliminary 
findings of successful protein encapsulation and delivery. 
For instance, Sarmento and co-workers demonstrated in 
vivo that insulin alginate/chitosan microparticles could be 
successfully delivered to rats’ intestine and thereby 
absorbed without substantial loss due to enzymatic 
degradation [203]. Rekha and Sharma showed the in vivo 
efficacy of lauryl succinyl chitosan nano- and microparticles 
as drug delivery systems for insulin, which could protect the 
peptide from enzymatic degradation and increased its 
bioavailability in diabetic rats [204]. 
2.3.3 Protein characterisation 
Protein structure and its stability are a major concern 
during its formulation. As earlier described, proteins have 
different structures that affect overall protein properties, 
such as solubility or therapeutic effect. An adequate 
characterisation of these structures during the formulation 
step and during in vitro or in vivo experiments is required 
as proof of protein stability for the proposed drug delivery 
system. If the chosen macromolecular API is a NBE, a 
thorough characterisation of the protein is part of 
pharmaceutical profiling before the formulation 
development. Several techniques are available to assess 
protein structure, its degradation, and potential 
aggregation phaenomena. A non-exhaustive list of suitable 
techniques for protein characterisation alone or in 
formulation can be found in Table 2.6 (modified from 
Jorgensen[13]). It is clear that many techniques describe 
similar protein characteristics, so only a limited selection of 
these approaches is necessary to evaluate the stability of a 
protein after formulation or administration. However, after 
the protein formulation, the composition of the dosage form 
must be carefully considered to avoid possible 
interferences in the protein analytical evaluation. 
2.4 Microencapsulation by prilling 
2.4.1 Prilling and vibrating nozzle technique 
Microencapsulation as formulation technique for 
macromolecules appears to be promising in terms of 
enzymatic protection and mucoadhesion. Many 
technologies for protein microencapsulation are available 
but not all may be suitable for protein formulation due to 
the mild condition needed [22,187,227]. Prilling is based on 
high speed extrusion of a polymeric solution through a 
small nozzle. Historically, the technique was first patented 
in Germany to form ammonium nitrate pellets [228]. The 
approach has then found further applications for example 
in the fertilising industry and, more recently, in cell biology 
and in pharmaceutics [229]. Prilling can be obtained by  
 
FIGURE 2.3 - Microparticle types. Microcapsules with 
single core (a) and with dispersed cores (b), and 
microspheres (c). 
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different methods and technologies, namely by simple 
dripping, dripping with concentric air jet, dripping and 
spraying with electrostatic forces, rotating disk and jet 
cutting, and vibrating nozzle (Figure 2.4). These techniques 
have been outlined by Heinzen et al. [229]. The vibrating 
nozzle method has found wide application in modern 
pharmaceutics. This technique has its physical explanation 
in the Plateau-Rayleigh instability [230]. 
TABLE 2.6 – Protein characterisation techniques. 
Technique Information References 
Chromatography 
  Size exclusion c. (SEC) 
  Ion-exchange c. (IEC) 
 
Molecular weight 
Degradation, molecular charge 
 
[205] 
[206] 
Electrophoresis 
  Sodium dodecyl sulphate 
  polyacrylamide gel e. (SDS-PAGE) 
  Capillary e. (CE) 
  Isoelectric focussing (IEF) 
 
Aggregates, impurities, molecular weight 
 
Aggregates, impurities, molecular weight 
Isoelectric point 
 
[207,208] 
 
[209] 
[210,211] 
Mass spectrometry (MS) Molecular weight, amino acid sequencing [212] 
Spectroscopy 
  Fourier transform infrared s. (FTIR) 
  Raman s. 
 
  Ultraviolet absorption s. (UV) 
  Fluorescence s. 
  Circular dichroism (CD) 
 
Secondary structure, crystallinity 
Secondary structure, three-dimensional structure 
c, crystallinity 
Protein content 
Three-dimensional structure c 
Secondary structure of protein 
[213] 
[214] 
[215,216] 
 
[82,217] 
[218] 
[219] 
Thermal techniques 
  Differential scanning calorimetry (DSC) 
  Thermogravimetric analysis (TGA) 
 
Protein stability, crystallinity, glass transition 
Water content 
 
[220,221] 
[220,221] 
Scattering 
  Dynamic light s. (DLS) 
  Static light s. (SLS) 
  Small angle X-ray s. (SAXS) 
  Small angle neutron s. (SANS) 
 
Aggregates, molecular weight 
Aggregates, molecular weight 
Three-dimensional structure 
Three-dimensional structure 
 
[222] 
[222] 
[223] 
[223] 
X-ray crystallography Three-dimensional structure [224] 
Nuclear magnetic resonance (NMR) Three-dimensional structure [225] 
Enzyme-linked immunosorbent assay (ELISA) Protein content, binding site integrity [226] 
Chemical assays 
  Lowry a. 
  Bradford a. 
  Bicinchoninic acid (BCA) a. 
  Biuret a. 
  O-phthalaldehyde conjugation 
  Nitrogen content 
Protein content [82] 
Activity d Enzymatic activity  
c localised to specific amino acids 
d if analysed protein is an enzyme 
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After a liquid is forced through a nozzle or orifice due to 
pressure or simple gravity, a liquid stream is formed. Small 
perturbations affect the stream’s regularity, and once a 
threshold vibration frequency is reached, the stream is 
broken into droplets (Figure 2.5). The frequency (f) of such 
perturbations is related to wavelength according to 
Equation 2.11: 
 𝑓 =
𝑣𝑗
𝜆
 2.11 
Where vj is the jet velocity and λ is the wavelength. The 
optimal wavelength of these vibrations to allow the jet 
breakup is calculated according to Equation 2.12: 
 𝜆𝑜𝑝𝑡 = 𝜋 ∙ √2 ∙ 𝑑𝑗  2.12 
Where λopt is the optimal wavelength, and dj is the jet 
diameter. Constantin Weber included the properties of the 
falling liquid and modified the equation as follows [231]: 
 
𝜆𝑜𝑝𝑡 = 𝜋 ∙ √2 ∙ 𝑑𝑗 ∙ √1 +
3 ∙ 𝜂
√𝜌𝑓 ∙ 𝜍 ∙ 𝑑𝑗
 2.13 
Where η represents viscosity, ρf is fluid density, and ς is the 
surface tension. Serp et al. first calculated the drop diameter 
dd according to Equation 2.14 [232]: 
 
𝑑𝑑 = √6 ∙
𝐹
𝜋 ∙ 𝑓
3
 2.14 
Where F represents liquid flow in terms of volume. Flow can 
be further expressed by Equation 2.15: 
 
𝐹 =
𝜋 ∙ 𝑑𝑛
2
4
∙ 𝑣𝑗  2.15 
 
FIGURE 2.4 - Different types of prilling. Dripping (a), concentric air jet (b), electrostatic force-driven dripping (c), jet 
cutting (d), and vibrating nozzle (e). 
 
FIGURE 2.5 – Development of the Plateau-Rayleigh 
instability on a liquid stream (black lines) due to 
perturbations in water (yellow lines). 
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Where dn is the nozzle diameter. By merging Equation 2.14, 
2.15 and 2.11, Equation 2.16 is obtained: 
 
𝑑𝑑 = √
3
2
∙ 𝑑𝑗
2 ∙ 𝜆𝑜𝑝𝑡
3
 2.16 
Clearly, liquid jet velocity and vibration frequency are 
paramount for the successful droplet formation [229,233]. 
The Plateau-Rayleigh instability can thus be used to form 
equally sized droplets from a liquid jet by applying 
vibration and this method is generally called the vibrating 
nozzle technique. An API can be loaded into the prilled 
liquid, which may be composed of a polymeric solution or 
of a non-aqueous carrier, such as fatty acids and waxes 
[234,235]. Suitable polymers for prilling are discussed in 
Paragraph 2.4.2. The droplets formed from the broken up 
liquid stream can solidify mid-air or can be collected in a 
hardening bath. In the latter case, the microencapsulation 
step takes place according to the properties of the 
microsphere-forming compound. In fact, the hardening may 
occur due to several physicochemical triggers, for instance 
temperature change, ionic cross-linking, pH variation, or a 
mixture thereof. Prilling has been confused with spray 
congealing (also known as spray chilling and spray cooling) 
if the microparticle solidification occurs mid-air rather than 
in a hardening bath [236,237]. The major difference 
between these techniques is that prilling does not require a 
nebulisation or atomisation step, which is instead 
fundamental for spray congealing. 
Many modifications have been proposed to the basic 
vibrating nozzle system. For example, Brandenberger et al. 
introduced an electrostatic ring to reduce drop coalescence 
mid-air and after entrance into the hardening bath [238]. 
Herein, the liquid stream falls through the electrostatic ring 
that charges each droplet mid-air to promote repulsion. The 
hardening bath is grounded to allow entrance of the falling 
droplets. Additionally, the nozzle employed can be single or 
concentric. The former system allows direct entrapment of 
the API within a matrix, whereas the latter forms a 
microcapsule with distinct core and shell compartments. 
With the concentric nozzle system, air can be flowed 
through the external annulus to reduce the particle size 
without causing atomisation. High viscosity is a known 
limitation for this system, but Rodríguez-Rivero and co-
workers proposed a modified pressurised system to allow 
prilling of systems with unfavourable rheological 
properties [239]. Brandenberger and Widmer, and Vilesov 
et al. separately proposed two systems to increase the yield 
of the prilling systems by using different geometries on a 
multi-nozzle apparatus [233,240]. This is an interesting 
technical approach as it demonstrates a possible modular 
scale-up for microparticles production. For example, 
Brandau introduced an industrially viable process which 
applies the vibrating nozzle principle to produce 
microspheres [241,242]. Prilling devices based on vibrating 
technology are already commercially available from 
different companies, e.g. the Encapsulator B-390 from 
Büchi Labortechnik AG (Flawil, Switzerland), the 
Spherisator S from BRACE GmbH (Karlstein am Main, 
Germany), and the Variation D from Nisco Engineering AG 
(Zürich, Switzerland). 
Many different products and compounds can be 
microencapsulated by using prilling or, in particular, the 
vibrating nozzle method. For instance, Chandramouli et al. 
formed alginate microspheres containing Lactobacillus 
acidophilus with the vibrating nozzle method in order to 
prevent gastric instability [243]. Much literature has been 
generated on this topic and this scientific field has been 
excellently reviewed [23,229,244]. Del Gaudio and co-
workers analysed the effects of the initial solution 
properties on the prilling process [27]. Working on a 
Variation D from Nisco Engineering AG, they differentiated 
between simple vibration-assisted dripping and laminar jet 
break-up, i.e. vibrating nozzle method. Recently, Auriemma 
et al. produced by prilling piroxicam-loaded pectin blend 
microspheres, which were further coated for colonic 
delivery [245]. Homar et al. showed how 
microencapsulation by prilling could be useful to formulate 
poorly soluble drugs [24]. In their study, they were able to 
form core/shell microcapsules with an Inotech IE-50 R 
encapsulator using a concentric nozzle apparatus. A 
ketoprofene-loaded self-microemulsifying system (SMES) 
provided the core compartment, whereas the outer shell 
was formed by employing an alginate solution. Several 
aqueous hardening baths were used, employing CaCl2, 
ZnCl2, AlCl3, or chitosan as cross-linking agents. More 
recently, Dorati and co-workers compared microcapsules 
formed using an Encapsulator B-395 Pro with 
microcapsules prepared by emulsion phase inversion 
[246]. The particles produced using the vibrating nozzle 
method demonstrated better entrapment, worked at mild 
conditions, avoided organic solvents, had high 
reproducibility, and could be prepared rapidly. Finally, a 
notable example of non-aqueous media for prilling was 
suggested by Zhang and Rochefort, who prepared 
polyethyleneimine microspheres loaded with enzymes 
using the vibrating nozzle [26]. This approach employed 
polymer interfacial reticulation with sebacoyl chloride that 
was dissolved in the cyclohexane hardening bath. The use 
of non-aqueous hardening baths has been pioneered by 
Buthe et al. [247], and it was proposed for protein 
microencapsulation by Zhou et al. [248]. However, it entails 
the complete removal of the toxic organic solvents of the 
hardening bath to be considered for pharmaceutical use. 
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2.4.2 Polymers for prilling 
Different compounds can be used for the prilling medium 
according to the characteristics required from the formed 
microparticles. Hydrophobic prilling media have been 
suggested, such as fatty acids [234,235,249] and 
poly(lactic-co-glycolic acid) (PLGA) in acetone [250]. 
However, these systems may not be suitable for 
macromolecule microencapsulation, for which an aqueous 
milieu is preferred. If hydrophilic media are selected, the 
use of a polymer is necessary to allow microparticle 
formation. Hydrogels, i.e., gels where the main liquid 
component is water, proved to be of critical importance in 
biomedical and pharmaceutical sciences, due to their 
favourable properties in terms of tissue engineering and 
drug carrying [251–253]. Furthermore, hydrogel 
properties can be tailored to meet the therapeutic needs 
and API characteristics. For example, many hydrogels 
respond to specific physiological triggers, which allow 
modified release, or have mucoadhesive properties [254]. 
The transition from polymeric solution to a gel requires 
cross-linking in the hardening bath. Several types of cross-
linking are known, both of chemical and physical nature, 
which have been thoroughly reviewed by Hennink and van 
Nostrum [255]. Most chemical cross-linkers have relevant 
toxicity, requiring potential health hazards and lengthy 
removal steps. Physical approaches, such as temperature, 
pH, ionic strength, non-covalent bonds, and hydro- and 
lipophilicity, are inherently less toxic and the gelling step 
can be easily controlled. Therefore, physical cross-linking is 
generally the preferred method for microcapsule 
production. 
Among the different hydrophilic polymers available (Figure 
2.6), alginates currently represent the state of the art for 
prilling [232,256,257]. This water-soluble anionic 
polysaccharide is composed of 1-4 linked β-D-mannuronate 
and α-L-guluronate, and it is found naturally in the cell walls 
of brown algae. The carboxylic groups allow cross-linking 
with divalent ions such as barium and zinc [258,259], but 
calcium is the most used for microencapsulation [260,261]. 
In terms of oral delivery, alginates have shown some 
mucoadhesive properties [262], especially in combination 
with other polymers [263], and are also suitable for protein 
entrapment [264]. Chemical modifications have been 
proposed to improve drug delivery properties [265,266]. 
Along with alginate, chitosan gels have demonstrated 
promising drug delivery and microencapsulating 
properties on in vitro and in vivo models [188,195,267,268]. 
Chitosan is a cationic polysaccharide formed by de-
acetylation of chitin, a polymer commonly found in 
crustacean shells, and is composed of 1-4 linked β-D-
glucosamine (Figure 2.6). Although this polymer is soluble 
only at acid pH, chitosan has successfully been used to 
 
FIGURE 2.6 - Chemical structures of natural and semi-synthetic polymers for prilling. 
Chapter 2. Theoretical section   20 
 
 
microencapsulate peptides and polymers [269]. The 
cationic nature of this polymer, due to the amine group on 
its glucosamine monomers, allows ionotropic gelling using 
tripolyphosphate ions [270,271] (Figure 2.6). Furthermore, 
chitosan microparticles possess mucoadhesive and 
permeation-enhancing properties useful for oral 
administration [169,272,273]. 
Many chitosan derivates have been synthesised to enhance 
its pharmaceutical properties, such as solubility across a 
wider pH range [192,274–276]. The most promising 
chitosan derivates are anionic mono-N-carboxymethyl 
chitosan (MCC) and cationic trimethyl chitosan (TMC) 
[277–279], and have been used for entrapment of 
macromolecules [280,281] and in prilling [28]. Several 
other polymers have been proposed for prilling. 
Carrageenan was used by Patil and Speaker to successfully 
encapsulate horse radish peroxidase via prilling [282]. 
Auriemma et al. compared prilled pectin and alginate-
pectin blends after Eudragit® S100 coating for piroxicam 
microencapsulation [245]. Due to ionotropic cross-linking, 
as well as thermal hysteresis, gellan gum has promising 
gelling characteristics suitable for prilling [283]. 
2.5 Multi-compartmental drug 
delivery systems (DDS) 
Multi-compartmental DDS appear as an attractive and 
promising formulation approach for advanced dosage 
forms, which has been gaining momentum in recent years. 
However, there is still a lack of an exact definition for these 
systems. A multi-compartmental DDS is a dosage form that 
has different and distinguishable structural regions, which 
may be also defined as domains or compartments. Each 
compartment may present itself in liquid, solid, or gaseous 
phase. Moreover, in case of liquids, different phases may be 
present that separate hydrophilic from lipophilic 
formulation domains. A compartmentalised drug delivery 
system is desired to exhibit reduced API diffusion or 
migration between regions. Different approaches can be 
used to ensure this separation, for example by creating 
physical boundaries (polymeric coating), by embedding the 
API in a solid structure (polymeric matrix, solid wax), or 
simply by chemical affinity (poorly water-soluble drugs in a 
micelle). Care must be taken not to confuse a multi-
compartmental DDS with a multiple unit dosage form. In the 
former case, a DDS is classified by the number of regions 
with identical physicochemical properties, whereas the 
latter definition simply indicates whether the dosage form 
is divided into smaller fractions. Multi-compartmental DDS 
are particularly advantageous due to their inherent 
versatility, which justifies their level of complexity. Each 
compartment possesses distinct features that allow 
different delivery possibilities and technical manufacturing 
solutions. For example, different release kinetics may be 
applied to each compartment, to ensure pulsatile delivery 
[284]. Different types of coatings can respond to different 
stimuli and triggers, ensuring optimal targeting [285]. 
Furthermore, size hierarchies (micro- and nanoparticles) 
can be used to exploit dimension and morphology-related 
properties [286]. One of the most prominent exponents of 
this last category, namely Nanoparticle-in-Microsphere 
Oral Systems (NiMOS), will be comprehensively discussed 
in Paragraph 2.5.1. 
Several types, geometries, and combinations of multi-
compartmental DDS have been proposed over the last 
decades. A typical approach to form these structured DDS is 
by applying multiple coatings over a central core. This 
creates a series of concentric layers with different 
properties (Figure 2.7a). For example, the group of Del 
Curto further developed the Chronotopic® system 
[285,287]. Herein, a fast-dissolving insulin-containing core 
(i) is coated with an HPMC layer (ii) to delay protein release 
and separate the API from the protease inhibitor-loaded 
 
FIGURE 2.7 – Schematics of multi-compartmental drug 
delivery systems. In (a): multi-layered Chronotopic® 
system, with insulin-containing core (i), first HPMC 
layer (ii), protease inhibitor-loaded coat (iii), second 
HPMC layer (iv), and enteric trigger coating (v). In 
(b): PORT System® capsule, with semi-permeable 
capsule body coating (vi), osmotically active 
compartment (vii), retarded release drug dose (viii), 
insoluble sliding plug (ix), immediate release drug 
dose (x), and water soluble capsule cap (xi). In (c): 
gastroretentive system, with drug-loaded alginate 
core (xii), air compartment (xiii), and buoyancy shell 
(xiv). In (d): different geometries of Janus 
nanoparticles with different drugs or properties. 
Chapter 2. Theoretical section   21 
 
 
layer (iii). This is in turn coated with a further HPMC coating 
(iv), which has defined swelling and erosion time to account 
for transit duration in the small intestine. Finally, an enteric 
coating (v) is applied, which acts as a trigger for the swelling 
of the most external HPMC layer (iv). 
Capsules can also be used to create multi-compartment 
systems. For example, the PORT System® first patented by 
Amidon in 1995 can be modified to have three 
compartments to achieve pulsatile release (Figure 2.7b) 
[288,289]. Briefly, a capsule body covered in semi-
permeable coat (vi) is filled with osmotically active 
excipient (vii) and a mixture of API (viii). This compartment 
is covered by an insoluble wax-based sliding separator (ix). 
On top of this separator, another compartment contains a 
separate dose of API (x), and finally the non-coated cap head 
is locked on the body (xi). After ingestion, the cap (xi) is 
readily dissolved and the first dose of API (x) is released. 
Meanwhile, water steadily penetrates through the body (vi) 
into the lower compartment (vii) and creates an osmotic 
pressure that pushes the separator layer (ix). At a given 
time, the separator exits the body and the second API dose 
(viii) can be released. Similar technologies, which are also 
available on the market, have been described in edited 
books by Rathbone and co-workers [290–292]. 
Another notable example of multi-compartment system is a 
gastroretentive formulation (Figure 2.7c), introduced by 
Iannuccelli et al. [293,294]. This system is formed by an 
API-containing alginate bead (xii) located in an empty 
cavity (xiii) formed within an alginate/polyvinyl alcohol 
(PVA) outer shell (xiv). The presence of the outer 
membrane (xiv) traps the air in the system (xiii), which 
allows buoyancy. Upon release, the alginate core (xii) may 
allow some mucoadhesion and prolong the release. 
Recently, multi-compartment anisotropic particles have 
been proposed as DDS. These systems are usually defined 
as Janus particles, but several geometries are available 
(Figure 2.7d). Janus particles are formed with different 
polymers using different techniques such as microfluidics 
[295] or electrohydrodynamic co-jetting [296]. In terms of 
drug administration, they have been used for API co-
administration [295], modified release kinetics [297,298], 
targeting [299,300], and theranostics [301]. Excellent 
reviews on manufacturing and on applications of these 
particles are available [30,302]. Further other pioneering 
multi-compartment DDS exist, for example vesosomes and 
dendrosomes [303–305], and this field of pharmaceutical 
sciences is rapidly moving towards highly structured 
systems and closely approaching that of biomimicry [306–
308]. 
2.5.1 Nanoparticle-in-Microsphere Oral System 
(NiMOS) as dosage forms 
NiMOS are multi-compartmental systems which have a 
hierarchical organisation. Kriegel defines NiMOS as solid-
in-solid multi-compartmental systems, differentiating them 
from solid-in-liquid systems (also known as nanoparticles-
in-emulsions, NiE) [309] and from liquid-in-liquid systems 
(such as W/O/W multiple emulsions) [310]. Specifically, 
NiMOS are API-loaded polymeric nanoparticles that are 
located in polymeric microspheres. The definition of NiMOS 
was first proposed by Bhavsar et al., who formed 
fluorescently labelled gelatine nanoparticles and embedded 
them in poly(ε-caprolactone) (PCL) microspheres [311]. 
Briefly, the nanoparticles were prepared by adding ethanol-
aided gelatine precipitation. The nanoparticle aqueous 
suspension was emulsified with PCL and dichloromethane. 
After addition of PVA, the dichloromethane was removed by 
evaporation and the microspheres were lyophilised. NiMOS 
demonstrated suitability for macromolecule delivery in 
subsequent experiments. Accordingly, these multi-
compartment systems were loaded with plasmid DNA 
vectors to test for local intestinal transfection and with 
small interfering RNA (siRNA) to treat inflammatory bowel 
disease [29,312–314]. A similar nano-in-micro approach 
was introduced by Kaye and his team for pulmonary 
delivery of a model antibody using a spray drying process 
[315]. 
NiMOS have shown a synergic combination of nanoparticles 
and microspheres [316]. Nanoparticles alone have shown 
great potential for oral delivery of proteins and other 
macromolecules [31,317,318]. The main characteristic of 
these particles is certainly their size. Nanoparticle sizes 
around 100 nm have proven especially effective in mucus 
penetration, and can eventually be taken up by local 
immune cells and macrophages [142,319]. Furthermore, 
the polymer used for this compartment may also be useful 
to optimise delivery and ensure uptake from the luminal 
lining. Polymer properties are also highly relevant for the 
microsphere compartment in which the nanoparticles are 
embedded. As earlier described, polymers can possess 
biopharmaceutically promising properties, such as 
mucoadhesion or permeation enhancement, or even a 
combination thereof. When a macromolecular drug is 
present and oral delivery is required, the polymer must 
allow the microsphere to protect the API from enzymatic 
degradation. To ensure macromolecular stability, protease 
inhibitors may be loaded in the microsphere compartment. 
NiMOS, thus, should possess the aforementioned properties 
whether local or systemic action is intended. 
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2.5.1.1. Clay nanotubes – halloysite (HNT) 
Currently, the geometry of NiMOS compartments is limited 
to spherical nanoparticles and microspheres. Among other 
nano-geometries suitable for this system, nanotubes have 
shown great potential in terms of drug delivery, but their 
toxicity and cost remain strong concerns for development 
[320,321]. In recent years, however, a new type of natural 
and non-toxic nanotubes called halloysite (HNT) has been 
proposed for biomedical applications [322,323]. Halloysite 
is an aluminium silicate clay mineral extracted from 
quarries worldwide. Its structure is formed by repeated 
Al2Si2O5(OH)4∙nH2O units that are distributed in layers 
[324]. These layers are overlapped and folded as a scroll to 
form a nanotubular structure (Figure 2.8a). The silicate 
groups SiO4 form tetrahedron-like structures placed on the 
external surface of the layer, whereas the aluminium groups 
AlO6 have an octahedral geometry and are located on the 
inner surface [325]. This diverse distribution of silicate and 
aluminate groups creates a specific charge distribution. The 
external nanotube surface is negatively charged, whereas 
the luminal surface has positive charge. Furthermore, the 
aluminium luminal groups are hydrated as Al(OH)2 
aluminol groups. Generally, HNT display a length from 
200 nm to 2 μm, inner diameter from 5 to 20 nm, and 
external diameter 40 to 100 nm [321]. The specific surface 
can vary greatly, between 50 and 150 m2 g-1. The great 
variability is to some extent due to the mining site of the 
halloysite clay [326,327]. HNT have been introduced as 
drug delivery systems by Price and co-workers [328]. 
Herein, two small molecules and a dinucleotide were loaded 
in HNT and were subsequently released, obtaining 
prolonged releases over several hours, which was 
depending on the given compound. The HNT use for 
pharmaceutical purpose has since increased, for example 
using doxycycline for periodontitis treatment [329], 
diltiazem and benzalkonium chloride [330], and different 
poorly water-soluble drugs [331]. The purpose of HNT-
based DDS is to have the API within the HNT lumen and 
adsorbed on the surface. To achieve HNT loading, the 
concentrated API solution is mixed with the suspended 
halloysite. Vacuum is applied to remove air from the lumen, 
as it hinders the capillary force-driven penetration of the 
API-containing solution due to surface tension [332–334]. 
While electrostatic interactions (due to HNT charge 
distribution) would lead to preferential attraction of the 
drugs molecules, these may still be adsorbed on either side 
of the nanotubes [321]. Furthermore, Cornejo-Garrido et al. 
showed promising anti-inflammatory properties of HNT 
per se [335]. In most recent applications, HNT have been 
used to form biocomposite nanomaterials and mesoporous 
drug carriers [334,336–338]. 
Halloysite is also interesting regarding its great versatility 
in terms of chemical modifications [322], and some 
examples are hereby listed. To increase loading capacity, 
the HNT lumen has been chemically etched both in acid and 
in alkaline conditions [339,340] as shown in Figure 2.8b 
[325]. In both cases, the chemical etching acts selectively in 
the inner lumen acting on the aluminium groups. Another 
chemical modification was proposed by Yuan et al., who 
functionalised the internal aluminol groups with 
γ-aminopropyltriethoxysilane (APTES) to increase dye 
loading [333]. Not only the dye loading was increased by 
interaction with the chemical groups introduced, but also 
the release kinetic was successfully modified. Guo and co-
workers modified HNT with respect to an application in 
cancer treatment [341]. Briefly, the external silica groups 
were activated and grafted with Fe3O4 and folic acid. The 
particles were finally loaded with doxorubicin, and 
selective cancer cell toxicity was demonstrated in vitro. In 
terms of polymer wrapping of HNT, Zhai et al. used chitosan 
to anchor horseradish peroxidase (HRP) to HNT for phenol 
removal from wastewater [342]. Chitosan, owing to its 
cationic nature, adhered to the negatively charged external 
HNT surface. Glutaraldehyde was used to activate the N-
termini of chitosan, and then the polymer-HNT was 
incubated with HRP. This system showed increased loading 
and HRP survived the grafting while maintaining its 
activity. Shamsi and co-workers proposed a technically 
advantageous polymeric wrapping of HNT by adhering DNA 
on its external surface, and were able to completely 
solubilise the nanodispersion, further increasing its 
stability [343]. 
 
FIGURE 2.8 – Chemical structure of halloysite 
nanotube before (a) and after chemical etching (b). 
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It is finally interesting to mention an analogue clay mineral, 
imogolite, which has inverted disposition of alumina and 
silica, and consequently opposite charge distribution [344]. 
It further displays longer length (1-5 μm), smaller diameter 
(2-10 nm external, 1-5 internal), and higher surface area 
(300-400 m2 g-1) [321]. Another major difference from 
HNT, is that imogolite is single-walled and available only in 
very small quantities, whereas halloysite is multi-layered 
and can be supplied on a scale of industrial quantities. 
2.6 Quality aspects of drug 
formulation 
2.6.1 Quality-by-Design (QbD) initiative and LB 
suspensions 
Quality in drug formulation is pivotal throughout the 
product’s life cycle, starting from the raw materials, going 
through manufacturing process and shelf-life, up to 
administration and in vivo performance. The definition of 
quality in pharmaceutical development comes from two 
viewpoints, one focusing on the compliance to 
specifications, the other on the respect of the expected 
therapeutic benefit [32,34,345]. In terms of pharmaceutical 
quality, the objective is to create a product capable of 
carrying out a therapeutic action, comply with regulatory 
aspects, be reproducible and thoroughly documented. 
Furthermore, it should be obtained according to a defined 
process where variables are accounted for and all potential 
issues are known and understood. According to the 
“Guidance for Industry, Q8(R2) Pharmaceutical 
Development” issued by the Food and Drug Administration 
(FDA) [34]: 
“The aim of pharmaceutical development is to design a 
quality product and its manufacturing process to 
consistently deliver the intended performance of the 
product. The information and knowledge gained from 
pharmaceutical development studies and manufacturing 
experience provide scientific understanding to support the 
establishment of the design space, specifications, and 
manufacturing controls” 
These guidelines are aimed to surpass a previously 
established concept of quality, namely Quality-by-Testing 
(QbT) [32,346]. QbT is based on the idea that drug product 
quality comes from raw material quality and the respect of 
FDA-approved specifications according to a static 
manufacturing process. Whenever the drug product does 
not meet specifications, the entire production batch is 
discarded. The manufacturer may submit supplements to 
the controlling authority to revise acceptance criteria. This 
process is usually time consuming and expensive, since 
each in-process variation needs to be adequately 
documented at the regulatory authority. Pharmaceutical 
Quality-by-Design (QbD) proposes a different approach to 
similar issues. According to Yu, pharmaceutical QbD 
represents an approach to develop a drug product by 
thoroughly understanding and controlling product and 
process by identifying a series of critical quality attributes, 
process parameters, and sources of variability [32,346]. 
Thus, the idea is that pharmaceutical quality should be 
designed into the drug product. The QbD approach was first 
proposed by Juran [347], and it has been eventually 
accepted for the pharmaceutical industry by the FDA in 
2004 [33]. The most important terms of QbD are listed in 
Table 2.7, as defined by the FDA [34]. 
Different tools are suggested to evaluate the criticalities of 
a pharmaceutical development process or of a given factor. 
Risk assessment tools can help identifying the critical 
variables in process and formulation, e.g., Ishikawa 
diagrams, and ranking said criticalities, e.g., by a failure 
mode and effect analysis (FMEA). The impact of each risk 
can be then evaluated through statistical analysis after 
conducting thorough and systematic experimental work. 
Gaining such extensive understanding of both process and 
formulation factors on CQAs is an important goal to define 
a design space. The most used approach that may be used 
here is the Design of Experiments (DoE), and this topic is 
described in Paragraph 2.6.2. QbD and DoE are so often 
jointly applied in formulation development that the 
definition of Formulation-by-Design (FbD) is used in these 
cases [348]. While FDA guidelines generally use the word 
critical material attributes (CMA) for raw material variables 
affecting CQAs of the final product, Singh used the more 
specific (but non-official) term critical formulation 
attributes (CFA).  
QbD, or rather FbD, has found application for different types 
of drug formulation processes, for example tabletting [349–
351], suspension [352], or co-precipitation [353], as well as 
for biotechnological products [354]. As for LB systems, 
formulation development according to QbD has been 
employed for different types of DDS. Dhawan and co-
workers developed a SLN formulation for quercetin to 
improve the permeation across the blood-brain barrier to 
better reach the central nervous system [355]. After 
defining CFAs and CPPs, Dhawan’s team could identify a 
formulation with a known design space that could meet the 
in vivo therapeutic specifications. After a preliminary QbD-
based evaluation of hydrophilic API in liposomes [356,357], 
Xu and co-workers recently analysed formulation and 
processing of enzyme-loaded liposomes within the QbD 
framework [358]. Not only they conducted a typical DoE-
modelled set of experiments, but they also proposed a risk 
assessment charts for each of the liposome’s CQA. This work 
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allowed the identification of a suitable design space for this 
formulation. A final example of successful implementation 
of QbD on a LB system was performed by the group of Pund 
during the formulation of cilostazol, a platelet aggregation 
inhibitor, as self-nanoemulsifying drug delivery system 
(SNEDDS) [359]. In this work, the QbD strategy was applied 
by using DoE to understand the effect of the formulation 
components on final LB system’s CQA. Multivariate analysis 
was employed as a complementary tool for DoE to correctly 
model the effect on the selected response variables, namely 
droplet size and its distribution, equilibrium solubility, 
ζ-potential, and dissolution efficiency, in order to chart an 
optimal design space for the SNEDDS. 
2.6.2 Design of Experiments (DoE) and statistical 
analysis 
A DoE, also called formal experimental design, is “a 
structured, organised method for determining the 
relationship between factors affecting a process and the 
output of that process” [34]. The main areas of application 
for DoE are comparing, screening, characterising, 
modelling, and optimising. Thus, in agreement with what 
was previously explained (Paragraph 2.6.1.), the DoE 
systematic approach can be viewed as integrated in the QbD 
initiative. Some DoE studies have not a particular focus on 
process understanding but rather emphasise how 
formulation factors impact CQA of the product. For 
example, Pawar et al. screened, developed, and optimised 
an oil formulation to increase curcumin oral bioavailability 
using DoE [360]. Many other studies employed DoE under 
the QbD initiative, including designs of LB DDS 
[355,358,359,361–363]. DoE represents an evolution of 
previously employed techniques to optimise process or 
formulations [35,364]. This traditional approach is defined 
as changing one single (or separate) variable or factor at a 
Time (COST). Other known definitions are one variable at a 
time (OVAT), or one factor at a time (OFAT) [365–367]. This 
approach is extremely specific and is unsuitable to evaluate 
multiple factors at the same time, because it ignores 
interactions among variables. Furthermore, the COST 
approach is extremely time consuming and expensive. DoE 
obviates these drawbacks of the COST approach [368,369]. 
Although DoE appears in the official FDA guidelines only at 
the beginning of the 21st century, DoE was first developed 
in 1925 by Fisher [370]. A main limitation to DoE 
implementation was the calculation of the mathematical 
equations underlying optimisation. With the advent of 
modern computers and dedicated software, however, this 
drawback was easily overcome. 
The core component of DoE is the layout of the 
experimental runs to be carried out, i.e., the experimental 
design. Several types of experimental designs are available, 
e.g., factorial [371], Placket-Burman [372], central 
composite design [373], Box-Behnken [374], or d-optimal 
[375], and have been reviewed, for example, by Singh [35]. 
The choice of the best experimental design is taken 
according to the study’s aim, the number of factors to be 
TABLE 2.7 – Brief glossary of Quality by Design terms. 
Term Definition 
Quality by Design 
(QbD) 
Systematic approach to development that begins with predefined objectives and 
emphasises product and process understanding and process control, based on sound 
science and quality risk management. 
Quality Target Product Profile 
(QTPP) 
Prospective summary of the quality characteristics of a drug product that ideally will 
be achieved to ensure the desired quality, taking into account safety and efficacy of the 
drug product. 
Critical Quality Attribute 
(CQA) 
A physical, chemical, biological, or microbiological property or characteristic that 
should be within an appropriate limit, range, or distribution to ensure the desired 
product quality. 
Critical Process Parameter 
(CPP) 
A process parameter whose variability has an impact on a critical quality attribute and 
therefore should be monitored or controlled to ensure the process produces the 
desired quality. 
Design Space The multidimensional combination and interaction of input variables (e.g., material 
attributes) and process parameters that have been demonstrated to provide assurance 
of quality. Working within the design space is not considered as a change. Movement 
out of the design space is considered to be a change and would normally initiate a 
regulatory post-approval change process. Design space is proposed by the applicant 
and is subject to regulatory assessment and approval. 
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analysed, and the type of model desired [376]. As earlier 
mentioned, a design model can be chosen according to the 
type of factor to be analysed, i.e., formulation, process, or 
both. The number of factors represents the number of 
independent variables to be considered during the DoE. 
Since DoE proposes an equation to fit and predict the 
relationship between experimental factors and response 
variables, the choice of the model basically defines the order 
and the complexity of this equation. Linear models result in 
a first approximation of the experimental main effects and 
interaction models are essentially a key advantage of DoE 
compared to the COST approach. Quadratic models are used 
especially in formulation optimisation, and higher order 
models are usually avoided in pharmaceutical DoE because 
the efficiency in terms of the number of experiments and 
gained information is comparatively low. The desired DoE 
output reflects the study’s objectives. Screening designs are 
employed to identify the effects deemed relevant for the 
formulation or process properties. Screenings can be 
carried out with a small number of experimental runs while 
investigating several factors. This approach avoids the use 
of large DoE study plans that would be excessively time 
consuming. The main drawback of using screening design is 
that the employed models are usually not suitable to 
identify factor interactions. Subsequently, a factor influence 
study can be carried out on significant factors, to assess the 
extent of the interactions between independent variables. 
Care must be taken in a critical analysis of the proposed 
interactions. In fact, the scientist must take in consideration 
the acceptability and the sense of the interaction which 
have been found statistically relevant. Finally, to define an 
optimal formulation or processing area, a response surface 
design may be used on the relevant factors. Herein, the DoE 
allows plotting a surface which includes factor interactions 
as well as non-linear terms. The factor effects (and 
interactions thereof) are plotted to better understand for 
example optima and minima of the response variables. 
Interesting is often also the region around a local extreme 
as it indicates how robust a “sweet spot” is. 
To obtain equations capable of fitting and predicting the 
effect relation between factors and responses, different 
mathematical and statistical tools can be applied: 
 Ordinary least square (OLS) regression [377]. Also 
defined as linear regression, is a method to 
correlate the explanatory factors (defined as 
independent variable X) with the response 
variables (defined as dependent variable Y) 
according to Equation 2.17: 
 𝑌 = 𝛽0 + 𝛽1 ∙ 𝑋1 2.17 
The values of coefficients β are found by 
minimising the error of prediction. OLS can be 
used also for higher orders of the same 
independent variable, as shown in Equation 2.18: 
 𝑌 = 𝛽0 + 𝛽1 ∙ 𝑋1 + 𝛽11 ∙ 𝑋1
2 2.18 
OLS is widely used but it cannot fit factor 
interactions.  
 Multiple linear regression (MLR) [378]. This 
technique uses the same principle as OLS, but it 
can be applied to different independent variables, 
as shown in Equation 2.19: 
 𝑌 = 𝛽0 + 𝛽1 ∙ 𝑋1 + 𝛽2 ∙ 𝑋2 + 𝛽1 ∙ 𝛽2 ∙ 𝑋1
∙ 𝑋2 
2.19 
Like OLS, MLR can be used for higher order 
interactions and terms. MLR, however, is not 
suited to fit more than one Y, and the data may be 
misinterpreted in case of co-linearity between X 
variables. 
 Principal component analysis (PCA) and principal 
component regression (PCR) [379]. PCA identifies 
the sources of highest data variation among the X 
variables. PCA is carried out by identifying 
eigenvectors and eigenvalues. When the data is 
represented in set of Cartesian axes, an 
eigenvector is a line that crosses the dataset to 
ensure the greatest variance among the data 
(Figure 2.9a). The eigenvalue represents the 
extent of this variation. The eigenvector with the 
highest eigenvalue is the principal component. 
The number of eigenvectors, and consequently 
eigenvalues, is the same as the number of the 
analysis’s dimensions. Furthermore, each 
eigenvector must be orthogonal to the other 
(Figure 2.9b). Eigenvectors with low eigenvalues 
can be discarded, thus creating systems with 
fewer dimensions but still accounting for most 
experimental variability. Thus, the data can be 
plotted using the discovered principal 
components as Cartesian axes, and used as 
classification tool to identify data clusters and 
outliers (Figure 2.9c). The PCR is then operated 
similarly to OLS or MLR, using the principal 
components as X variables versus the selected 
response variable (Figure 2.9d). PCR can be 
carried out with a very high number of X variables 
without having a higher sample number, and is 
not altered by X variable co-linearity. 
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 Partial least squares (PLS) regression [380]. This 
regression technique allows fitting and predicting 
several X variables with different Y variables. In 
PLS, a vector explaining the most variation in Y is 
plotted, similarly to a principal component 
(Figure 2.10a). Then, a vector that best explains 
the Y vector is plotted among the X variables 
(Figure 2.10c). The second vector, however, is not 
necessarily a principal component for X variables. 
The scores of these factors can be plotted on a 
Cartesian system and a model equation can be 
fitted (Figure 2.10b). More vectors can be fitted to 
account for additional variation among Y and X 
variables. PLS regression can evaluate on different 
X and Y variables at the same time and it copes 
with data multiple co-linearity. Furthermore, 
categorical X variables can be analysed with 
partial least square discriminant analysis (PLS-
DA). 
 While different models can be plotted with the 
aforementioned tools, the fitting and the predictivity of 
these systems is usually evaluated with R2 and Q2, 
respectively. The R2 is calculated according to Equation 
2.20: 
 
𝑅2 = 1 −
𝑆𝑆𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙
𝑆𝑆𝑡𝑜𝑡𝑎𝑙
 2.20 
Where SSresidual is the residual sum of squares and SStotal the 
total sum of square, which are calculated according to 
Equation 2.21 and 2.22, respectively. 
 𝑆𝑆𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 = ∑(𝑦𝑖 − 𝑓𝑖)
2 2.21 
 𝑆𝑆𝑡𝑜𝑡𝑎𝑙 = ∑(𝑦𝑖 − ?̅?)
2 2.22 
Where yi represents a given data point, fi is a predicted data 
point, and ӯ is the mean of observed data. In case of the Q2, 
instead, the calculation follows Equation 2.23: 
 
FIGURE 2.9 – Graphical explanation of principal 
component analysis (PCA) and principal component 
regression (PCR). Identification of first principal 
component (PC; a), identification of orthogonal PC 
(b), dimension reduction and Cartesian system 
change (c), and regression (d). 
 
FIGURE 2.10 – Graphical explanation of partial least square (PLS) regression. Plotting of vector u1 that explains most Y 
variability (a), plotting in X of vector t1 that explains Y variability (c), and plotting of data scores using u1 vs. t1 as 
Cartesian system (b). 
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𝑄2 = 1 −
𝑃𝑅𝐸𝑆𝑆
𝑆𝑆𝑡𝑜𝑡𝑎𝑙
 2.23 
Where PRESS is the predicted residual sum of squares. 
PRESS is a form of cross-validation that is obtained from the 
observed values yi and the predicted values (fi,-i). The value 
fi,-i is obtained by omitting the relative observed value from 
its calculation, one at a time. The PRESS calculation is 
expressed as Equation 2.24: 
 𝑃𝑅𝐸𝑆𝑆 = ∑(𝑦𝑖 − 𝑓𝑖,−𝑖)
2
 2.24 
Many other mathematical, statistical, and graphical tools 
are available to evaluate and optimise DoE, as well as to 
understand large datasets, e.g., artificial neural networks 
[381,382]. Statistics are strongly entwined in modern 
pharmaceutics to develop novel formulations, identify 
relevant effects in all steps of development, and embed 
quality in a pharmaceutical process. 
 
 
 Chapter 3 
Design and manufacturing of 
novel LB systems for oral protein 
delivery 
3.1 On prilling of hydrophilic 
microgels in lipid dispersions using 
mono-N-carboxymethyl chitosan for oral 
biologicals delivery † 
3.1.1 Summary 
Oral delivery of biologicals is a thriving field in 
pharmaceutics and a first challenge is to achieve a stable 
drug product. Interesting is prilling of an API as microgel 
into an aqueous hardening bath where cross-linking occurs. 
However, to deliver a final dosage form, e.g., soft gelatine 
capsules, the aqueous hardening bath must be removed, 
thus leading to manufacturing processes that are 
potentially harmful for the active. The current work 
introduces a prilling method with a lipid-based hardening 
bath, which could theoretically be filled directly into 
capsules. Bovine serum albumin (BSA) and mono-N-
carboxymethyl chitosan (MCC) were selected as model 
biological and encapsulating polymer, respectively. Several 
non-aqueous formulations of the receiving bath were 
investigated; calcium chloride was added to these 
formulations to allow the MCC gelling. The obtained 
microgels had average diameters of ~300 µm and spherical 
to toroidal shapes, according to the hardening bath 
                                                                        
†  de Kruif JK et al. On prilling of hydrophilic microgels in lipid dispersions using mono-N-carboxymethyl chitosan for 
oral biologicals delivery. Journal of Pharmaceutical Sciences, 2014, 103, 3675-3687. 
composition. Along with a high encapsulation efficiency 
(> 85%), the microgels protected the BSA from any 
denaturing effect of the hardening bath. The release study 
showed a rather fast BSA release within the first 10 minutes 
from most microgels. This novel approach demonstrated 
technical viability for encapsulation of biologicals using 
lipid formulations regarding oral delivery. 
3.1.2 Introduction 
Microencapsulation, which is the formulation of an API or 
cells in a microsphere, microgel, or microcapsule, is a 
well-established approach for oral delivery of active 
compounds. Since its introduction, drug inclusion in such 
microparticles has constantly gained interest, both from 
academia and industry, in terms of scientific publications 
and patents [383]. Microencapsulation has also been 
identified as a very promising platform for the 
administration of proteins,[187,384,385] because these 
compounds require specific characteristics from their 
delivery system, e.g., prevention from gastrointestinal 
degradation, targeted release, and absorption 
enhancement, which can potentially be enabled by this 
method [183]. Several microencapsulation techniques have 
been introduced in the literature, such as coacervation 
[386], emulsification [227], spray drying [387], and 
microfluidics [388], and have been reviewed elsewhere 
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[22,389]. However, these processes require complex 
handling and several steps to successfully achieve a final 
dosage form with an acceptable yield and product stability. 
Particularly critical for macromolecules are processes that 
use high–shear forces (emulsification), and extreme 
temperatures, such as drying and lyophilisation [12,175]. 
The vibrating nozzle technique is based on the extrusion of 
a laminar jet of a polymeric solution, which is broken up 
into separate droplets by vibration. This technique is also 
known as prilling. The API is usually dissolved or 
suspended in the extruded liquid. The forming droplets are 
collected in a hardening bath, where the gelling or cross-
linking of the polymer takes place (Figure 3.1). This 
technique, which was first introduced by Hulst et al. [390], 
finds its physical explanation in the Plateau-Rayleigh 
instability [230]. Herein, the surface tension of the falling 
liquid stream forms droplets to minimise the surface area. 
The applications of this technique are wide, embracing 
fields such as pharmaceutics (e.g., modified release drug 
delivery systems) and biology (e.g., microbeads for cell 
entrapment), and are elsewhere well described [23,229]. 
The vibrating nozzle system has been further developed 
with a ring electrode that charges electrostatically the 
droplets and thus prevents their coalescence by 
electrostatic repulsion (Figure 3.1) [238]. Moreover, 
Brandenberger and Widmer proposed a scale-up version of 
the system, although without the ring electrode [233]. 
Many polymers have been used with the prilling technique, 
such as alginate [391,392], chitosan [267], PLGA [250], or 
even polymeric mixtures [245]. Especially chitosan, a 
natural linear polysaccharide composed of D-glucosamine 
and N-acetyl-D-glucosamine, displays interesting 
properties for drug delivery [268,269,393]. However, its 
aqueous solubility profile represents a limitation when 
neutral to alkaline pH is required, because it only dissolves 
in acidic conditions. Many modifications have therefore 
been proposed to optimise its potential as a suitable 
polymer for oral drug delivery [192]. Among others, the 
chitosan derivates N,N,N-trimethyl chitosan and 
mono-N-carboxymethyl chitosan (MCC) , showed 
promising results for drug delivery, although the former has 
comparatively higher cell toxicity issues than the latter, due 
to the cationic interaction of the trimethylated amine with 
cell membranes [278,394]. Moreover, MCC is also known 
for its mucoadhesive and permeation enhancing properties, 
which can contribute to improve oral bioavailability 
[169,395,396]. 
For an efficient encapsulation, the polymers used in prilling 
should display a prompt onset of gelling. The fastest way to 
allow it is by ionotropic cross-linking. This is achieved by 
adding a counter-ion (e.g., calcium chloride or pentasodium 
triphosphate for alginates and for chitosan, respectively) 
into the receiving bath before dropping the polymeric 
solution. Calcium ions are suitable to cross-link MCC, as 
shown by Liu et al. [397], due to the ionic interaction 
between the divalent cation and the carboxylic group 
attached on the N-terminus of the glucosamine monomers. 
This approach also avoids the toxicity of chemically cross-
linking agents, e.g., glutaraldehyde or polyethyleneimine. 
Different cross-linking methods were excellently reviewed 
by Hennink and van Nostrum [255]. Traditionally, only 
water solutions have been used to dissolve the counter-ions 
to allow the ionotropic gelling. A notable exception is the 
work from Buthe et al. [247], who used n-hexane and 
calcium chloride dissolved in n-butanol to form alginate 
microgels. However, the polymer drops only pass through 
the non-aqueous layers but are finally gathered again in a 
water solution. The use of water as a final receiving bath for 
microgel implies that a direct filling into capsules is not 
possible, due to the expected shell incompatibility. Thus, a 
further drying process is needed to obtain a final oral 
dosage form, and the active macromolecule could therefore 
be harmed during manufacturing.  
Our aim is to introduce prilling of hydrophilic microgels in 
lipid-based systems that allow the ionotropic gelling of the 
polymer in media that are suitable for direct filling into 
 
FIGURE 3.1 – Schematics of vibrating nozzle apparatus. 
1 pumping system (syringe) containing the API and 
the polymeric solution; 2 vibrating unit; 3 nozzle; 4 
electrode ring; 5 hardening bath. 
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capsules. Accordingly, a viable dosage form for oral delivery 
of macromolecules would be achieved using this process, 
which can then be further tailored according to the target 
region in the human gastrointestinal tract. Bovine serum 
albumin (BSA) was selected as a model protein and the 
novel microgel dispersions were fully characterised in 
terms of loading efficiency, protein stability, and release 
from the microgels. 
3.1.3 Materials and methods 
3.1.3.1 Materials 
Transcutol® HP (ethoxydiglycol or highly purified 
diethylene glycol monoethyl ether; DEGEE) and Labrafil® 
M2125CS (linoleoyl macrogol-6 glycerides) were kindly 
offered by Gattefossé SAS (Saint-Priest, France). Capmul® 
MCM EP (glyceryl monocaprylocaprate) and Capmul® 
MCM C8 EP (glyceryl monocaprylate) were generously 
supplied by ABITEC Co. (Janesville, US). 
Mono-N-carboxymethyl chitosan (deacetylation degree 
96.1%, carboxymethylation degree 82.1%, loss on drying 
20.5%) was purchased from Shanghai Boyle Chemical Co. 
Ltd (Shanghai, China). Peppermint oil was and Imwitor® 
742 (glyceryl caprylocaprate) obtained from Hänseler AG 
(Herisau, Switzerland), and polyethylene glycol (PEG 600) 
was bought from AppliChem GmbH (Darmstadt, Germany). 
Bovine serum albumin 96% (BSA), calcium chloride 
anhydrous, propylene carbonate, guanidine hydrochloride, 
sodium chloride, sodium dihydrogen phosphate dihydrate, 
sodium hydroxide, potassium dihydrogen phosphate, and 
dipotassium hydrogen phosphate were purchased from 
Sigma-Aldrich (Saint-Louis, US). 
Tris(hydroxymethyl)aminomethane (TRIS), sodium 
dodecyl sulphate, bromophenol blue, dithiothreitol, 
glycerol, NuPAGE® MOPS SDS Running Buffer, NuPAGE® 
Bis-Tris-Gel, and SimplyBlue™ SafeStain were purchased 
from Invitrogen™ Life Technologies Inc. (Grand Island, US). 
DC™ Protein Assay, and Novex® Sharp Protein Standard 
were purchased from BioRad Laboratories AG (Cressier, 
Switzerland). The Micro BCA™ Protein Assay Kit was 
purchased from Thermo Fisher Scientific Inc. (Rockford, 
US). 
3.1.3.2 Preparation of polymeric solution and 
hardening baths 
After screening several possible polymer concentrations, a 
4.76% (dry substance; w/v) solution of MCC was prepared 
by dissolving it in demineralised water, and the complete 
hydration of the polymer was allowed by mixing overnight. 
The solution was then vacuum-filtered through glass 
microfiber filters Whatman™ GF/D, and appropriate 
amounts of BSA and sodium azide were added therein to 
obtain a 2.5% and 0.05% (w/v) solution, respectively. The 
solution was subsequently stored in a glass brown bottle at 
+4°C, and it was allowed to reach room temperature before 
each use. The blank solutions were prepared in the same 
way without adding any BSA to the solution. 
 
FIGURE 3.2 – Ternary phase diagrams of mixtures for 
formulation HBE. Evaluation of components' 
miscibility (A), calcium chloride solubility (B), and 
MCC gelling (C). White, grey, and black areas 
indicate good, medium, and poor properties of the 
formulation, respectively. 
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Several ternary phase diagrams were prepared to find a 
suitable composition for the hardening baths. Each ternary 
phase diagram comprised of 25 mixtures. An example of 
these ternary phase diagrams is shown in Figure 3.2. All 
mixtures comprised one co-solvent (ethanol or 
ethoxydiglycol), one glyceride (Imwitor® 742, Capmul® 
MCM, Capmul® MCM-C8, or Labrafil® M2125CS), and one 
complementary capsule-compatible excipient (propylene 
carbonate, PEG 600, or peppermint oil). The three 
components of the mixtures were weighed in a glass vial to 
the appropriate concentration and then mixed for one hour. 
First, the miscibility of the components was evaluated by 
visual inspection after one-hour equilibration at room 
temperature. After addition of anhydrous calcium chloride 
(4.76% w/w), the turbidity of the mixture was assessed 
after mixing thoroughly for 24 hours at room temperature. 
In the last step, the droplet gelling was evaluated by 
dropping the polymeric solution from a syringe into the 
hardening baths. The suspended droplets were then 
immediately mixed vigorously on an Ika® Vortex Genius 3 
(Hüber & Co. AG, Reinach, Switzerland) to confirm their 
gelling. The ternary phase diagrams are overlaid to select 
an optimum region where the formulations display the 
required properties [398]. Four mixtures, and three pure 
solvents and co-solvents were chosen. The compositions of 
these seven hardening baths are listed in Table 3.1. 
3.1.3.3 Hardening bath characterisation 
Since the viscosity range of the proposed hardening bath 
formulations was low, a chip-based capillary rheometer 
m-VROC™ (RheoSense Inc., San Ramon, US) was used to 
assess the rheological properties of the hardening baths. 
This device measures the viscosity from the pressure drop 
of a sample while it flows through a microfluidic slit. A 
constant shear rate of 1000 s-1 was applied while 
maintaining the sample at 25°C ± 0.15°C by means of a 
ThermoCube 200/300/400 (Solid State Cooling Systems 
Inc., Wappinger Falls, US). 
The surface tension of the samples was measured at 
25°C ± 0.5°C with the bubble method using a DynoTester 
(SITA Messtechnik GmbH, Dresden, Germany). 
TABLE 3.1 – Hardening bath composition. 
Hardening bath  Composition Ratio (w/w) Quantity e (w/w) 
HBW Water 1 95.24% 
EtOH Ethanol 1 95.24% 
HBA Transcutol® HP (ethoxydiglycol) 1 95.24% 
HBB Transcutol® HP (ethoxydiglycol) 
Imwitor® 742 (glyceryl caprylocaprate) 
Propylene carbonate 
1 : 1 : 1 31.74% 
31.74% 
31.74% 
HBC Transcutol® HP 
Capmul® MCM-C8 EP (glyceryl monocaprylate) 
Propylene carbonate 
2 : 1 : 1 47.62% 
23.81% 
23.81% 
HBD Transcutol® HP (ethoxydiglycol) 
Capmul® MCM EP (glyceryl monocaprylocaprate) 
PEG 600 
2 : 1 : 1 47.62% 
23.81% 
23.81% 
HBE Transcutol® HP (ethoxydiglycol) 
Labrafil® M2125CS (macrogol-6 glycerides) 
Peppermint oil 
1 : 1 : 1 31.74% 
31.74% 
31.74% 
e after adding calcium chloride to 4.76% of total 
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3.1.3.4 Stability of capsules filled with hardening 
baths 
Different types of two-piece hard capsules and soft capsules 
were filled with the hardening baths, and stored for two 
weeks at 40°C / 75% relative humidity and for four weeks 
at 25°C / 45% relative humidity. The excipient 
compatibility with the capsule shell materials was assessed 
visually. 
The two-piece hard capsules used were gelatine Licaps® 
(Capsugel France SAS, Colmar, France; HGC) and 
hydroxypropyl methylcellulose (HPMC) Quali-V® 
(Qualicaps® Europe SAU, Alcobendas, Spain). The capsule 
types were opaque white and of size 0. Moreover, oval soft 
capsules of size 10 with different shell materials, namely 
gelatine (SGC), starch (VegaGels®), and starch-based 
polyvinyl alcohol (S-PVA) [102], were supplied by Swiss 
Caps AG (now Aenova GmbH, Kirchberg, Switzerland). The 
two-piece hard capsules were loaded with 500 µL of the 
hardening bath formulations. The soft capsules were all 
filled with the same quantity of hardening bath formulation 
by means of syringes equipped with a 20 gauge needle. The 
thereby formed opening in the capsule was subsequently 
sealed on a hot plate. 
3.1.3.5 Manufacturing of microgels 
Microgels were prepared by means of the vibrating nozzle 
technique using the Encapsulator Biotech 
(EncapBioSystems Inc., Greifensee, Switzerland; this 
product is now commercialised by Büchi Labortechnik AG, 
Flawil, Switzerland). The solution of BSA and MCC was 
loaded in 20 mL Omnifix® plastic syringes (B. Braun 
Melsungen AG, Melsungen, Germany). The polymeric 
solution was then pumped through a 150 µm stainless steel 
nozzle, at a nominal flow rate of 3.10 mL min-1 (3.79 g min-1 
of polymeric solution). A total of 5 g of polymeric solution 
was used for each batch. The droplets were formed by 
applying a frequency of 1240 Hz and by setting the 
electrode ring to 1500 V. The hardening bath (100 mL) was 
stirred at 400 rpm at room temperature, and the droplets’ 
fall distance was approximately 13 cm. The aforementioned 
conditions were found to be optimal for the microgel 
manufacturing during preliminary investigations. The 
microgels were then left in the hardening baths for 
20 minutes before further analyses. 
3.1.3.6 Microgel morphological characterisation 
The microgels collected from the different hardening baths 
were observed through an Olympus CKX41SF microscope 
(Olympus Co., Tokyo, Japan) equipped with an Olympus 
SC30 digital camera. Pictures were taken at different 
magnifications to visually inspect the shape of the produced 
microgels. 
The particle size and shape of the microgels were assessed 
by dynamic image analysis with an XPT-C flow-through cell 
particle analyser (PS-Prozesstechnik GmbH, Basel, 
Switzerland). The microgels were suspended in their 
hardening bath, and then flowed (n = 1000) in front of a 
near-infrared light source. The particle size was expressed 
as Waddle disk diameter, which is the diameter of a disk 
with the same area as the detected particle. The particle 
shape was described by the elongation factor, which is the 
maximum (max) Feret diameter (the linear segment 
connecting the two perimeter points that are the furthest 
apart) divided by the Feret equivalent rectangular short 
side (the shortest side of the rectangle with the same area 
as the particle and the longest side equal in length to the 
max Feret diameter). The particle size distribution was 
expressed by the 10th, 50th, and 90th percentiles, x10, x50, and 
x90, respectively. 
3.1.3.7 Encapsulation efficiency of bovine serum 
albumin (BSA) in microgels 
For the sample preparation, the complete microgel batch 
was passed through a 125 µm opening stainless steel sieve, 
and then washed with water, then ethanol, and again with 
water to remove the remaining hardening baths. The 
samples were then dissolved with phosphate buffer saline 
pH 6.8 and stirred for 24 hours. The samples were 
subsequently stored at +4°C. Before each analysis, the 
required amount of solution was centrifuged at 10 000 rpm 
for 10 minutes in a 5415C centrifuge (Eppendorf GmbH, 
Leipzig, Germany), and then the supernatant was filtered 
through Titan3 nylon filters 0.45 µm (SMI-LabHut Ltd, 
Maisemore, UK). The encapsulation efficiency was 
measured via the total protein content by means of DC™ 
Protein Assay, which is based on the Lowry protein assay 
[399,400], according to the protocol supplied by the 
company. The protein content was determined using a Jasco 
V-630 UV-Vis spectrophotometer (Jasco Inc., Easton, US) at 
750 nm in 1 cm optical path Plastibrand® disposable 
semi-micro PMMA cuvettes (Brand GmbH + CO KG, 
Wertheim, Germany). The encapsulation efficiency (EE) is 
expressed in percentage as the ratio between the BSA 
encapsulated and the amount of BSA present in the 
polymeric solution used for manufacturing. To evaluate the 
BSA leakage from the microgels to the receiving bath, the 
encapsulation efficiency was estimated over a period of 4 
weeks. The suspended microgels in the corresponding 
receiving baths were kept at 25°C over a period of one 
month in amber bottles; the EE was measured at weeks 1, 
2, 3, and 4. The leakage is expressed in percentage as the EE 
at a given time point compared to the time zero EE. 
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3.1.3.8 Degradation of BSA 
To investigate the degradation of the microgel loaded BSA 
the following methods were used: circular dichroism, 
sodium dodecyl sulphate gel electrophoresis (SDS-PAGE), 
and fluorescence spectroscopy. 
To evaluate possible changes in the secondary structure of 
the protein, the circular dichroism spectra of the BSA after 
release from the microgels was recorded using a Jasco J-810 
spectropolarimeter (Jasco Inc., Easton, US). The sample was 
loaded in a 1 cm optical path quartz cuvette and the spectra 
were taken in the range between 200 and 260 nm from the 
far-UV. The data are expressed as mean residue ellipticity 
[θm], which is equal to θ (n c l)-1, where θ is the measured 
ellipticity in mdeg, n is the number of amino acids in BSA, l 
is the optical path length in cm, and c is the BSA 
concentration in g mL-1. For comparison, the spectra of a 
reference BSA solution and of BSA denatured with an 8 M 
solution of guanidine hydrochloride were also recorded. 
The SDS-PAGE was conducted to detect protein aggregation 
or degradation. All samples were mixed with an equal 
volume of 2x Laemmli buffer (100 mM 
tris(hydroxymethyl)aminomethane pH 6.8, 4% SDS, 0.2% 
bromophenol blue, 3.1% dithiothreitol, and 20% glycerol) 
and applied to a NuPAGE® Bis-Tris-Gel in a MOPS SDS 
running buffer. The gels were stained with a SimplyBlue™ 
SafeStain reagent according to the manufacturer’s 
instructions. 
Fluorescence spectroscopy was employed to gain 
information about potential changes in protein folding. The 
fluorescence emission profile was obtained from a 
SpectraMax M2e (Molecular Devices LLC, Sunnydale, US). 
The instrument was set to an excitation wavelength (λex) of 
280 nm and the emission wavelengths (λem) were recorded 
in the range from 300 to 500 nm. The samples were 
prepared by loading 700 µL of buffered solution in 48-well 
clear plates Falcon® Multiwell™ (Becton Dickinson France 
SA, Le Point De Claix, France). The emission spectra from a 
BSA solution and BSA denatured with an 8 M guanidine 
hydrochloride solution were used as references. 
3.1.3.9 In vitro release of BSA from microgels 
The in vitro release of BSA from the microgels was tested by 
using an Erweka DT 600 dissolution tester (Erweka GmbH, 
Hausenstamm, Germany) equipped with paddle, as 
described in the European Pharmacopoeia [82]. Briefly, 
each dissolution vessel was filled with 500 mL of phosphate 
buffer saline pH 6.8, which was heated to 37 ± 0.5°C and 
stirred at 50 rpm. Then, washed BSA-loaded microgels 
were added (n = 3) to a nominal total content of 15 mg of 
BSA per vessel. At different time points (5, 10, 15, 20, 30, 45, 
60, 90, and 120 minutes), a 1 mL sample was withdrawn 
from the release medium and filtered through nylon filters 
0.45 µm; the corresponding volume of release medium 
withdrawn was then compensated with fresh buffer. A final 
aliquot was taken after 12 hours at 100 rpm, to obtain the 
BSA release from the microgels at equilibrium. Due to the 
high dilution of the samples, the BSA content was measured 
with a protein assay kit. The employed Micro BCA™ Protein 
Assay Kit (Thermo Fisher Scientific Inc., Rockford, US) had 
the advantage of accurately detecting BSA at very low 
levels. This method is based on the bicinchoninic acid 
protein assay [401–404]. The samples were prepared 
according to the protocol supplied by the company, loaded 
in 96-well clear BRANDplates® pureGrade™ (Brand GmbH 
+ CO KG, Wertheim, Germany) and the absorbance was 
measured in the SpectraMax M2e at λ = 562 nm. The values 
obtained are expressed as a percentage of the release at the 
equilibrium value. 
3.1.3.10 Data analysis 
All measurements are in triplicate (n = 3) and means are 
given together with standard deviations as error bars, 
where not otherwise specified. STATGRAPHICS Centurion 
XVI version 16.1.18 (StatPoint Technologies Inc., 
Warrenton, US) was used as statistical software package. 
The Spearman rank correlation (p ≤ 0.05) was employed for 
non-linear correlation analysis. The statistical significance 
of the difference of means was analysed with Student’s 
t-test (p ≤ 0.05). 
3.1.4 Results 
3.1.4.1 Hardening bath characterisation 
An initial mixture screening indicated that the presence of a 
co-solvent, namely ethoxydiglycol and ethanol, typically 
allowed a better miscibility of the components, higher 
solubility of calcium chloride, and gelling of the polymeric 
droplets [398]. However, pure organic co-solvents are not 
suitable for direct filling into capsules due to well-known 
shell compatibility issues. Such pure co-solvents were 
therefore compared to more promising excipient mixtures 
that were selected from the initial hardening bath screening 
(Table 3.1). 
The data generated from the surface tension and viscosity 
measurements are shown in Table 3.2. These data indicate 
that, among the batches containing ethoxydiglycol, an 
increase in viscosity occurred in presence of glycerides and 
other excipients (especially PEG 600). Considering surface 
tension, the highest value was obtained from the aqueous 
system and noteworthy is the comparatively high value for 
the hardening bath formulation containing PEG 600. 
However, all the formulation mixtures showed a surface 
tension within the same range which was significantly 
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different than the surface tension of receiving baths made 
of water or ethanol. 
The next step was to generate first preliminary capsule 
compatibility data using different shell materials. Table 3.3 
summarises the compatibility assessment of the different 
capsule types with the proposed receiving bath mixtures. 
After four weeks at 25°C and 45% relative humidity, the 
HGC containing HBB, HBC, HBD, and HBE were visually 
intact, despite the relative high amounts of co-solvent. In 
these conditions, HBD was compatible also in HPMC 
capsules. All other capsules and formulations caused 
rupture or softening of the capsule. After two weeks at 40°C 
and 75% relative humidity, only HPMC hard-shell capsules 
and S-PVA soft capsules, both filled with formulation HBD, 
exhibited suitable shell compatibility, while all other 
capsule samples showed leakage or softening of the shell. 
3.1.4.2 Microgel characterisation 
3.1.4.2.1 Morphological characterisation 
Microscopic images demonstrated that the microgels’ shape 
was strongly influenced by the selected hardening bath 
(Figure 3.3). Microgels from HBW (Figure 3.3A) formed 
very thin, concave particles, which appeared similar to 
deformed contact lenses. Particles gathered from EtOH 
hardening bath showed elliptic to almost spherical shapes 
(Figure 3.3B). The microgels obtained from hardening bath 
HBA exhibited a toroidal shape (Figure 3.3C and 3.3D), 
which resembled that of erythrocytes. The microgels from 
HBB had a spherical to irregularly elongated shape 
(Figure 3.3E). Interestingly, the microgels collected from 
HBC and HBD had an irregular, mushroom-like cap 
(Figure 3.3F and 3.3G, respectively), which was possibly 
linked to a higher ratio of ethoxydiglycol. Finally, the 
microgels from hardening bath HBE showed a spherical to 
irregularly spherical shape (Figure 3.3H). Microscopy also 
revealed some droplets that may indicate traces of a phase 
separation. Adhesion of such droplets on the surface of a 
HBE microgel can result in a bias in the automated shape 
analysis. 
The data from size distribution and particle shape are 
shown in Table 3.4. The microgels with lowest x50 and x90 
values were those obtained from EtOH, while those formed 
in HBW demonstrated the largest particle size at all the 
three percentiles analysed. HBW also showed higher 
elongation factors for its microgels when compared to all 
the other systems. Among the formulations containing 
ethoxydiglycol, HBA exhibited the lowest median value for 
the microgels formed, whereas the HBD hardening bath 
yielded microgels with the highest size on x10, x50, and x90. 
The microgels produced from these two hardening baths, 
however, shared practically the same mean elongation 
factor. The dynamic size and shape analysis of the toroidal 
microgels (using formulation HBA) is illustrated in a scatter 
plot (Figure 3.4). The shape in terms of the elongation factor 
was not a constant but depended on the detected size, as it 
is graphically highlighted in the Figure 3.4. 
Since the gelling takes place as soon as the droplet impacts 
the hardening bath surface, we correlated statistically 
(Spearman rank test) viscosity and surface tension of the  
TABLE 3.2 – Hardening bath characterisation. 
Hardening bath  
Viscosity 
(mPa s) 
Surface tension 
(mN m-1) 
HBW ≈ 1 73.5 ± 0.36 
EtOH ≈ 1 22.2 ± 0.06 
HBA 9.14 ± 0.03 30.7 ± 0.35 
HBB 22.99 ± 0.12 30.4 ± 0.06 
HBC 18.29 ± 0.09 31.5 ± 0.76 
HBD 56.79 ± 0.20 33.9 ± 0.27 
HBE 21.02 ± 0.27 30.6 ± 0.25 
TABLE 3.3 – List of capsule compatible with the 
proposed hardening baths. 
Hardening 
bath  
Compatible capsule shells 
after 2 weeks, 40°C 
/ 75% RH 
after 4 weeks, 25°C 
/ 45% RH f 
HBB - HGC 
HBC - HGC 
HBD HPMC, S-PVA HGC, HPMC 
HBE - HGC 
f S-PVA not tested at these conditions 
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FIGURE 3.3 – Microscope pictures of BSA-loaded microgels from hardening baths HBW (A, at 4x), EtOH (B, at 4x), HBA 
(C, at 4x; D, at 10x), HBB (E, at 4x), HBC (F, at 4x), HBD (G, at 4x), and HBE (H, at 4x). The scale bar in the bottom 
right corner of each picture represents 1 mm, except figure D where it is 500 µm. 
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 hardening baths with the resulting particle size and shape. 
As a result, both particle size and shape of the microgels 
were significantly correlated (0.5902 and 0.2679, 
respectively; p < 0.05) with the surface tension of the 
hardening bath. Based on the experimental data, an 
increase in surface tension could have increased the 
particle size and decreased the sphericity. On the other 
hand, the correlation between viscosity and microgel 
morphology was not statistically significant. 
3.1.4.2.2 Encapsulation efficiency and leakage 
 The fraction of BSA that could be loaded in the microgels is 
shown in Table 3.5. Interestingly, all microgels formed in 
non-aqueous hardening baths were able to encapsulate 
much more BSA than those produced in the aqueous 
hardening bath (HBW). The microgels from formulation 
HBE showed a lower mean EE compared to the other 
lipophilic systems, whilst the microgels formed from HBD 
and EtOH exhibited highest EE among the prepared 
formulations. There was no statistical difference (p > 0.05) 
in BSA content between time zero and 4 weeks for all 
hardening baths containing ethoxydiglycol. On the other 
hand, the microgels from hardening baths HBW and EtOH 
revealed a statistically significant protein loss over one 
month. While the leakage in EtOH was limited (-6.3%), the 
microgels in HBW resulted in an EE drop below 5% already 
after the first week. Water as receiving bath was obviously 
leading to continuous diffusion of BSA out of the microgels. 
 
FIGURE 3.4 – Scatter plot of the BSA-loaded microgels 
obtained in hardening bath HBA (n = 1000). The red 
dotted line highlights the trend of the microgels due 
to the toroidal shape. 
TABLE 3.4 – Microgel shape and size characterisation. 
Hardening bath  
Particle size (µm) 
Elongation factor 
x10 x50 x90 
HBW 295.4 410.0 473.7 2.9 ± 0.54 
EtOH 236.9 292.9 346.4 2.1 ± 0.64 
HBA 228.1 300.5 347.8 2.0 ± 0.57 
HBB 255.6 320.7 364.1 1.8 ± 0.50 
HBC 247.4 319.9 364.1 1.8 ± 0.58 
HBD 259.0 332.7 400.3 2.0 ± 0.53 
HBE 223.0 316.0 355.6 1.7 ± 0.46 
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FIGURE 3.5 – Overlaid circular dichroism spectra of BSA-loaded microgels formed in HBE (left) and EtOH (right) 
according to time. Reference (grey long dashes), denatured BSA solution (black dots), time zero (dark green), one 
week (light green), two weeks (yellow), three weeks (orange), four weeks (red). 
TABLE 3.5 – Encapsulation efficiency (EE) and leakage of the microgels after 4 weeks. Significance of difference of 
encapsulation efficiency, g p ≤ 0.001, h p ≤ 0.01, and i p ≤ 0.05. 
Hardening bath  
Encapsulation efficiency (%) 
time zero 4 weeks difference 
HBW 19.40 ± 2.17 3.74 ± 0.27 -80.73 ** 
EtOH 95.04 ± 3.49 89.09 ± 3.02 -6.26 * 
HBA 93.69 ± 6.86 95.86 ± 1.03 2.32 
HBB 91.99 ± 4.16 85.68 ± 4.14 -6.86 
HBC 92.41 ± 2.57 92.91 ± 0.91 0.54 
HBD 98.42 ± 5.22 93.82 ± 1.79 -4.68 
HBE 86.79 ± 10.62 92.43 ± 7.97 6.50 
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3.1.4.3 Degradation of BSA 
3.1.4.3.1 Circular dichroism 
Circular dichroism is a spectropolarimetric technique based 
on the differential absorption of the circularly polarised 
components of a radiation through an optically active 
substance [219]. This approach allows, for example, to 
study the secondary structure of a protein, as well as to 
detect some specific amino acids and bonds. The recorded 
circular dichroism profiles generally showed no sign of BSA 
denaturation over time. However, in the case of the 
microgels gathered from receiving bath HBE, a clear trend 
could be identified over the course of 4 weeks’ stability, as 
seen in Figure 3.5. 
The major area of interest is between 205 and 255 nm, 
which best describes the far-UV profile of the protein α-
helix [219]. In the case of the BSA encapsulated with 
hardening bath HBE, the spectrum shifted toward the 
profile obtained by BSA denatured with an 8 M solution of 
guanidine hydrochloride in phosphate buffer saline pH 6.8. 
Such a shift has been also shown by Liu et al. [405], when 
BSA was denatured with increasingly higher quantities of 
ethanol. However, in the present work, the BSA 
microencapsulated in the EtOH hardening bath did not 
exhibit any specific trend over time. This demonstrates that 
the resulting microgels were able to protect the loaded BSA 
from any denaturing effect of the ethanol hardening bath. 
This protection from denaturation was found also in all the 
other proposed formulations, except HBE. 
3.1.4.3.2 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
The gel electrophoresis of the samples after 4 weeks can be 
seen in Figure 3.6. A 25 µg BSA sample without any further 
treatment was used as a positive control to compare with 
the BSA loaded in microgels (nominal quantity of 37.5 µg 
BSA). 
The BSA sample (lane 1) had several bands on a gel with a 
major band around 67 kDa (in the red dotted circle) and 
several high molecular weight bands. All samples 
(lanes 3-9), as well as a reference sample of MCC+BSA 
(lane 10), showed patterns similar to a BSA sample and no 
degradation bands were observed. The sample obtained 
from HBW showed an extremely reduced band at 67 kDa 
due to the very poor encapsulation efficiency. We also 
analysed samples without any BSA (data not shown); these 
samples did not show any traces of proteins. Thus, after 4 
weeks’ incubation, the results did not show any degradation 
of BSA when the microgels are exposed to the hardening 
baths. 
3.1.4.3.3 Fluorescence profile 
The fluorescence of BSA and of other proteins comes from 
the presence of specific amino acids, namely tryptophan, 
tyrosine, and phenylalanine. In BSA, the fluorescence of the 
Trp-212 has a predominant role given by its position in an 
internal hydrophobic pocket of the protein [406]. The 
presence of ethanol or denaturing compounds can alter the 
three-dimensional structure of the protein, thus exposing 
the Trp-212 residue to the external environment. This, in 
turn, modifies its fluorescence emission spectrum, serving 
as an indicator of protein denaturation [405,407]. 
Figure 3.7 depicts the spectrofluorimetric profiles of BSA 
encapsulated from different hardening baths at time zero 
and after 4 weeks. 
The emission spectra recorded from the microgels formed 
in receiving bath formulations EtOH and HBA were the 
closest to the reference curve (maximum λem = 342 nm). In 
contrast, the emission spectra from BSA encapsulated using 
the hardening baths HBB, HBC, and HBD underwent a 
hypsochromic shift (maximum λem = 332-336 nm), whereas 
the BSA from hardening bath HBE maintained the 
maximum λem as the reference. Hardening baths HBB, HBC, 
HBD, and HBE caused a drop in the intensity at the 
maximum λem, which could be a sign of structural protein 
change [405]. Interestingly, no difference in the emission 
profile of BSA was found over time, indicating that the 
protein changes probably occurred during the 
manufacturing step. 
 
FIGURE 3.6 – SDS-PAGE of BSA loaded in microgels 
after four weeks in the hardening bath. In the lanes, 
from left to right, BSA standard, protein marker, 
HBW, EtOH, HBA, HBB, HBC, HBD, HBE, and 
MCC+BSA (before gelling). The dotted circle marks 
the 67 kDa major band of BSA. 
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3.1.4.4 In vitro release of BSA from microgels 
The release profiles of the BSA-loaded microgels are shown 
in Figure 3.8. 
The microgels formed in HBW were not analysed due to the 
poor EE. All proposed microgels appeared to immediately 
release most of their content (> 75%) within the first 20 
minutes. Such fast release probably occurred because BSA 
was already in solution inside a swollen microgel, and thus 
could readily diffuse to the outer medium. The microgels 
that showed comparatively slower release were formed in 
the EtOH hardening bath. Microgels obtained from 
hardening baths containing ethoxydiglycol were similar 
regarding BSA release with the exception of HBB. The latter 
system demonstrated also a comparatively lower total 
amount of BSA released by the microgels 
(90.32% ± 8.56%). After 2 hours testing, the total amount 
of released protein was in all cases above 90% of the initial 
content. 
3.1.5 Discussion 
The current work introduces a novel approach to 
microencapsulate a model protein by means of prilling 
directly in a lipid-based system. This technique should 
enable a subsequent liquid-filling of the microgel 
dispersions into pharmaceutical capsules, without the need 
for further steps of microgel collection from the hardening 
bath and drying prior to filling into capsules. The obtained 
results are discussed with respect to the gelling in the  
hardening baths, the encapsulation efficiency, the protein 
stability, as well as the drug release from the formulations. 
3.1.5.1 Hardening bath properties and microgel 
morphology 
A hardening bath for prilling would have to fulfil several 
requirements to obtain suitable microgels. A composition 
should certainly not display any phase separation and the 
bath should further have some polarity or dielectric 
properties for ions to dissolve and hence allow ionotropic 
gelling. However, the polarity of the composition should not 
be similar to aqueous media because otherwise this would 
likely result in capsule incompatibility. Balanced medium 
properties were therefore targeted for finding suitable 
hardening baths. The co-solvent ethoxydiglycol was found 
to be interesting with respect to facilitating polymer gelling. 
This excipient may have also contributed to lower the 
surface tension and viscosity of the mixtures (final 
hardening baths) compared to glyceride and non-glyceride 
excipients alone. The surface tension and the viscosity of 
the hardening bath can theoretically influence the microgel 
shape, due to their effect on the impacting droplets. 
However, only the first property could be statistically 
correlated to the microgels’ morphology. HBW had a rather 
low viscosity but a very high surface tension, whereas HBA 
showed higher viscosity and lower surface tension. Both 
systems failed to form spherical microgels. For instance, 
EtOH exhibited the lowest surface tension among the 
proposed formulations and also a very low viscosity, which 
led to the formation of spherical microgels. The presence of 
 
FIGURE 3.7 – Fluorescence spectra of BSA-loaded microgels from different hardening baths at time zero (left) and after 
four weeks (right). Reference (grey dashes), denatured BSA (black dots), EtOH (red line), HBA (orange line), HBB 
(yellow line), HBC (green line), HBD (blue line), HBE (purple line). 
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PEG 600 in receiving baths formulated with ethoxydiglycol 
seemed to enhance the shape curvature as seen in batch 
HBD. Interestingly, Lee et al. showed in a study regarding 
calcium alginate beads that the viscosity of the polymer 
solution played a major role in the microgel size and shape 
[408]. However, in our case, surface tension was primarily 
found to be relevant for the microgel morphology, which 
may point to the importance of the individual system 
composition. This emphasises the complexity of shape as a 
response in a micro-gelling process like prilling. 
The morphology of colloids or microparticles can be viewed 
as the result of spontaneous curvature that is based on 
surface bending energy [409]. The latter energy is 
influenced by several material factors and additional 
process factors of prilling contribute to the complexity. We 
therefore described the morphology primarily on an 
empirical basis and noted changes of the individual 
hardening bath composition on the shape of the microgels. 
However, one aspect that should be discussed regarding 
microgel shape as well as size is the degree of polymer 
cross-linking/gelling. 
The extent of polymer swelling and the nature of the 
microgel surface are known to be influenced by the 
surrounding medium properties, i.e., the affinity between 
the solvent molecules and the polymer chains [410]. A 
lower affinity causes the polymer to prefer self-contact over 
interaction with the solvent [55]. This leads to surface-
localised coiling of the polymeric chains. Consequently, the 
overall surface of the gel shrinks and the gel size decreases. 
Some hardening baths were therefore “better solvents”, in 
the sense that complete swelling was retained when 
compared to the other hardening bath compositions. In 
terms of particle size, ethanol and the ethoxydiglycol-based 
hardening baths showed least affinity for MCC, which led to 
lower polymer swelling and a smaller particle size 
compared to batch HBW. 
Other authors have used alginate or chitosan as ionically 
cross-linking polymers [24,392]. In the present work, the 
latter could not be used due to the very poor solubility of 
the chitosan counter-ion, namely pentasodium 
triphosphate, in the proposed formulations. Alginate is still 
the most commonly used polymer in prilling and can be 
easily cross-linked with calcium ions. However, alginate 
failed our preliminary tests, since it did not form any stable 
microgel when dropped in lipid media. However, Buthe et 
al. could form microgels in a n-hexane and n-butanol system 
by dropping the polymer solution with a syringe in the 
hardening bath [247]. Surprisingly, MCC could gel in water 
[397], but also in ethanol and other lipophilic media, as 
shown in the present work. 
Another required property is the capsule stability upon 
filling with the hardening bath. At mild storage conditions, 
i.e., 25°C / 45% relative humidity, all formulations were 
compatible with HGC. However, only the filled HPMC and 
the S-PVA capsules were stable at 40°C, and only with 
formulation HBD. This preliminarily stability study 
indicates that these combinations could directly form a final 
dosage form, since all capsules used in this work, except for 
S-PVA, are currently commercially available. Further 
modifications of the receiving bath formulation may be 
needed to allow an improved stability at stress conditions. 
However, this represents further development work that is 
outside of the current research scope and proof of this 
microencapsulation concept. 
3.1.5.2 BSA encapsulation efficiency, leakage, and 
release from microgels 
The surprisingly high EE of the microgels formed in all 
non-aqueous hardening baths (Table 3.5), could be 
described by the structure of the microgel itself. As 
previously mentioned, the gel formed by MCC in the 
receiving bath is in a relative “swollen” state, which is 
determined by the polymeric chains’ hydration and the 
formed network. This network is maintained by cross-
linking interactions between calcium ions and the 
carboxylic groups of the modified chitosan. The microgel 
can therefore be viewed as a leaky mesh, where the water 
and the dissolved BSA may partition between the microgel 
and the bulk of the hardening bath. Such partitioning most 
likely explains why the system proved to be very “leaky” 
 
FIGURE 3.8 – BSA release profiles of microgels in PBS 
pH 6.8, 50 rpm, and 37°C. Microgels were prepared in 
hardening baths EtOH (red diamonds), HBA (orange 
squares), HBB (yellow triangles), HBC (green dashes), 
HBD (blue asterisks), and HBE (purple circles). Error 
bars represent standard deviation (n = 3). 
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when left in the aqueous hardening bath (HBW) for several 
weeks, in contrast to the other lipid-based formulations. 
The BSA entrapment in the microgels from the EtOH 
hardening bath presents similarities with an aqueous 
receiving bath, but with a comparatively lower polarity of 
the medium. This polarity is expected to play an important 
role for a less extensive polymer swelling, and hence for the 
lower diffusion of the large BSA molecule. 
Sano et al. demonstrated that the alcohol content strongly 
influences the gel stability made from chitosan solutions 
[411]. Since polymer swelling is closely linked to the solvent 
properties, the MCC microgel may form a rather tight and 
dense network, which may hinder BSA release, during 
exposure to the receiving bath medium. Such 
considerations about medium polarity and the degree of 
microgel swelling apply not only to the EtOH formulation, 
but also to all the other systems. 
The BSA’s EE obtained in our system was higher than the 
one obtained in the system composed of the same polymer 
and protein from the work of Liu et al. [397]. Herein, the 
authors reported that the droplets were hardened in a 
calcium chloride aqueous solution and further hardened by 
chitosan. The presence of chitosan could increase the EE 
from 44.4% up to 73.2%. Such increase could be also 
induced by the electrostatic interaction between the 
cationic chitosan and the anionic MCC, which form 
poly-electrolyte complexes. The BSA, whose isoelectric 
point is 4.7 [412], has prevalently negative charges in the 
solution used, therefore it can electrostatically interact with 
both the chitosan and the calcium ions. 
Regarding the in vitro release test, all the systems could 
successfully liberate the model biological within 20 
minutes. This fast release was explained by the facilitated 
BSA diffusion through the completely swollen MCC 
microgel in the aqueous environment. The only remarkable 
variation occurred with the EtOH system, where BSA 
released from the microgel was slower than in the other 
proposed systems. Such difference in the release profile 
may again be explained by the different solvent properties 
of the receiving medium and their impact on the network 
density, when compared to the ethoxydiglycol-based 
formulation. However, the rather fast release would require 
development of enteric coated capsules filled with the 
microgels to bypass possible degradation in gastric fluids. 
Further biopharmaceutical research would have to prove 
an adequate protein protection from the intestinal fluids by 
the microgels.  
3.1.5.3 Protein denaturation 
The data regarding protein stability showed that the 
microgels prepared in lipid-based hardening baths could 
protect BSA from denaturation in most cases. Some of the 
excipients from the selected hardening baths are known to 
harm or modify proteins and their structure. For instance, 
ethanol is regarded as a protein denaturing agent, due to its 
major role in the disruption of tertiary structure and in the 
modification of α-helices in the secondary structure 
[405,413–415]. Propylene carbonate has been described in 
literature as a potential protein denaturant [416]. 
According to our findings, the BSA loaded into microgels 
formed in EtOH was unmodified for the entire study length. 
The BSA in the microgel formulation HBA, i.e., containing 
only ethoxydiglycol and calcium chloride, proved to have no 
detectable denaturation by means of spectropolarimetry, 
gel electrophoresis, and spectrofluorimetry. These results 
were consistent over a four-week stability period at room 
temperature. To the best of our knowledge, no literature 
data is available on the influence of ethoxydiglycol on 
protein stability. 
SDS-PAGE has previously been used to study other particle-
based drug delivery systems to evaluate the structural 
integrity of encapsulated macromolecules [319,417]. When 
using this method, there were no indications that the 
process or the lipid-based systems harmed the model 
protein in terms of degradation. However, according to the 
circular dichroism spectra, the BSA from formulation HBE 
showed a variation in the α-helix region over time. The 
signal in this region varied with a constant trend during a 
four-week period by moving from the reference profile to 
the denatured profile. A plausible interpretation of this 
result is based on the known fact that the end-products of 
lipid peroxidation can lead to protein damage and 
denaturation due to their interaction with lysine groups in 
proteins [418,419]. The Labrafil® M2125CS contained in 
formulation HBE is a mixture of lineoyl macrogol-6 
glycerides, which means that the additive contains 
polyunsaturated fatty acids. If oxidation stress occurs on 
the unsaturated chains, the subsequent end-products, e.g., 
malondialdehyde, can interact with the ε-amine of lysine. 
This amino acid has a very high α-helix propensity [420], 
and its modification could disrupt this structure, hence 
altering the circular dichroism spectra in the corresponding 
range. Similar effects could also be caused by the presence 
of oxidising impurities in this excipient that are derived by 
the PEGylation step of the glycerides. 
An interesting effect was seen on the fluorescence emission 
profiles. The maximum λem from a guanidine 
hydrochloride-denatured protein undergoes a 
bathochromic shift, as described by Pajot [421]. In the case 
of BSA, such as in the present work, this red shift moves the 
peak to 350 nm. Whilst the spectra emitted from the BSA 
encapsulated using the receiving bath formulations EtOH 
and HBA maintained a maximum λem = 342 nm, the 
formulations containing glycerides appeared to modify the 
profiles. The hypsochromic effect shown in BSA by these 
systems can be due to an increase in lipophilicity due to the 
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hardening bath, which moves the Trp-212 further into a less 
polar area in the lipophilic cavity in sub-domain IIA [407]. 
Overall, the emission intensity undergoes a hypochromic 
effect, which may be caused by quenching following nearby 
three-dimensional rearrangement [422]. Such explanation 
implies a possible modification of the secondary structure 
of the protein. This was probably a rather subtle effect as it 
was not shown by the spectropolarimetric data. Moreover, 
such a change in conformation may not necessarily lead to 
an activity loss in case of a therapeutic protein. 
3.1.6 Conclusions 
This work introduced a novel lipid-based dispersion of MCC 
hydrophilic microgels suitable for macromolecules 
encapsulation and compatible with hard- or soft-shell 
capsules by means of prilling. The vibrating nozzle system 
produced microgels with reproducible particle size by 
means of Ca2+-mediated gelling, directly in a lipid hardening 
bath. The lipid-based dispersion can be loaded directly into 
hard or soft capsules, whereas an alternative water-based 
system would cause strong incompatibilities with the 
capsule shell materials. This approach allows a simpler and 
straightforward manufacture of a final dosage form for oral 
drug delivery, thus bypassing further time-consuming 
manufacturing steps, like drying or lyophilisation. The 
presence of a water compartment within the “swollen” gel 
may grant a fast release of the macromolecule when 
exposed to the physiological fluid, as well as optimal 
stability. The proposed system showed high encapsulation 
efficiency (> 86%) for all the lipid-based dispersions. Also, 
the loaded BSA did not show, in most systems, clear signs of 
denaturation, even in presence of pure ethanol in the 
hardening bath after a four-week long stability 
investigation at room temperature.  
The findings presented here introduce a novel, viable, and 
robust approach for macromolecule microencapsulation, to 
achieve a straightforward production of a dispersion that 
can be directly filled in commercially available capsules, 
which can then be further tailored according to the product 
specification. 
                                                                        
‡  de Kruif JK et al. On prilled Nanotubes-in-Microgel Oral System for protein delivery. European Journal of 
Pharmaceutics and Biopharmaceutics, 2016, submitted 
3.2 On prilled Nanotubes-in-
Microgel Oral Systems for protein 
delivery ‡ 
3.2.1 Summary 
Newly discovered active macromolecules are highly 
promising for therapy, but poor bioavailability generally 
hinders their oral use. Microencapsulation approaches, like 
protein prilling into microspheres, may enable protection 
from enzymatic degradation in the gastrointestinal tract, 
which could increase oral bioavailability mainly for local 
delivery. This work’s purpose was to design a novel 
architecture, namely a Nanotubes-in-Microgel Oral System, 
by prilling for protein delivery. Halloysite nanotubes (HNT) 
were selected as orally acceptable clay particles and their 
lumen was enlarged by alkaline etching. After loading 
albumin as model drug, the HNT were entrapped in 
microgels by prilling. The formed Nanoparticles-in-
Microsphere Oral System (NiMOS) was assessed regarding 
morphology, entrapment efficiency, and release profile. 
Protein stability was determined throughout the 
microencapsulation process and after in vitro enzymatic 
degradation. The results showed successful HNT lumen 
enlargement, which facilitated higher protein loading. 
Prilled NiMOS had spherical shape and good entrapment 
efficiency. Release profiles depended largely on the 
employed system and HNT type. NiMOS prilling did not 
harm the protein structure, and this novel composite 
system demonstrated even higher in vitro enzymatic 
protection compared to pure nanotubes or microgels. 
Therefore, prilled NiMOS were shown to be a promising and 
flexible multi-compartment system for oral (local) 
macromolecular delivery. 
3.2.2 Introduction 
New proteins as active pharmaceutical ingredients (API) 
have drawn much attention to scientists in modern 
pharmaceutics [10,18,423]. The oral delivery of these 
compounds is challenging in terms of bioavailability, which 
is substantially reduced by the conditions in the 
gastrointestinal (GI) tract [14,183]. The GI barriers to 
overcome consist of drug solubility, enzymatic drug 
digestion, mucus penetration of the API or of the delivery 
system, and absorption of the API [424]. If primarily luminal 
activity is required for the therapeutic action of the 
macromolecule, only enzymatic protection must be 
achieved, which is a still challenging but realistic 
pharmaceutical objective. Herein, microencapsulation has 
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shown potential to overcome this major hurdle by 
protecting proteins from the GI environment [20–22,425]. 
Among several other techniques, prilling can be a way to 
formulate proteins as microparticles [23]. The mild 
conditions of the process avoid thermally induced protein 
degradation. Prilling is also known as vibrating nozzle 
technique. This approach embeds the macromolecular API 
in a polymeric microgel by dropping a solution of both 
components in a hardening bath. Herein, the API-containing 
polymeric solution is extruded through a nozzle. The liquid 
stream is then broken into droplets by applying vibration. 
The droplets pass through a ring electrode that charges 
them electrostatically to avoid mid-air coalescence [238]. 
Finally, the droplets are collected in a hardening bath where 
cross-linking occurs and the API is efficiently entrapped. 
Both polymer and hardening bath may be varied to achieve 
a suitable formulation for the process. Several polymers 
have been proposed for prilling, like alginate [391,392], 
pectin [245], and chitosan [267]. Chitosan is a natural linear 
polysaccharide formed by D-glucosamine and N-acetyl-D-
glucosamine, and this excipient displays interesting drug 
delivery properties [268,269,393]. Many chemical 
modifications of this compound were suggested to enhance 
or modify its physicochemical properties [192]. A most 
promising chitosan derivate is mono-N-carboxymethyl 
chitosan (MCC). Mucoadhesive and permeation enhancing 
properties have been reported for this polymer, as well as 
improved tolerability compared to chitosan and other of its 
cationic derivates [169,394–396]. The hardening bath is 
generally aqueous, but lipid-based pharmaceutical 
compositions were recently identified as technically 
feasible for prilling. [28]. The hardening bath can then be 
optimised for later steps of manufacturing, such as capsule 
filling of the microgel dispersion [426]. Prilled microgels 
have therefore shown flexibility and suitability in terms of 
protein formulation as a final oral dosage form. 
Apart from the technology of microgels, nanoparticles have 
become an important field for oral delivery of 
macromolecules, such as proteins [319] and nucleotides 
[427,428]. This formulation approach has been excellently 
reviewed by several authors [31,194,318]. It seems 
particularly attractive to embed a nanoparticulate system 
into microgels or microspheres [314]. Thus, the 
biopharmaceutical formulation properties may be 
improved by forming highly versatile Nanoparticles-in-
Microsphere Oral Systems (NiMOS). Such systems have 
been proposed as multi-compartment carriers and were 
especially applied in RNA and DNA delivery [316]. Bhavsar 
et al. pioneered this field with a multi-compartment system 
by using gelatine nanoparticles encapsulated in poly(ε-
caprolactone) microspheres for intestinal mucosal delivery 
of proteins, and were reported to be more successful for 
oral macromolecule administration than nanoparticles 
alone [311,312,316]. The promising multi-compartment 
has seen only a preliminary application of solid nanotubes 
for oral delivery of proteins. A first example of nanotubes 
that were intended as potential drug delivery system was 
carbon nanotubes [429]. However, their costs and toxicity 
may strongly hinder their application in pharmaceutics 
[320,321]. Halloysite is, by contrast, a natural and 
inexpensive aluminium silicate clay with a hollow 
nanotubular structure. It is regarded as non-toxic, and there 
are preliminary findings of even anti-inflammatory 
properties [335,430,431]. Hallyosite nanotubes (HNT) are 
extracted from clay quarries, and their characteristics vary 
according to the extraction site [326,327]. The use of 
halloysite in drug delivery was first proposed by Price et al. 
[328], and has since then gained increasing interest [329–
331,432]. These clay nanotubes showed the capacity of 
storing APIs in their lumen or to adsorb compounds on their 
surface. Both luminal and surface additions and 
modifications to HNT have been proposed as a strategy to 
increase the loading efficiency of the tubes or to modify the 
drug release properties of this system 
[332,333,343,433,434]. For example, to improve the 
control over the drug release profiles from HNT, lumen end-
stoppers were implemented [321,435]. Many of these 
modifications were reviewed elsewhere [322]. Most 
notably, chemical etching of the inner clay surface has been 
proposed to enlarge the luminal diameter thereby 
increasing the loading capacity of the tubular structure 
[325,339,340]. While HNT have been loaded with small 
molecules, peptides, small proteins, and nucleotides, the 
addition of larger proteins into the lumen may be hindered 
by the macromolecule size. 
First steps in formation of halloysite-containing gel 
structures were attempted to achieve nanocomposite films 
[336] and beads [337]. In both cases, the nanocomposite 
systems were evaluated only in terms of structure, 
physicochemical and mechanical properties, as well as 
biocompatibility. Wang et al. recently developed ofloxacin-
containing magnetic microspheres obtained by spray-
drying [436]. This approach allowed successful loading the 
model API in HNT-containing magnetic microspheres. 
Thinking of a macromolecular drug, however, the spray-
drying process may cause thermal drug degradation. Chao 
and co-workers proposed an interesting structural 
architecture for enzymatic immobilisation outside of the 
pharmaceutical field by forming a HNT-based mesoporous 
microgel [338]. There is certainly much biopharmaceutical 
promise in such multi-compartment systems. However, the 
risk of the system complexity to become a major hurdle for 
scale-up and manufacturing still remains. In fact, drug 
delivery systems are required not only to show 
biopharmaceutical promise, but also to be viable for later 
stages of galenical development regarding clinical research 
and finally the market [31]. 
The aim of this work is to design and manufacture 
Nanotubes-in-Microgel for protein (local) oral delivery, 
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which falls under the umbrella of Nanoparticles-in–
Microsphere Oral System (NiMOS). A simple 
microencapsulation method is introduced to form such 
complex structures, namely prilling (Figure 3.9). 
This mild process has the potential to embed protein-
loaded HNTs into a microgel. HNTs were chemically etched 
in order to increase drug loading capacity and to allow 
protection from enzymatic protein degradation. The 
feasibility of the prilling approach was assessed, and the 
obtained NiMOS were characterised in terms of 
morphology, protein loading, and release. The protein 
stability after manufacturing was evaluated. A preliminary 
biopharmaceutical characterisation was performed by 
evaluating the enzymatic digestion of the proposed NiMOS 
compared to HNT and microgels alone. 
3.2.3 Materials and methods 
3.2.3.1 Materials 
Mono-N-carboxymethyl chitosan (MCC; deacetylation 
degree 96.1%, carboxymethylation degree 82.1%, loss on 
drying 11.2%, MW = 9000-13000 g mol-1) was purchased 
from Boylechem Co Ltd (Shanghai, China). Ethanol (brand 
J.T. Baker® Chemicals) was obtained from Avantor 
Performance Materials BV (Deventer, The Netherlands) and 
hydrochloric acid solution 1 M from Scharlau SL 
(Sentmenat, Spain). Miglyol® 812 (triglyceryl 
caprylocaprate) was supplied by Hänseler AG (Herisau, 
Switzerland). Transcutol® HP (diethylene glycol 
monoethyl ether; DEGEE) was a kind gift of Gattefossé AG 
(Luzern, Switzerland). Acetic acid, bovine serum albumin 
96%, calcium chloride anhydrous, guanidine hydrochloride, 
 
FIGURE 3.9 – Schematic approach of Nanotubes-in-Microgels (as a Nanoparticle in Microparticle Oral System, NiMOS) 
manufacturing by means of prilling. 1, loading of protein into halloysite nanotubes possibly hindered by lumen 
diameter; 2, chemical etching enlarges nanotube lumen; 3, loading of protein onto nanotubes; 4, dispersion of protein-
loaded nanotubes in polymeric solution; 5, prilling process; 6, prilled NiMOS. Red circles are BSA, azure circles 
represent sodium hydroxide, and purple lines indicate polymer chains. The schematic figure is not to scale. 
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halloysite nanotubes (HNT), potassium phosphate dibasic, 
potassium phosphate monobasic, sodium chloride, sodium 
hydroxide, sodium phosphate monobasic, sodium 
phosphate tribasic, trypsin, trypsin inhibitor from Glycine 
max, glycerol and Tween® 80 (polyoxyethylene (20) 
sorbitan monooleate) were purchased from Sigma-Aldrich 
Chemie GmbH (Buchs, Switzerland). Acrylamide/Bis 40% 
solution, ammonium persulfate (APS), Coomassie Brilliant 
Blue G-250, bromophenol blue, dithiothreitol (DTT), 
sodium dodecyl sulphate (SDS), 
tetramethylethylenediamine (TEMED) were purchased 
from Bio-Rad Laboratories AG (Cressier, Switzerland). 
Tricine, tris-(hydroxymethyl)-aminomethane (Tris) base 
and Tris hydrochloride (Tris-HCl) were purchased from 
Carl Roth GmbH & Co KG (Karlsruhe, Germany). The Micro 
BCA™ Protein Assay Kit and the molecular weight marker 
PageRuler™ Plus Prestained Ladder were obtained from 
Fisher Scientific AG (Reinach, Switzerland). 
3.2.3.2 Halloysite nanotubes (HNT) activation by 
luminal etching 
The HNT internal lumen diameter was enlarged by alkaline 
chemical etching according to a previously reported 
method [340]. Briefly, HNT were suspended in a 2 M 
solution of sodium hydroxide in a ratio 1:10 (w/w). The 
dispersion was sonicated for 50 minutes at 50°C. The HNT 
samples were centrifuged at 4000 rpm for 15 minutes. 
Then, the supernatant was removed and 40 mL of 
demineralised water were added. Subsequently, both 
centrifugation and washing steps were repeated three 
times using phosphate buffer saline (PBS) pH 6.8 instead of 
demineralised water. A final centrifugation and washing 
steps were repeated with demineralised water. This base-
modified HNT (bHNT) was desiccated at 105°C until no 
weight variation could be detected. The pH of a 1% (w/w) 
dispersion bHNT and non-treated HNT (nHNT) were 7.3, 
and 6.8, respectively. 
3.2.3.3 HNT characterisation 
3.2.3.3.1 Particle size and ζ-potential 
A mean HNT size was measured by dynamic light scattering 
using a Nano-Zetasizer (Malvern Instruments Ltd, Malvern, 
UK). The same instrument was employed for the ζ-potential 
determination of the different HNT. One part of HNT was 
suspended in 500 parts of demineralised water and 
sonicated for 3 hours. The particle size and the ζ-potential 
were then measured at room temperature in a 1.5 mL semi-
micro disposable cuvette Plastibrand® (Brand GmbH + CO 
KG, Wertheim, Germany) and in a folded capillary cell 
(Malvern Instruments Ltd), respectively. The particle size 
distribution was expressed as the span, as described in 
Equation 3.1, where d90, d10, and d50 represent the 90th 
percentile, the 10th percentile, and the median particle size, 
respectively. 
 
𝑆𝑝𝑎𝑛 =
𝑑90 − 𝑑10
𝑑50
 3.1 
3.2.3.3.2 Specific surface area, pore volume, and pore 
diameter 
The BET (Brunauer-Emett-Teller) specific surface area was 
measured on a Gemini™ V (Micromeritics Instrument Inc., 
Norcross, GA). The test tubes and approximately 500 mg of 
sample were dried overnight at 105°C under nitrogen. The 
dry weight was measured and the sample was then 
transferred into the instrument that analysed the specific 
surface area, the pore volume, and the pore diameter. 
3.2.3.4 Loading of HNT with bovine serum albumin 
(BSA) 
The BSA was loaded by modifying previously proposed 
methods [332,333]. One gram of dried non-treated (nHNT) 
or base-modified (bHNT) halloysite was added to one 
millilitre of BSA solution at different concentrations, 
namely 2.5, 5.0, 7.5, 10.0, 12.5, and 15.0% (w/v). The 10% 
(w/v) concentration was found to be optimal and was used 
for all further testing. The samples were mixed for 5 
minutes on an IKA® Vortex Genius 3 (Huber & Co AG, 
Reinach, Switzerland). Subsequently, they were put in a 
vacuum chamber at room temperature for 1 minute at 
100 mbar. This step was repeated twice to remove air in the 
suspensions and from the nanotube lumen. The suspension 
was then centrifuged for 10 minutes at 4000 rpm. After 
removing the supernatant, a fresh aliquot of BSA solution 
with identical concentration was added, and the loading 
process repeated to ensure highest loading efficiency. Once 
the supernatant was removed again, the sample was dried 
at 40°C for about 20 hours in an XYTS 11 vacuum oven 
(Renggli AG, Rotkreuz, Switzerland). 
3.2.3.5 HNT imaging 
3.2.3.5.1 Transmission electron microscopy (TEM) 
Images of the nanoparticles were taken with a Morgagni 
268D TEM (FEI Europe BV, Zürich, Switzerland) by using an 
acceleration voltage of 80 kV. The samples were prepared 
by suspending HNT in demineralised water in a ratio of 
1:500, and subsequently sonicating for 15 minutes. A 5 µL 
suspension aliquot was loaded on a copper grid and 
incubated for 60 seconds at room temperature. Finally, the 
sample was loaded in the microscope and analysed. 
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3.2.3.5.2 Scanning electron microscopy (SEM) 
SEM pictures of the different HNT were gathered with a 
Supra 40 VP microscope (Carl Zeiss AG, Oberkochen, 
Germany) using an extra high tension of 5 kV. The 
nanotubes were suspended in demineralised water in a 
ratio of 1:500. Then, the suspensions were sonicated for 15 
minutes with a PELCO® Mica Sheet Grade V5 (Ted Pella 
Inc., Redding, CA). The adhesive sheets were then fixed on 
conductive stickers (Plano GmbH, Wetzlar, Germany). 
3.2.3.6 Formation of NiMOS by prilling 
Prilling was carried out on an Encapsulator Biotech from 
EncapBioSystems AG (Greifensee, Switzerland; currently 
commercialised by Büchi Labortechnik AG, Flawil, 
Switzerland). A polymeric solution containing 4% (w/v; dry 
weight) of MCC was prepared in PBS pH 6.8. The solution 
was stirred overnight to allow complete dissolution and 
hydration of the MCC polymeric chains. Subsequently, the 
solution was vacuum filtered through a Whatman™ GF/D 
glass microfiber filter (GE Healthcare AG, Glattbrugg, 
Switzerland). The BSA-loaded HNT, both non-treated and 
alkali-activated, were added to the polymeric solution 
(ratio 1:20 w/w). This ratio was found to be optimal after 
screening several possible combinations from 1:1 to 1:50 
(w/w). The system was then thoroughly mixed for 30 
minutes and sieved through a 125 µm mesh stainless steel 
sieve to separate HNT clusters. Three different hardening 
bath compositions were chosen to collect the droplets 
falling from the prilling device, namely ethanol, DEGEE, and 
water. Calcium chloride anhydrous was added up to 4% 
(w/w) concentration in the hardening baths and these were 
stirred until complete dissolution of the salt. Tween® 80 
was also added in the aqueous solution to a 2% (w/w) 
concentration to reduce its surface tension, according to the 
Encapsulator Biotech instructions. 
An Omnifix® syringe (B. Braun Melsungen AG, Melsungen, 
Germany) was filled with HNT-loaded polymeric solution 
and then attached to the prilling device. This solution was 
pumped through a 300 µm nozzle with a 12.5 mL min-1 flow 
rate. The vibration was set to a 1240 Hz frequency and to an 
amplitude of 9. The droplet stream passed through the 
electrode ring charged with 2500 V. The droplets were 
collected after a ~13 cm fall into a grounded beaker 
containing 75 mL of hardening bath. A total quantity of 5 g 
of polymeric solution was prilled for each batch. The HNT-
containing microgels were left in the hardening baths for 30 
minutes. The microgels loaded with nHNT were named 
under the term nNiMOS, whereas those containing bHNT 
were called bNiMOS. “Blank” microgels, i.e., without HNT 
but still loaded with BSA, were produced using the same 
settings. 
3.2.3.6 NiMOS and microgel characterisation 
NiMOS and blank microgels were filtered through a 125 µm 
mesh stainless steel sieve. All the microgels were then 
washed with water, ethanol, and water again. The microgel 
batches were gently dried in a glass oven B-585 (Büchi 
Labortechnik AG) at 40°C for 3 hours in 20 mbar vacuum, at 
a rotation speed of 20 rpm. The dried microgels were stored 
in sealed vials at 4°C. 
3.2.3.6.1 Particle size by laser diffraction 
The microgel particle size was measured with the laser 
diffraction sensor Helos/KF equipped with a CUVETTE 
holder (Sympatec GmbH, Clausthal-Zellerfeld, Germany). A 
50 mL optical glass cuvette was used to disperse the 
microgels. Non-dried microgels were suspended in pure 
ethanol, whereas the dry microparticles were dispersed in 
Miglyol® 812. 
3.2.3.6.2 Particle shape by dynamic image analysis 
An XPT-C particle analyser (PS Prozesstechnik GmbH, Basel, 
Switzerland) was used for the dynamic image analysis of 
the microparticles. The non-dried microgels were 
redispersed in their respective hardening baths, whereas 
the dry microgels were suspended in ethanol. 
Subsequently, the dispersions were flowed through the 
1.5 mm diameter cell of the XPT-C, where the images were 
taken. The shape of the microgel is expressed by the 
elongation factor, which is the maximum Feret diameter 
(the linear segment linking the two perimeter points that 
are the furthest apart) divided by the Feret equivalent 
rectangular short side (the shortest side of the rectangle 
with the same area as the particle and the longest side equal 
in length to the maximum Feret diameter). The more 
elliptical the particle is, the higher its elongation factor. A 
perfectly spherical particle has an elongation factor of 4/π 
(~1.27). 
3.2.3.6.3 Particle imaging by optical microscopy 
The microgels were observed through an Olympus optical 
microscope CKX41SF (Olympus Schweiz AG, Volketswil, 
Switzerland) equipped with an Olympus SC30 digital 
camera. Pictures of both non-dried and dry microgels were 
taken to evaluate their morphology. 
3.2.3.7 Protein content 
3.2.3.7.1 Loading efficiency of BSA onto HNT 
An aliquot of 200 mg of BSA-loaded HNT was dispersed in 
1 mL of PBS pH 6.8 to allow complete release of the protein 
48 hours. Then, the sample was centrifuged for 10 minutes 
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at 14 000 rpm with a 5415C centrifuge (Eppendorf 
Instrumente GmbH, Hamburg, Germany). The loading 
efficiency is given by the quantity of BSA loaded onto one 
gram of HNT (mg g-1) as described in Equation 3.2. 
 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝑚𝑔 ∙ 𝑔−1)
=  
𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑜𝑓 𝐵𝑆𝐴 𝑜𝑛 𝐻𝑁𝑇 (𝑚𝑔)
𝑄𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑜𝑓 𝐻𝑁𝑇 (𝑔)
 
3.2 
The BSA content was measured with a Micro BCA™ Protein 
Assay Kit, which is based on the bicinchoninic acid method 
for protein content assessment [401–404]. An aliquot of 
supernatant from the centrifuged sample was taken and the 
protein content was measured according to the protocol 
supplied by the manufacturer. The measurement was 
carried out on a 96-well plate pureGrade™ (Brand GmbH + 
CO KG, Wertheim, Germany) in a SpectraMax M2e 
microplate reader (Molecular Devices LLC, Sunnyvale, CA). 
3.2.3.7.2 Encapsulation efficiency of BSA in microgels 
Batches of prilled microgels were suspended in PBS pH 6.8 
at a ratio 1:4 (w/w). The suspension was mixed for 12 hours 
at room temperature to allow complete BSA release. 
Aliquots of the samples were then centrifuged in a 5415C 
centrifuge (Eppendorf Instrumente AG) at 14 000 rpm for 
10 minutes. The protein content was measured using a 
Micro BCA™ Protein Assay Kit according to the 
manufacturer’s instructions. The protein content is then 
expressed as the encapsulation efficiency, as shown in 
Equation 3.3. 
 𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%)
=
[𝐵𝑆𝐴]𝑖𝑛 𝑚𝑖𝑐𝑟𝑜𝑔𝑒𝑙𝑠
[𝐵𝑆𝐴]𝑖𝑛 𝑝𝑜𝑙𝑦𝑚𝑒𝑟𝑖𝑐 𝑚𝑖𝑥𝑡𝑢𝑟𝑒
∙ 100 
3.3 
Where the term at the denominator represents the protein 
content of the BSA-loaded polymeric solution used for 
prilling. The microgels and NiMOS formed in the alcoholic 
hardening bath were chosen for further characterisation. 
3.2.3.8 Release test 
The BSA release test was carried out on the different HNT, 
on the blank dried microgels, and on the different NiMOS 
obtained using the ethanol hardening bath. These samples 
were transferred into 15 mL CellStar® tubes (Greiner Bio-
One GmbH, Frickenhausen, Germany) and 10 mL of PBS 
pH 6.8 were added as dissolution medium. Each sample was 
repeated 6 times. The test tubes were laid horizontally in a 
Multitron Standard shaking incubator (Infors AG, 
Bottmingen, Switzerland), incubated at 37.0°C and shaken 
at 200 rpm. Aliquots of 100 µL were drawn at selected time 
points (5, 10, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, and 
210 minutes). A final aliquot was taken after 24 hours at 
equilibrium. After each withdrawal, the sample taken was 
replaced with 100 µL of fresh medium. The samples were 
centrifuged for 10 minutes at 14 000 rpm and the 
supernatant was further filtered. The protein content was 
assessed with the Micro BCA™ Protein Assay Kit as 
previously described. Where applicable, the release profiles 
were compared with the f2 similarity factor [437–439]. If f2 
is below 50, the release profiles were considered different. 
The comparison was carried out using the freely available 
add-in programme DDSolver [440]. 
3.2.3.8 Protein stability after prilling process 
3.2.3.8.1 Circular dichroism 
The potential denaturation of the protein secondary 
structure during the process was assessed by 
spectropolarimetry. The circular dichroism spectra of BSA 
were recorded on a Jasco J-810 spectropolarimeter (Jasco 
Inc., Easton, MD) in a range between 200 nm and 260 nm. 
The samples were prepared by allowing the BSA release 
from blank microgels, HNT, and NiMOS in PBS pH 6.8. After 
centrifugation at 14 000 rpm for 10 minutes, the 
supernatant was filtered through 0.45 µm Titan3 filters 
(Fisher Scientific AG). The filtered solution was then 
transferred in 1 cm optical path quartz cuvettes and 
measured. The circular dichroism data is expressed in 
terms of mean residue ellipticity (mdeg cm2 g-1), which is 
calculated according to Equation 3.4: 
 𝑚𝑒𝑎𝑛 𝑟𝑒𝑠𝑖𝑑𝑢𝑒 𝑒𝑙𝑙𝑖𝑝𝑡𝑖𝑐𝑖𝑡𝑦 (𝑚𝑑𝑒𝑔 ∙ 𝑐𝑚2
∙ 𝑔−1)  =
𝜃
𝑛 ∙ 𝑐 ∙ 𝑙
 
3.4 
Where θ is the measured ellipticity (mdeg), n is the number 
of amino acids in BSA, c is the BSA concentration (g mL-1), 
and l is the optical path length of the quartz cuvette (cm). 
The circular dichroism profiles were then deconvoluted to 
obtain quantitative information regarding the secondary 
protein structure with the software CDNN [441]. The 
calculated α-helix fraction of BSA was chosen for the 
statistical evaluation. A positive control for protein 
denaturation was also measured by denaturing BSA in 
presence of an 8 M guanidine hydrochloride solution. 
3.2.3.8.2 Fluorescence profile 
The emitted fluorescence spectra of BSA were obtained 
with a SpectraMax M2e microplate reader. The fixed 
excitation wavelength (λex) was set to 280 nm, whereas the 
Chapter 3. Formulation of novel lipid-based systems for protein delivery  48 
 
 
emission wavelength (λem) was recorded from 310 nm to 
450 nm. The BSA emitted fluorescence in this range is given 
by a tryptophan residue in position 212 of the protein. A 
volume of 700 µL of each sample was loaded in 48-well 
clear plate Falcon® Multiwell™ (Becton Dickinson France 
SA, Le Point de Claix, France). The emission maximum (λmax) 
and the area under the curve (AUC) were measured to 
evaluate bathochromic or hypsochromic shifts, and 
hyperchromic or hypochromic variations, respectively. 
Similarly, to the spectropolarimetric measurements, a 
positive control for protein denaturation was measured on 
BSA denatured in an 8 M solution of guanidine 
hydrochloride. 
3.2.3.9 Protein stability after enzymatic digestion 
3.2.3.9.1 Enzymatic digestion 
To simulate the enzymatic digestion, the microgels were 
incubated in PBS pH 6.8 containing trypsin (5 mg mL-1) at 
37°C in a Multitron Standard shaking incubator (Infors AG) 
with an agitation of 200 rpm. The enzymatic digestion was 
then halted after one hour by adding trypsin inhibitor 
(5 mg mL-1). The incubation was allowed for further 3 hours 
at the same temperature and shaking. After the entire 
incubation period, the samples were then evaluated by 
means of sodium dodecyl sulphate gel electrophoresis 
(SDS-PAGE). To evaluate the extent of BSA digestion by 
trypsin, we prepared negative controls by adding the 
trypsin inhibitor at the beginning of the enzymatic digestion 
and positive controls by allowing digestion of BSA standard. 
3.2.3.9.2 SDS-PAGE 
The SDS-PAGE was carried out according to the work from 
Schägger and von Jagow [442]. Briefly, the 13.3% 
separating gel consisted of 4.0 mL of a 3 M Tris-HCl and 
0.3% SDS solution at pH 8.5, 1.3 mL of Milli-Q water, 2.7 mL 
of glycerine solution 64%, 4.0 mL of 40% Acrylamide/Bis 
solution, and 0.1 mL of a 10% APS solution. The 6% stacking 
gel was composed of 1.8 mL of a 3 M Tris-HCl and 0.3% SDS 
solution at pH 8.5, 4.2 mL of Milli-Q water, 1.0 mL of 40% 
Acrylamide/Bis solution, and 0.1 mL of 10% APS solution 
10%. In both cases, 10 µL of TEMED were added before 
casting to begin polymerisation. A 10 µL aliquot of loading 
dye (100 mM Tris-HCl pH 6.8, 8% SDS, 24% glycerine, 4% 
DTT, 6 M urea, and 0.05% bromophenol blue) was mixed to 
10 µL of each sample. These solutions were first incubated 
for 5 minutes at 95°C in an Eppendorf Thermomixer 
(Eppendorf Instrumente GmbH), and then loaded into each 
well at room temperature. The cathode buffer was 
composed of 10 mM Tris, 10 mM tricine, and 0.01% SDS, 
whereas the anode buffer was composed by a 20 mM 
Tris-HCl solution. The electrophoresis apparatus Mini-
PROTEAN® Tetra Cell (Bio-Rad Laboratories AG) was set to 
100 V and 20 W. The electrophoresis was run for ~1.5 
hours. The gels were incubated in an aqueous fixing 
solution containing 5% aluminium sulphate, 10% ethanol, 
0.02% Coomassie Brilliant Blue 250-G, and 2.35% 
phosphoric acid for one hour. All percentages are intended 
as w/v, unless otherwise specified. The gels were then dried 
at 70°C for one hour. The dried gels were then scanned and 
the bands’ intensities were compared semi-quantitatively 
with the image processing and analysing software ImageJ 
v1.48v (National Institute of Health, Bethesda, MD). The 
band intensities were normalised to avoid influence of total 
protein concentration differences. The digested BSA band 
intensity was taken at ~60 kDa, whereas the intact BSA 
band intensity y at ~66.5 kDa. The protection from trypsin 
digestion is expressed by Equation 3.5 (below). 
3.2.4 Results 
3.2.4.1 HNT characterisation 
The nanotubular structure of halloysite clay, before and 
after chemical modification, was studied using different 
analytical methods. Results of this characterisation are 
listed in Table 3.6. The measured particle size of the 
nanotubes was in good agreement with literature [323]. 
The rather high variation in particle size distribution 
(span ≥ 1) was expected and is due to the anisotropic 
geometry of the nanotubes. In fact, the measured particle 
size represents the statistical average of HNT’s projections 
in different orientations, which includes their length and 
diameter as extreme values. As a result, chemical treatment 
did not show a significant variation in terms of particle size 
and span. 
The measured ζ-potential values were consistent with 
literature [323]. These surface charge values were not 
significantly influenced by the chemical treatment that is 
expected to act on the luminal surface. While chemical 
 
𝑃𝑟𝑜𝑡𝑒𝑐𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑡𝑟𝑦𝑝𝑠𝑖𝑛 𝑑𝑖𝑔𝑒𝑠𝑡𝑖𝑜𝑛 (%) =
[
 
 
 
 
1 − −
(
𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 𝐵𝑆𝐴
𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 𝐵𝑆𝐴 + 𝑖𝑛𝑡𝑎𝑐𝑡 𝐵𝑆𝐴)
𝑠𝑎𝑚𝑝𝑙𝑒
(
𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 𝐵𝑆𝐴
𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 𝐵𝑆𝐴 + 𝑖𝑛𝑡𝑎𝑐𝑡 𝐵𝑆𝐴)𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑐𝑜𝑛𝑡𝑟𝑜𝑙 ]
 
 
 
 
∙ 100 3.5 
Chapter 3. Formulation of novel lipid-based systems for protein delivery  49 
 
 
etching increased the pore volume and the pore size of the 
nanotubes, the HNT specific surface exhibited only a slight 
variation. Student’s t-test showed statistically significant 
difference in pore volume and size (p < 0.05), whereas such 
significance could not be confirmed for the specific surface 
area. 
3.2.4.2 HNT imaging 
The TEM pictures of the HNT, which are shown in the left 
column of Figure 3.10, confirmed the hollow nanostructure 
of the halloysite clay. The analysed nanotubes had a 
strongly elongated structure, which appeared to be longer 
than 200-300 nm in most cases. The inner diameter of the 
nanotubes shown in Figure 3.10a was ~6 nm, whereas the 
external diameter of the HNT was ~30 nm. The bHNT 
represented in Figure 3.10c retained the same external 
diameter as nHNT, but the lumen diameter was increased 
up to ~20 nm. Figure 3.10e exhibits bHNT after protein 
loading and their external surface appeared to be 
comparatively rougher and less defined. This may suggest 
BSA adsorption on the external HNT surface in addition to 
a likely penetration into the lumen of the clay nanotubes. In 
the right column of Figure 3.10 are shown the images 
gathered from SEM microscopy. The nanoparticle appeared 
to form large clusters in the micrometre range (Figure 
3.10b). Despite the formation of such agglomerates, the 
tubular and elongated structure of each nanoparticle can 
still be clearly identified in both nHNT and bHNT (Figures 
3.10d and 3.10f, respectively). 
3.2.4.3 Microgel and NiMOS size and morphology 
The size and the morphology of the microgels were 
evaluated to understand the HNT influence on the gel 
TABLE 3.6 – Comparison of non-treated and treated nanotubes (nHNT and bHNT, respectively). Statistical significance 
calculated by Student’s t-test (n = 3). Significance expressed as *** (p < 0.001), ** (p <0.01), and (p <0.05). 
Property nHNT bHNT Significance 
Nanoparticle characterisation 
  Particle diameter (nm) 
  Span 
  ζ-potential (mV) 
 
202.0 ± 8.5 
0.969 ± 0.178 
-48.7 ± 3.2 
 
215.3 ± 2.5 
1.190 ± 0.085 
-43.6 ± 1.6 
 
 
 
Surface area measurements 
  Specific surface area (m2 g-1) 
  Pore volume (µL g-1) 
  Pore diameter (nm) 
 
55.53 ± 0.68 
153.6 ± 10.9 
11.00 ± 0.78 
 
53.41 ± 1.16 
216.3 ± 11.9 
16.23 ± 0.60 
 
 
** 
*** 
Protein content 
  Loading efficiency (mg g-1) 
 
36.15 ± 2.50 
 
59.60 ± 4.20 
 
** 
 
FIGURE 3.10 – TEM (left column) and SEM (right 
column) pictures of HNTs. nHNT (a, b, d) bHNT (c, 
f), and bHNT loaded with BSA (e). The nanotubes’ 
lumen is indicated by the arrows. 
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structure during prilling. The median particle sizes of the 
different microgels loaded with HNT are summarised in 
Table 3.7. Microgels produced in water had the largest 
particle size, whereas those formed in DEGEE 
demonstrated smallest particle size. The drying step greatly 
reduced the median particle size for ethanol (~39%). 
Instead, the diameter reduction for particle formed in 
DEGEE after drying was ~23%. The particles formed in 
water could not be measured after drying because of 
significant microgel clustering. Results indicated at least for 
the non-aqueous hardening baths that particle size 
distribution decreased after drying of the microgels. 
 
FIGURE 3.11 – Optical microscope images of prilled microgels. Microgels formed in ethanol (left column), in DEGEE 
(central column), and in water and Tween® 80 (right column). Their composition is non-dried microgels (first row), 
dried microgels (second row), non-dried NiMOS (third row), and dried NiMOS (fourth row). The scale bar is 500 µm 
for all images, except (i) where it is 1 mm. The arrows highlight the thinner central structure of the toroidal-like 
microgels. 
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The pictures taken by optical microscopy are shown in 
Figure 3.11. The microgels formed in ethanol showed 
spherical geometry (Figure 3.11a), which was retained 
regardless of drying (Figure 3.11d) or of the presence of 
HNT (Figure 3.11g and 3.11j). However, the microgels 
prilled into DEGEE (Figure 3.11b, 3.11e, 3.11h, and 3.11k) 
displayed a rather toroidal shape, which was retained after 
drying and was further not affected by inclusion of HNT. 
The microgels obtained in the aqueous hardening bath 
displayed irregular shapes. The non-dried microgels 
resembled thin disks (Figure 3.11c), whereas the dried 
microgels could not maintain structural integrity and 
cracked (Figure 3.11f). After being loaded with HNT, the 
microgels had enhanced irregular shape (Figure 3.11i). 
3.2.4.4 Protein content 
The loading efficiency (Table 3.6) was calculated to 
understand how much protein was either loaded into the 
lumen or adsorbed onto the external surface of HNT after 
loading with the BSA solution. The chemical modification of 
the nanotubes obviously enabled a significantly higher 
incorporation of protein compared to the non-treated 
particles (p < 0.05). However, in either case, it was not 
possible to differentiate how much was adsorbed on the 
particle surface in comparison to the protein fraction that 
entered the nanotubes’ lumen. The encapsulation efficiency 
was assessed in blank microgels and in both types of NiMOS 
dropped in different hardening baths. The data are 
summarised in Table 3.8. The encapsulation efficiency was 
found to be higher in non-aqueous media, in accordance to 
previous reports [28,426]. Both NiMOS showed lower 
encapsulation efficiency than the blank microgels. The 
nHNT-containing microgels displayed higher encapsulation 
efficiency when formed in a DEGEE bath and in aqueous 
medium. bNiMOS had higher encapsulation efficiency when 
formed in ethanol. These differences were found to be 
statistically significant (p ≤ 0.01) after ANOVA testing. 
In light of these findings, further characterisation of the 
microgels and NiMOS, i.e., release test and protein stability, 
was conducted only using systems formed in ethanol as 
hardening bath. 
3.2.4.5 Release test 
Overall, 5 different samples were tested over 24 hours, and 
the initial 4 hours of BSA release are depicted in Figure 3.12. 
Blank microgels were used as a reference. Up to ~95% of 
their BSA content was released and the microgels displayed 
initially almost zero order release kinetics after 24 h. Then,  
TABLE 3.7 – Particle size and shape of nNiMOS formed in different hardening baths 
Hardening bath 
Median particle size 
(µm) 
Particle size span Elongation factor 
wet dry wet dry wet dry 
Water and Tween® 80 1193.1 n.a.g 0.91 n.a.g n.a.h n.a.h 
Ethanol 502.9 311.3 0.68 0.38 1.70 1.70 
DEGEE 396.7 306.7 0.61 0.49 1.66 1.80 
g Dried microgels in water formed large clusters 
h The microgels formed in water, both wet and dry, were too large for the flow-through cell 
TABLE 3.8 – Encapsulation efficiency of NiMOS and blank microgels (i.e., without clay nanotubes) formed in different 
hardening baths. Data are expressed as mean value ± standard deviation (n = 3). 
Type of microgels 
Encapsulation efficiency in different hardening baths (%) 
Ethanol DEGEE Water + 2% Tween® 80 
Blank 75.05 ± 5.18 86.09 ± 6.47 68.33 ± 1.88 
nNiMOS 57.27 ± 3.81 52.95 ± 5.55 45.16 ± 4.31 
bNiMOS 63.16 ± 4.66 48.07 ± 5.39 39.30 ± 2.19 
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 after about 105 minutes a plateau state was reached and 
the final fraction released after 4 hours is 96.9% ± 0.7%. As 
for the BSA-loaded HNT, these samples released their 
content in a first phase rapidly (> 70% in 30 minutes) and 
then released continuously at a slow rate. After 4 hours, 
nHNT and bHNT exhibited a release of 95.3% ± 0.3% and 
84.1% ± 1.4%, respectively. In both cases, the 24-hour 
release was above 95% of the nominal content. An 
interesting behaviour was observed for the BSA release 
from nNiMOS. The initial release rate was between that of  
 the reference and of nHNT, while matching the slower 
release kinetic of the latter after ~90 minutes. nNiMOS 
eventually released 90.3% ± 1.2% of their nominal content. 
bNiMOS showed a sigmoidal release profile of BSA. A brief 
initial lag phase occurred for the first 15 minutes. 
Subsequently, the BSA was released almost linearly until 
60% after 90 minutes. Finally, the profile stabilised to 
match the release kinetics of the BSA-loaded bHNT and 
reached 89.2% ± 2.2% release after 24 hours. The f2 
similarity factors are represented in Table 3.9. All release 
 
FIGURE 3.12 – BSA release profiles over four hours in PBS pH 6.8. Left graph: dried microgels as a reference (circles and 
continuous line), nHNT (triangles and long dashes), and nNiMOS (squares and dotted line). Right graph: dried 
microgels as a reference (circles and continuous line), bHNT (triangles and long dashes), and bNiMOS (squares and 
dotted line). Error bars represent standard deviations (n = 6). 
TABLE 3.9 – f2 similarity factors calculated from the release profiles. Values expressed between 0 and 100; if f2 < 50, 
profiles are considered different. 
f2 similarity factors 
 Microgel nHNT bHNT nNiMOS bNiMOS 
Microgel - 33.6 34.9 44.9 31.8 
nHNT  - 58.0 33.7 21.1 
bHNT   - 38.7 24.1 
nNiMOS    - 37.3 
bNiMOS     - 
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profiles appeared different from one another, except the 
comparison between treated and non-treated HNT. 
3.2.4.6 Protein stability after prilling 
The protein structure stability after manufacturing was 
assessed by spectropolarimetry and spectrofluorimetry. 
The stacked circular dichroism profiles of the samples are 
shown in Figure 3.13. The observed profiles describe the 
typical α-helix structure of BSA with a small contribution of 
its β-sheet fraction [219]. No difference between the BSA 
reference curve and the other samples can be observed, 
neither after loading on the HNT, nor after the prilling step. 
This was further confirmed by the data obtained from the 
circular dichroism spectra deconvolution (Table 3.10). In 
fact, differences in the α-helix fraction of the different 
samples compared to the reference (53.27 ± 1.20%) were 
minimal and they were found to be statistically non-
significant after ANOVA testing. Also, the profiles did not 
show the decrease in intensity and shape modification seen 
in the denatured BSA profile, which had also significantly 
lower α-helix fraction (29.13 ± 3.31%). 
The data collected from the spectrofluorimetric analysis 
confirmed the findings from the circular dichroism profiles 
(Table 3.10). BSA’s three-dimensional structure appeared 
to remain unscathed throughout the manufacturing 
process. The emitted fluorescence profile, in fact, could be 
closely associated to the profile of the BSA standard 
(λmax = 351 nm), which can be seen in Figure 3.14. However, 
a modest yet statistically significant hypochromic effect was 
found for the HNT-loaded BSA according to calculated AUC 
for the measured range. Similar effects have been 
previously reported, and could be due to small electrostatic 
interactions with unbound carboxylic groups of MCC with 
unusually low pKa. However, this hypochromic effect 
cannot be attributed to any structural change [443]. Also, 
the samples’ fluorescence intensity was clearly higher than 
the denatured BSA profiles. 
TABLE 3.10 – Comparison of protein stability after manufacturing and enzymatic digestion. Significance (Sign.) 
expressed as *** (p < 0.001), ** (p <0.01), and * (p <0.05) after ANOVA testing. Data are expressed as mean value ± 
standard deviation (n = 3). 
Stability Microgel i nHNT bHNT nNiMOS bNiMOS Sign. 
Circular dichroism 
  α-helix fraction (%) 
 
51.4 ± 0.7 
 
51.6 ± 0.5 
 
52.0 ± 0.9 
 
51.3 ± 0.3 
 
51.4 ± 0.6 
 
 
 
Fluorescence 
  AUC (RFU nm) 
 
  λem (nm) 
 
95980 ± 541 
349.3 ± 1.5 
 
105809 
± 1996 
351.0 ± 1.0 
 
105753 
± 2207 
351.0 ± 1.0 
 
96075 ± 258 
350.0 ± 1.0 
 
96339 ± 198 
350.3 ± 1.5 
 
*** 
 
 
 
SDS-PAGE 
  Protection from 
  digestion (%) 
 
4.85 ± 4.38 
 
45.99 ± 6.99 
 
56.53 ± 6.98 
 
62.22 ± 9.64 
 
81.54 ± 3.76 
 
*** 
i dried microgel obtained from prilling into the ethanol hardening bath 
 
FIGURE 3.13 – Overlaid circular dichroism profiles of 
denatured BSA with guanidine hydrochloride (a), of 
BSA standard (b), and of BSA loaded in dried 
microgels (c), nHNT (d), bHNT (e), nNiMOS (f), and 
bNiMOS (g). 
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 3.2.4.7 Protein stability after enzymatic digestion 
The microgels and the NiMOS were digested with trypsin to 
evaluate the extent of their protein protection from 
enzymatic degradation. The results of the SDS-PAGE 
analysis are shown in Figure 3.15. The BSA standard (lane 
2) exhibits a large band between the protein marker bands 
at ~55 and ~70 kDa, which was in agreement with BSA’s 
molecular weight of 66.5 kDa. Also, a secondary band 
appeared at higher molecular weight, which was due to 
impurities and BSA aggregates. A blank sample containing 
trypsin (~22.3 kDa) and trypsin inhibitor (20.1 kDa) is 
shown in lane 3. A second band close to the trypsin inhibitor 
band was present, which was apparently due to the self- 
digested trypsin enzyme. The positive and the negative 
controls are in lanes 4 and 5, respectively. The positive 
control was obtained by directly adding BSA standard in the 
trypsin digesting medium, and then adding trypsin 
inhibitor after one hour, similarly to the other samples. The 
negative control had the inhibitor added from the start of 
the digestion. The BSA after enzymatic digestion appeared 
as a shorter band with a molecular weight between that of 
BSA and ~55 kDa (indicated by the arrow in the figure, in 
lane 4). The BSA-loaded microgels showed poor protection 
of the protein, either when non-dried (lane 6) or when dried 
(lane 7). The protection from trypsin digestion was, in both 
cases, below 5%. The use of non-treated and treated HNT 
considerably increased protection to 46.0 ± 7.0% (lane 8) 
and 56.5 ± 7.0% (lane 9), respectively. However, by forming 
NiMOS with the nHNT, 62.2 ± 9.6% of BSA remain 
unscathed, as seen in lane 10. Finally, the luminal etching of 
halloysite combined with microencapsulation, i.e. bNiMOS, 
demonstrated protection from enzymatic digestion to a 
highest value of 81.5 ± 3.8% (lane 11). The differences 
between these means were found to be statistically 
significant after ANOVA testing (n = 3, p < 0.001), as seen in 
Table 3.10. 
3.2.5 Discussion 
This work designed and studied a novel multi-compartment 
system obtained by prilling for potential oral protein 
delivery. Thus, protein-loaded natural clay nanotubes were 
dispersed in a polymeric solution followed by prilling into a 
hardening bath to form microgels. The results are discussed 
in terms of nanotube characterisation, feasibility and 
properties of prilled NiMOS, which includes protein 
stability in this multi-compartmental drug delivery system. 
3.2.5.1 HNT characterisation 
The used HNT exhibited morphological and 
physicochemical properties that were consistent with data 
reported in the literature. Moreover, the alkaline activation 
step did not alter the external appearance of the HNT and 
did not change the average particle size. Chemical etching 
led to larger lumen size by reducing the nanotube wall 
thickness, which agreed well with previous findings [340]. 
The alkaline groups in the lumen may have selectively 
removed aluminium-containing internal layers from the 
nanotubes. However, the inner layer removal did not result 
in greatly impaired mechanical wall strength, because no 
indication of collapsed tubes was detected. A similar 
nanotubular structure was clearly visible for both the 
treated and the non-treated HNT by TEM and SEM. While 
TEM images could only provide an indication of enlarged 
luminal size, the BET data confirmed an increased lumen 
diameter and volume thereby demonstrating the success of 
the chemical etching step. 
A key finding from the loading efficiency measurements 
(Table 3.6) was that the chemical etching improved the BSA 
loading of HNT. Given the rather large structure of BSA 
(14 × 4 × 4 nm [444,445]), the steric hindrance caused by 
the ~10 nm wide HNT lumen may limit protein access into 
the nanotubes. This luminal enlargement effect is 
interesting because previous work often had small 
molecules loaded into HNT [328,329] and the inner 
diameter was there less critical for drug loading. Especially 
for BSA, the inner surface of the nanotubes is important 
because the protein has an isoelectric point of  4.7 [412] so 
 
FIGURE 3.14 – Overlaid emitted fluorescence profiles 
of BSA as standard (a), loaded in dried microgels (b), 
nHNT (c), bHNT (d), nNiMOS (e), and bNiMOS (f), 
and denatured with guanidine hydrochloride (g). 
λex = 280 nm. 
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that a net negative charge is given at neutral conditions. A 
similar net negative surface charge is expected on the 
surface of HNT caused by the SiO2 groups and was 
confirmed by the measured negative ζ-potential. Different 
from this outer surface chemistry is the inner layer of the 
nanotubes, which is dominated by aluminium hydroxide 
and displays a positive ζ-potential at neutral conditions 
[321]. This positive surface charge could be beneficial for an 
interaction with BSA regarding efficient loading into the 
HNT. Due to the layered structure of HNT, the positively 
charged inner surface layer may be retained after chemical 
etching. Our finding of a high protein loading into the 
treated HNT may confirm that even though the pores were 
enlarged, the surface charge was likely to remain positive at 
the luminal surface layer. 
Compared to the chemical etching and loading of BSA 
primarily into the HNT, there are other methods reported 
for drug loading. Drug was for example adsorbed onto the 
HNT external surface by using charged polymers [342], or 
formation of a mesoporous structure [338]. The loading of 
a therapeutically active protein into the lumen, however, 
may provide a biopharmaceutical advantage by granting 
degradation protection. As mentioned earlier, halloysite 
from different extraction sites exhibited different 
properties, such as larger luminal diameter [327]. 
Consequently, a suitable chemical activation may need to be 
fine-tuned according to the geometry of the employed HNT. 
3.2.5.2 Prilled NiMOS characterisation 
An important finding was that prilling proved to be a 
suitable technology for manufacturing Nanotubes-in-
Microgel Oral Systems. MCC was employed as microgel-
forming polymer to host the HNT that incorporated BSA as 
model protein. This nanocomposite material seems very 
interesting regarding the regulatory acceptance of the 
excipients employed and the rather narrow size 
distribution of the microparticles. Different ratios of HNT-
to-polymer solution were tested. From a manufacturing 
perspective, a lower solid fraction is preferred to reduce 
viscosity, while otherwise highly concentrated suspensions 
 
FIGURE 3.15 – SDS-PAGE of BSA loaded into different dried microgels, HNTs, and NiMOS. From left to right, protein 
marker (lane 1), BSA standard (lane 2), blank with trypsin and trypsin inhibitor (lane 3), positive control (lane 4), 
negative control (lane 5), non-dried microgels (lane 6), dried microgels (lane 7), nHNT (lane 8), bHNT (lane 9), 
nNiMOS (lane 10), and bNiMOS (lane 11). Further description of the samples in the different lanes is given in the text. 
The arrow highlights the trypsin-digested BSA protein. 
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could lead to processing issues. Inadequate rheological 
properties are a more general issue in pharmaceutical 
dispersion manufacturing. A high viscosity at a given 
processing shear rate can for example negatively affect 
quality attributes, such as the filling adequacy into capsules 
[446]. Viscosity is also a key factor in the process of prilling 
when the liquid stream is passing through the narrow 
prilling nozzle and for liquid jet breakup [23,231,249,391]. 
From a formulation viewpoint, however, a higher solid 
fraction is preferred for it would allow a higher 
macromolecule loading into the microgels. While a HNT-to-
polymer solution ratio of 1:10 (w/w) was found to be close 
to the limit of technical processability, a ratio of 1:20 (w/w) 
appeared to optimally balance drug-loading and 
manufacturing aspects. 
The NiMOS formation by prilling further revealed lower 
encapsulation efficiency, compared to blank microgels. As 
known from previous literature, the presence of nanotubes 
appears to affect the microgel matrix [447]. This is 
especially critical during the hardening step as part of the 
prilling process. The likely mechanism of hardening in a 
non-aqueous medium has been described earlier by De 
Kruif et al. [28,426]. Briefly, when the droplets enter the 
hardening bath, the polymers undergo local surface coiling, 
which is caused by the difference in physicochemical 
properties between the aqueous microgel medium and the 
non-aqueous hardening bath environment [55,410]. In 
parallel, the polymer chains begin cross-linking by the Ca2+ 
ions present in the hardening bath. Both effects may cause 
a shrinking of the microgel especially close to the surface 
layer. In presence of HNT, this complex hardening process 
was evidently disturbed and the strength of the MCC cross-
linking affected by the presence of solid material, which was 
finally leading to poorer encapsulation efficiency due to BSA 
leakage. When using an aqueous hardening bath, the 
surface coiling of the polymers due to the different 
properties of the microgel solution and the hardening bath 
is barely given. Gel strength is here primarily achieved by 
the cross-linking via Ca2+-ions.  
However, the network formed by the MCC gel may not be 
tight enough to prevent the BSA leakage from the microgel 
of HNT. The encapsulation efficiency of the aqueous 
hardening bath may therefore have been lower than in non-
aqueous systems. 
The kinetic profiles of nHNT and bHNT showed a 
comparatively fast initial release, followed by a phase of 
much slower release rate. Different compounds have shown 
different release profiles from the nanotubes [328]. Diverse 
release profiles are mainly determined by electrostatic 
interactions of given APIs with the outer or inner surface of 
the nanotubes. As previously mentioned, BSA (pI 4.7) was 
to some extent loaded into the HNT at pH 6.8, so that the 
model drug could interact with the positive charges of the 
inner HNT surface. However, the external HNT surface still 
possessed a considerably high surface area, thus allowing 
here at least some absorption of BSA. These two 
interactions may explain the bimodal release of the BSA 
from HNT, namely rapid kinetics from the surface and 
slower release from the lumen. Previous reports have 
shown that HNT alone released macromolecules between 
50-500 hours [321]. However, such long release times are 
less relevant for oral delivery, which is limited by GI transit 
time. We selected 24 hours as observation time to obtain a 
good overview of the release kinetics, while still being 
physiologically relevant. Within this time frame, HNT 
showed initially a faster release that in a second phase 
stabilised at a lower release rate over time. Such 
comparatively fast initial release was also previously 
observed with for example insulin release from HNT within 
a 24-hour time span [321]. 
Blank dried microgels had initially a kinetic order close to 
zero (R2 = 0.97). The slower release of blank microgels 
compared to BSA-loaded HNT was linked to the swelling 
process that is typical for a dried hydrophilic polymer-
based microgel. Before releasing the content, the MCC 
chains need to be hydrated and go through a swelling step. 
Consequently, water can penetrate the gradually swelling 
polymer structure and allow BSA diffusion into the 
surrounding medium. 
Both BSA-loaded HNT revealed significantly different 
profiles compared to the blank microgels alone. However, 
the presence of HNT obviously influenced the release of BSA 
from the microgels. In fact, the release behaviour of NiMOS 
was evidently determined by the combination of both HNT 
and microgel. As earlier described, HNT interacts with the 
microgel structure. Cavallaro et al. for example showed that, 
in HNT-filled dried alginate beads, the nanotubes tended to 
be more concentrated closer to the core than to the surface 
of the droplet [447]. This effect may explain the initial lag 
time in the release of the bNiMOS. Already the pure 
nanotubes demonstrated a complex release behaviour that 
consisted of more than one kinetic phase. It was assumed 
that the fractions of albumin in the nanotubes as well as on 
the external surfaces may have caused such different kinetic 
phases. The added microgel present in the NiMOS further 
added complexity in terms of structure and release 
mechanism. Interesting was that initial release from 
nNiMOS and bNiMOS exhibited larger differences compared 
to nHNT and bHNT. 
Considering particle morphology, the presence of HNT 
appeared not to modify the shape of the prilled microgels. 
Similarly, HNT also helped the NiMOS to retain their shape 
even after the drying step. The close interaction of the clay 
nanoparticles with the polymer was probably 
strengthening the swollen MCC gel structure during drying. 
Consequently, the particle size reduction after gelling was 
diminished in presence of HNT compare to blank microgels. 
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Finally, the choice of the hardening bath seemed to 
influence the microgel particle, as previously reported [28]. 
Of all formulations, ethanol allowed higher sphericity, 
smaller microgels, and reduced particle size distribution. 
The toroidal shape formed by DEGEE-based hardening 
baths, instead, was maintained and enhanced by the 
presence of HNT in the microgel. This further confirmed the 
influence of HNT presence on microgel morphology during 
prilling. 
3.2.5.3 Protein stability 
The protein stability was evaluated after the prilling 
process and following enzymatic digestion. This stability 
study was important to preliminarily assess the delivery 
system’s protection from GI enzymes. Moreover, it allowed 
to differentiate the individual effects of nanotubes, 
microgels, and NiMOS using an in vitro enzymatic digestion 
test. One of the key findings of this work is that NiMOS 
indeed showed superior protection from trypsin digestion. 
Compared to the positive control, blank microgels were not 
able to offer significant protection from the enzymatic 
digestion. Treated and non-treated HNT alone provided 
limited benefit to protein stability. Instead, NiMOS showed 
a significant increase in BSA protection from digestion. 
Furthermore, the treated bHNT exhibited an advantage in 
terms of protection both when used alone and when it was 
present in microgels. The mechanistic explanation for this 
protection is both challenging and interesting. The release 
kinetics could be contributors to the results obtained by 
NiMOS, but this may not be the only relevant mechanism. In 
fact, BSA was released from HNT in a shorter time than from 
blank microgels, whereas the enzymatic protection was 
higher. Electrostatic interactions between anionic MCC 
polymer and trypsin could have influenced the result. 
Bovine trypsin has an isoelectric point of ~10.3 [448] which 
was likely resulting in a positive charge on the enzyme 
surface at the buffered pH 6.8 [449]. Trypsin may have 
interacted with the negatively-charged external wall of the 
nanotubes to a higher extent than BSA. Both compounds, in 
fact, have been shown to interact with and adhere on 
silicate surfaces [450,451]. The mechanistic explanation of 
the enzymatic degradation reduction may be a balance and 
combination of the aforementioned effects, as well as due to 
prolonged release. In light of these findings, there is a strong 
biopharmaceutical rationale in favour of NiMOS compared 
to HNT alone. NiMOS could be further loaded as dry powder 
into hard or soft capsules. The capsules can be provided 
with enteric coating to enhance the protection from 
enzymatic degradation. 
An important finding was that the manufacture of NiMOS 
via prilling appeared to be harmless to the protein structure 
in case of the model drug. The BSA loading on HNT did not 
alter the protein three-dimensional structure. Also, the 
chemical activation was correctly achieved without leaving 
residues potentially harmful for the protein. While prilling 
in non-aqueous media has been earlier described as feasible 
for proteins [28], some lipid-based formulations have 
shown to be potentially detrimental [426]. An example of a 
known protein denaturant is ethanol [415].Potential 
conformational changes in the protein, which may be 
caused by ethanol denaturation, should be detected in 
either circular dichroism or Trp-212 emitted fluorescence 
spectra [407,421,422]. Despite the influence of HNT on the 
microgel structure, ethanol was apparently not able to 
cause harm to the loaded protein, as shown by α-helix 
fractions and the fluorescence emission spectra. 
3.2.6 Conclusion 
The present work demonstrated the successful feasibility of 
Nanotubes-in-Microgel Oral System (NiMOS) prepared by 
prilling for delivery of macromolecules. The manufacture of 
these nanocomposite microgels appeared to be not harmful 
for the model protein BSA. Halloysite (HNT), a natural, 
cheap, and non-toxic clay, proved suitable for protein 
loading due to its favourable nanotubular hollow structure. 
The chemical etching of the nanotube lumen was leading to 
improved loading efficiency. The prilling approach allowed 
formulation of a nanocomposite hydrogel, which showed 
interesting properties in terms of enzymatic protection and 
modified release. Especially, the preliminary in vitro 
assessment of protection from enzymatic degradation 
showed promising results for the NiMOS for local oral 
protein delivery. The combination of nanotubes and 
microgels had a synergic effect that prevented our model 
protein’s digestion. NiMOS provide a versatile DDS, either 
dispersed with lipid-based system [28,426] or directly filled 
in capsules as a dry powder as suggested in the present 
paper. 
An adequate fine-tuning of the polymer type and properties 
may allow modification of the release profiles of the system, 
thus adapting the NiMOS to the therapeutic needs of the 
loaded macromolecule. The multi-compartment system 
could be further used to create fixed-dose combination 
dosage forms, with tailored release profiles and optimal 
enzymatic protection from the gastrointestinal 
environment. Prilling also bears the potential to provide a 
two compartment system, i.e., a microcapsule with a core 
and a shell, thus forming a highly versatile and adaptable 
system. Further research on the proposed NiMOS may 
explore the advantages of such structured systems, as well 
as address in-depth in vitro modelling and preliminary in 
vivo biopharmaceutical studies of therapeutically active 
proteins. 
 
 Chapter 4 
Manufacturing and formulation 
quality aspects of LB 
pharmaceutical dispersions as 
drug delivery systems 
4.1 A systematic study on 
manufacturing of prilled microgels into 
lipids for oral protein delivery § 
4.1.1 Summary 
The development of novel systems with oral protein 
delivery as ultimate goal represents an important field of 
pharmaceutics. Prilling of protein-loaded polymeric 
solutions into lipid-based hardening baths could provide 
here an attractive formulating technology. Since the 
obtained microgel dispersion can be directly capsule-filled, 
no drying step is required and thermal drug degradation is 
avoided. This study aims to find excipient combinations for 
the novel prilling process and investigate systematically 
diverse material and process factors. Bovine serum albumin 
and mono-N-carboxymethyl chitosan were selected as 
model protein and prilling polymer, respectively. The 
prilling suitability of 880 formulations was screened with 
60 ternary phase diagrams comprising two co-solvents, ten 
different glycerides and three so-called complementary 
                                                                        
§  de Kruif JK et al. A systematic study on manufacturing of prilled microgels into lipids for oral protein delivery. Journal 
of Pharmaceutical Sciences, 2015, 104:3351-3365. 
excipients. Preliminary capsule compatibility was tested for 
one month on 245 formulations in hard and soft capsules 
with different shell materials. Ternary phase diagrams’ 
centre points were used to evaluate morphology, 
encapsulation efficiency, and protein stability of the prilled 
microgels. As result, several formulations proved suitable 
for prilling and compatible for capsule filling. Statistical 
analysis using partial least square regression revealed 
significant factors regarding different quality attributes of 
microgel dispersions. Therefore, an improved 
understanding was obtained for this promising drug 
delivery approach. 
4.1.2 Introduction 
Oral delivery of protein drugs is a challenging field of 
modern pharmaceutical sciences, and there is a rising 
interest in this type of drug delivery [18,185,383,423]. 
However, the gastrointestinal tract (GI) represents a major 
hurdle in terms of bioavailability for proteins and peptides 
administered orally. Macromolecules like proteins and 
peptides generally require protection from gastric 
degradation and enzymatic digestion. Additionally, they 
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must cross the mucus and mucosal layer if absorption is 
needed to achieve a therapeutic effect [183]. Depending on 
the pharmacological target, it is possible that only luminal 
activity or additional mucus penetration is sufficient to 
ensure the macromolecule’s efficacy. Many approaches 
have been proposed over the years to overcome the GI tract 
biopharmaceutical barriers. Microencapsulation was found 
to be very promising for oral protein delivery especially in 
terms of protection from enzymatic degradation 
[21,22,389]. Furthermore, some polymers used for 
microencapsulation, like chitosan derivatives, are known to 
have mucoadhesive properties and even permeation 
enhancing characteristics [192,278,396]. Such properties 
have been reported for the non-toxic and water-soluble 
mono-N-carboxymethyl chitosan (MCC), which may thus 
qualify as a polyfunctional polymer [169,394,395]. 
Hydrogels formed from similar polymers are further able to 
create a suitable environment for a macromolecule, e.g., in 
terms of pH and ionic strength, to ensure drug integrity 
[21,389,397,452]. Moreover, the microencapsulation may 
allow protection from the GI milieu [20]. A combination of 
microgels and lipid-based drug delivery was targeted in this 
work by means of a prilling process. This approach holds a 
biopharmaceutical promise, but its primary formulation 
rationale is of technical nature to enable a manufacturing in 
capsules as oral dosage form. Prilling is a mild 
microencapsulation technique that is suitable for protein 
loading [22]. This technique allows the entrapment of an 
API into a hydrogel by dropping a drug-containing 
polymeric solution into a hardening bath [245,250]. During 
prilling (Figure 4.1), a liquid stream of the polymer and API 
solution is extruded from a nozzle. The stream is disrupted 
into droplets of the same size by applying a vibration at high 
frequency. The droplets can be visualised mid-air through a 
set of vertically aligned stroboscopic lights. The droplets 
can be charged by falling through a ring electrode, to 
prevent mid-air coalescence [238]. Finally, they are 
collected into the hardening bath, where gelling can occur, 
for example, by ionic cross-linking or by changes in 
temperature. The conventional hardening baths are water-
based [245,250,453], but this leads to further 
manufacturing steps, such as drying, that may harm a 
loaded macromolecule. A notable exception to aqueous 
hardening baths was presented by Buthe et al., who 
proposed n-butanol as a calcium-containing non-aqueous 
medium to harden alginate beads [247]. However, this 
reference study neither reported the loading of API into the 
beads, nor employed an orally acceptable excipient. De 
Kruif et al. recently introduced a non-aqueous lipid-based 
hardening bath to obtain protein-loaded hydrophilic 
microgels formed by ionic cross-linking [28]. This new 
approach provides a lipid-based fill mass ready to be 
directly loaded into hard or soft shell capsules without any 
intermediate drying step. Nevertheless, there are multiple 
formulation and process factors that can influence the 
microgel dispersion quality. Therefore, our aim was to 
systematically study the influence of different excipient 
factors on various formulations attributes. The final 
purpose was to explore a potential design space for the 
formulation principle. 
4.1.3 Materials and methods 
4.1.3.1 Materials 
Transcutol® HP (diethylene glycol monoethyl ether; 
DEGEE), Maisine™ 35-1 (glyceryl monolinoleate), and 
Labrafil® M2125CS (linoleoyl macrogol-6 glycerides) were 
 
FIGURE 4.1 – Scheme of vibrating nozzle system. 1 
polymeric solution feed; 2 vibrating unit; 3 nozzle; 4 
stroboscopic light; 5 electrode ring; 6 grounding; 7 
magnetic stirrer; 8 hardening bath. Not to scale. 
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kindly offered by Gattefossé SAS (Saint Priest, France). 
Absolute ethanol was obtained from Brenntag 
Schweizerhall AG (Basel, Switzerland). Capmul® MCM EP 
(glyceryl monocaprylocaprate), Capmul® MCM-C10 EP 
(glyceryl monocaprate), Capmul® MCM-C8 EP (glyceryl 
monocaprylate), Captex® 8000 (glyceryl tricaprylate), 
Captex® 1000 (glyceryl tricaprate), and Acconon® CC-6 
(caprylocaprate macrogol-6 glycerides) were purchased 
from ABITEC Co. (Janesville, WI). Miglyol® 812 (glyceryl 
tricaprylocaprate), Imwitor® 742 (glyceryl 
caprylocaprate), and peppermint oil were bought from 
Hänseler AG (Herisau, Switzerland). Polyethylene glycol 
(PEG) 600 was obtained from AppliChem GmbH 
(Darmstadt, Germany). Mono-N-carboxymethyl chitosan 
(deacetylation degree 96.1%, carboxymethylation degree 
82.1%, loss on drying 20.5%, molecular weight 
9000-13 000 g mol-1) was supplied by Shanghai Boyle 
Chemical Co. Ltd (Shanghai, China). Beta-mercaptoethanol, 
bovine serum albumin 96% (BSA), calcium chloride 
anhydrous, propylene carbonate, potassium dihydrogen 
phosphate, sodium dihydrogen phosphate dihydrate, 
sodium hydroxide and dipotassium hydrogen phosphate 
were purchased from Sigma-Aldrich (Saint-Louis, MO). The 
Low Molecular Weight Reagent Kit was purchased from 
Perkin Elmer (Schwerzenbach, Switzerland) and the Micro 
BCA™ Protein Assay Kit was obtained from Thermo Fisher 
Scientific AG (Rockford, IL). 
4.1.3.2 Polymeric solution preparation 
The polymeric solution was prepared by modifying a 
previously reported method [28]. Briefly, a 4.5% (dry 
substance; w/v) solution of MCC was prepared by 
dissolving the polymer in demineralised water. The 
complete hydration of the polymer solution was allowed by 
mixing thoroughly overnight. The polymeric solution was 
then vacuum-filtered through glass microfiber filters 
Whatman™ GF/D and BSA was added to the solution to 
obtain a 2.5% (w/v) concentration. This solution was 
subsequently stored in a brown glass bottle at +4°C, and it 
was allowed to reach room temperature before each use. 
The solutions were discarded after one week from 
preparation, to avoid possible microbial contamination. 
Placebo solutions were prepared in the same way without 
adding any BSA to the solution. 
4.1.3.3 Ternary phase diagrams 
The ternary phase diagrams were prepared by mixing three 
components at different ratios, namely one co-solvent 
(DEGEE or ethanol), one glyceride (Acconon® CC-6, 
Capmul® MCM, Capmul® MCM-C8, Capmul® MCM-C10, 
Captex® 8000, Captex® 1000, Imwitor® 742, Labrafil® 
M2125CS, Maisine™ 35-1, or Miglyol® 812), and one 
complementary excipient (PEG 600, propylene carbonate, 
or peppermint oil). The glycerides were chosen according 
to their high diversity in chemical composition. In fact, the 
glycerides’ composition varied in terms of fatty acid chain 
length (caprylates, caprates, and linoleates), predominance 
of unsubstituted glyceride hydroxyl groups (“free hydroxyl 
groups”), as well as presence of a PEG group. The 
predominance of unsubstituted glyceride hydroxyl groups 
was categorised according to the hydroxyl value of the 
glycerides in low (less than 150 mgKOH g-1), medium 
(between 150 and 300 mgKOH g-1) and high (more than 
300 mgKOH g-1). The hydroxyl values were obtained from the 
glycerides’ certificate of analyses. Table 4.1 summarises the 
properties of all the components employed in the ternary 
phase diagrams. Each ternary phase diagram comprised 25 
mixtures. While all the mixtures were prepared at room 
temperature, the single components were heated or melted 
before use, according to the excipient manufacturers’ 
instructions. The components were weighed into a glass 
vial to the appropriate ratio and subsequently mixed at 
room temperature for one hour with a magnetic stirrer. 
After one-hour equilibration, the miscibility of the 
components was visually assessed and a score was assigned 
to each formulation. The score was labelled as 2 for a 
homogeneous system, 1 for signs of incomplete miscibility 
or turbidity, or 0 for an immediate phase separation. An 
aliquot of calcium chloride anhydrous (4.5% w/w) was 
added to the mixture and the turbidity was evaluated after 
thorough mixing for 24 hours. In this case, the score 
assigned was 2 for a clear solution, 1 for opalescence or 
slight turbidity, or 0 in any other case. Finally, the MCC 
polymeric solution was dripped from a syringe mounted 
with a blunt needle (gauge size 18) into each hardening 
bath formulation. The suspended droplets were 
immediately mixed at maximum speed using an Ika® 
Vortex Genius 3 (Hüber & Co. AG, Reinach, Switzerland) to 
verify their gelling. The assigned score was 2 for spherical 
hydrogels, 1 for irregular or partially coalesced droplets, 
and 0 if gelling did not occur. After overlaying the ternary 
phase diagrams of the different mixture characteristics, an 
overall score was assigned by multiplying each partial score 
according to Equation 4.1. 
 𝑂𝑣𝑒𝑟𝑎𝑙𝑙 𝑠𝑐𝑜𝑟𝑒 = 𝑚𝑖𝑠𝑐𝑖𝑏𝑖𝑙𝑖𝑡𝑦 𝑠𝑐𝑜𝑟𝑒
×𝑠𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦 𝑠𝑐𝑜𝑟𝑒
×𝑔𝑒𝑙𝑙𝑖𝑛𝑔 𝑠𝑐𝑜𝑟𝑒 
4.1 
Therefore, possible values of this overall score were 0, 1, 2, 
4, or 8. 
4.1.3.4 Capsule compatibility with hardening bath 
excipients 
Four types of commercially available capsules were filled 
with the hardening baths and stored for 4 weeks at 25°C 
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and 45% relative humidity. The two-piece hard capsules 
were gelatine Licaps® (Capsugel France SAS, Colmar, 
France) and hypromellose Quali-V® (Qualicaps® Europe 
SAU, Alcobendas, Spain). Both capsule types were opaque 
white and of size 0. The soft capsules were oval and of size 
10, and their shell material was gelatine (SGC) or starch 
(VegaGels®), both supplied by Aenova GmbH (Kirchberg, 
Switzerland). All capsules were kindly provided by their 
respective manufacturer. Only formulations with an overall 
score higher than 1 and a co-solvent fraction lower than 
0.35 were selected for capsule filling. The two-piece hard 
capsules were loaded with 500 µL of the hardening baths. 
The same quantity of hardening bath formulation was 
injected in the soft capsules with a 20 gauge needle. The 
opening thereby formed was sealed on a hot plate. All 
capsules were kept in the darkness in upright position for 
four weeks. After each week, the capsules were inspected 
for signs of incompatibility, e.g. deformations or leaking. 
Capsules which showed signs of incompatibility already 
after the first week were classified as “immediately” 
incompatible. If the capsules showed signs of 
incompatibility after the second or third week, then they 
were described by “short-term” incompatibility. Finally, 
capsules without any sign of capsule deformation, crack 
formation, or leaking were assigned to the “absent” 
incompatibility category. 
4.1.3.5 Prilling of the polymeric solution 
The hydrophilic microgels were prepared with the 
vibrating nozzle technique using the Encapsulator Biotech 
(EncapBioSystems Inc., Greifensee, Switzerland; currently, 
this instrument is manufactured and distributed by Büchi 
Labortechnik AG, Flawil, Switzerland). The polymeric 
solution containing BSA was loaded into 60 mL Omnifix® 
plastic syringes (B. Braun Melsungen AG, Melsungen, 
Germany). This solution was then extruded through a 
300 µm stainless steel nozzle at a rate of 12.1 mL min-1, 
using a vibration frequency of 1060 Hz and an amplitude set 
to 9. The droplets flowed through the electrode ring 
charged at 2460 V and fell from ~15 cm into 100 mL of the 
hardening bath containing dissolved calcium chloride, 
which was stirred at ~600 rpm. These conditions were 
found to be optimal for the prilling process. A total of 5 g of 
polymeric solution was used for each batch and the 
produced microgels were left in their respective hardening 
bath for one hour before further analysis. 
4.1.3.6 Morphological characterisation of the 
microgels 
The microgels were analysed in term of particle size and 
shape by dynamic image analysis using an XPT-C 
TABLE 4.1 – Hardening bath component list and properties of the selected glycerides. 
Excipient list 
Glyceride properties 
Free hydroxyl group 
content j 
Chain length PEGylation 
Co-solvents 
  Ethanol 
  DEGEE k 
   
Glycerides 
  Acconon® CC-6 
  Imwitor® 742 
  Captex® 8000 
  Captex® 1000 
  Capmul® MCM-C8 
  Capmul® MCM-C10 
  Miglyol® 812 
  Capmul® MCM 
  Labrafil® M2125CS 
  Maisine™ 35-1 
 
medium 
medium 
low 
low 
high 
high 
low 
high 
low 
medium 
 
8-10 
8-10 
8 
10 
8 
10 
8-10 
8-10 
18 
18 
 
yes 
no 
no 
no 
no 
no 
no 
no 
yes 
no 
Complementary excipients 
  PEG 600 
  Propylene carbonate 
  Peppermint oil 
   
j categorised according to the hydroxyl value; further explanation in the text 
k diethylene glycol monoethyl ether 
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flow-through cell particle analyser (PS-Prozesstechnik 
GmbH, Basel, Switzerland). The microgels (n = 200) were 
suspended in their hardening bath and then pumped into 
the flow-through cell of the instrument. The particle size 
was described in terms of Waddle disk diameter, which is 
the diameter of a disk with the same area as that projected 
by a given particle. 
The particle shape was expressed as the elongation factor, 
which is the maximum Feret diameter (the linear segment 
connecting the two perimeter points that are the furthest 
apart) divided by the Feret equivalent rectangular short 
side (the shortest side of the rectangle with the same area 
as the particle and the longest side equal in length to the 
maximum Feret diameter). For a perfectly spherical 
particle, the elongation factor is 4/π (≈1.27). The XPT-C 
equipment also allowed the imaging of each analysed 
particle to visually assess the morphology of the microgels. 
4.1.3.7 BSA encapsulation efficiency in microgels 
Each 5 g batch of hardened microgels was filtered over a 
125 µm opening stainless steel sieve. The particles were 
washed with absolute ethanol to remove traces of 
hardening bath, which could interfere with the protein 
assay. The samples were first dissolved in phosphate buffer 
saline pH 6.8 overnight at room temperature to release BSA 
completely, and then stored at +4°C before further analysis. 
The required amount of solution was centrifuged at 
10 000 rpm for 10 minutes in a 5415C centrifuge 
(Eppendorf GmbH, Leipzig, Germany), and the supernatant 
was subsequently filtered through Titan 3 nylon filters 
0.45 µm (SMI-LabHut Ltd, Maisemore, UK). The protein 
content of the sample was determined using the Micro 
BCA™ Protein Assay Kit, which is based on the bicinchoninic 
acid assay [401–404]. After treating the sample according 
to the protocol supplied by the manufacturer, the protein 
content was measured spectrophotometrically in a 
SpectraMax M2e plate reader (Molecular Devices LLC, 
Sunnydale, CA) at 750 nm after being loaded in 96-well 
clear BRANDplates® pureGrade™ (Brand GmbH + CO KG, 
Wertheim, Germany). The encapsulation efficiency (EE) is 
expressed as shown in Equation 3.3. 
4.1.3.8 Protein stability 
4.1.3.8.1 Circular dichroism of BSA 
The modification of BSA’s secondary structure was 
evaluated by comparing the protein circular dichroism 
spectra after release from the microgels. The spectra were 
recorded on a Jasco J-810 spectropolarimeter (Jasco Inc., 
Easton, MD). The sample was loaded in a 1 cm optical path 
quartz cuvette and analysed in the far-UV range 
(200-260 nm). For a visual and qualitative analysis, the 
profiles were normalised by their intensity to remove the 
influence of protein concentration on the evaluation. The 
data are expressed as mean residue ellipticity 
(mdeg cm2 g-1), which is calculated according to Equation 
3.4. 
For quantitative assessment, the profiles were 
deconvoluted with the software CDNN v2.1 [441]. The 
software calculates the fraction of the protein’s secondary 
structures, namely α-helices, β-coil, antiparallel β-sheet, 
parallel β-sheet, and random coils. The modification of 
BSA’s secondary structure was assessed from the change in 
α-helix fraction. Our reference BSA sample’s α-helix content 
was 54.7%, which was in good agreement with the 
literature [454]. 
4.1.3.8.2 Microfluidic capillary electrophoresis 
The microfluidic capillary electrophoresis was conducted to 
detect potential protein aggregation or degradation. The 
analysis was carried out on a LabChip® GXII high 
throughput chip microfluidic capillary electrophoresis 
(Caliper Life Sciences, Hopkinton, MA) by using the Low 
Molecular Weight Reagent Kit. The samples were prepared 
both in reducing and non-reducing conditions. In the 
former case, beta-mercaptoethanol was used as a reducing 
agent. The samples were measured according to the 
protocol supplied by the manufacturer. The software used 
to evaluate the acquired data was LabChip® GX (Caliper 
Life Sciences). The output of the instrument is analogous to 
a chromatographic curve, with the retention time 
substituted by the molecular weight. The aggregates and 
impurities are defined as any signal other than the BSA peak 
at 66.5 kDa, and are expressed as a fraction of the whole 
sample. 
4.1.3.9 Data handling and partial least square (PLS) 
regression analyses 
The data generated in the different steps of this work were 
analysed by partial least square (PLS) regression. When 
several experimental factors and response variables have 
been measured, PLS allows fitting a model to the data that 
can represent the variation of the responses to the variation 
of the factors. The statistical software used for the PLS 
regression analyses was MODDE v10.1 (Umetrics AB, Umeå, 
Sweden). Three separate PLS regressions were used to 
evaluate the ternary phase diagrams, the capsule 
compatibility, and the microgel properties. The data were 
arranged according to a user-specified d-optimal design. 
The number of components was chosen according to 
significance by cross-validation. The models obtained were 
evaluated in terms of goodness of fit (R2) and cross-
validation value (Q2). Specifically, R2 is the percent of the 
response variation that could be explained by the model. Q2 
is the percent of the response predicted by the model 
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according to cross-validation. The cross-validation of each 
regression was carried out by removing one element at a 
time. The Q2 is calculated by the statistical software 
according to Equation 4.2. 
 
𝑄2 = (1 −
𝑃𝑅𝐸𝑆𝑆
𝑆𝑆
) ∙ 100 4.2 
Where PRESS is the prediction residual sum of squares 
(Equation 2.22), and SS is the total sum of squares of the 
response variables corrected for the mean (Equation 2.24). 
R2 and Q2 are expressed as a percentage, and the analysed 
models are considered to have statistical relevance if higher 
than 50%. 
The experimental factors used for the ternary phase 
diagram evaluation were the co-solvent fraction, the 
glyceride fraction, the glyceride chain length, the glyceride 
hydroxyl value, and the glyceride PEGylation. For the 
purpose of statistical evaluation, the chain lengths were 
classified in medium chain (caprylates and caprates) and 
long chain glycerides (linoleates). The hydroxyl values were 
grouped in low (< 150 mgKOH g-1), medium (between 
150 and 300 mgKOH g-1), and high (> 300 mgKOH g-1). The 
response variable chosen for the evaluation was the overall 
score. The initial sample set (n = 880) was divided 
according to the type of co-solvent employed, thus 
providing two separate subsets. After the first screening, 
some outliers with high standardised residuals were 
removed. Thus, the models applied for the ethanol subset 
and the DEGEE subset had n = 497 and n = 534, 
respectively. 
 
The statistical analysis of the capsule compatibility was 
carried out on 245 samples. The experimental factors 
chosen were the same as listed for the ternary phase 
diagram evaluation. The response variables were the 
compatibility of the prepared receiving bath mixtures in 
each of the four capsule types, namely Licaps®, Quali-V®, 
SGC, and VegaGels®. The levels for these variables were 
“immediate incompatibility”, “short-term compatibility”, 
and “absent incompatibility”. 
Further properties of the prilled microgels, such as their 
morphology, the EE, and the protein stability, were also 
evaluated in a PLS analysis. The centre points of the 60 
phase diagrams were used as data set. The chosen 
experimental factors and the response variables are listed 
in Table 4.2. 
4.1.4 Results 
4.1.4.1 Ternary phase diagrams 
Based on initial experiments, mixtures of glycerides with a 
co-solvent were found to be of interest regarding a suitable 
hardening bath for prilling microgels into lipids. While 
ethanol and DEGEE were main candidates for suitable co-
TABLE 4.2 – List of response variables and experimental factors for partial least square regression analysis of the 
microgel properties. 
Experimental factors Response variables 
Name (type) Level Name (unit) Objective (target) 
Glyceride chain length 
(continuous, multi-level) 
Medium chain, long chain 
Microgel size 
(µm) 
Minimise 
(min. 300 µm) 
Hydroxyl value (continuous, 
multi-level) 
Low, mid, high Microgel shape 
Minimise 
(min. 1.27) 
PEGylation (categorical) Yes, no 
Encapsulation efficiency 
(%) 
Maximise 
(max. 100%) 
Complementary excipient type 
(categorical) 
PEG 600, propylene 
carbonate, peppermint oil 
α-helix content l 
(%) 
Hit target 
(54.7%) 
Co-solvent type (categorical) 
Ethanol, 
DEGEE 
Electrophoresis impurities 
(%) 
Minimise 
(min. 0%) 
l percentage of α-helix structure after deconvolution 
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solvents, there was also the possibility to include additional 
excipients to the mixtures. The additional or 
“complementary” excipient constituted a third component 
in diverse phase diagrams that used the excipients as listed 
in Table 4.3. A total of 60 ternary phase diagrams provided 
an overview of the interactions occurring between the three 
components in terms of excipient miscibility, calcium 
chloride solubility, and MCC gelling. Once these mixture 
characteristics were assessed, the ternary phase diagrams 
were overlaid to calculate an overall score of the 
formulations, as shown in Figure 4.2. The findings of the 
mixture characteristics are discussed in the following 
paragraphs and are summarised in Table 4.3, together with 
a report of the statistical factor significance. 
4.1.4.1.1 Excipient miscibility 
It was evident that the fraction of both co-solvents 
increased the overall score of the formulations. There was a 
trend showing that miscibility of the excipients was even 
more favoured in the presence of ethanol compared with 
DEGEE as co-solvent. In the case of glycerides, mono- and 
diglycerides were miscible in most formulations and at 
various ratios. Triglycerides could also be mixed with the 
other components preferentially with ethanol as a co-
solvent. However, longer chain glycerides tended to have 
less favourable miscibility profiles. There was a net positive 
effect of PEGylation noted for miscibility (Table 4.3). 
Moreover, the three different types of complementary 
excipients seemed to alter the miscibility in the ternary 
phase diagrams according to their polarity. As expected, the 
least polar complementary excipient, i.e. peppermint oil, 
was found to be better miscible with triglycerides than 
propylene carbonate or PEG 600. 
4.1.4.1.2 Calcium chloride solubility 
Sufficient calcium chloride dissolution to achieve a suitable 
hardening bath for prilling was targeted in the lipid-based 
mixtures. It was expected that the salt solubility would be 
strongly dependent on the overall polarity of the mixtures. 
It was found in all systems that a minimum amount of co-
solvent was required to dissolve calcium chloride. Only in 
few cases, the binary mixtures alone of glyceride and 
complementary excipient could solubilise the calcium 
chloride completely. Ethanol was especially effective in 
dissolving this excipient salt. Furthermore, free hydroxyl 
groups of glycerol in mono- and diglycerides increased the 
formulation polarity, and thereby contributed to the 
calcium chloride solubility. After the salt addition, some 
formulations containing medium chain triglycerides 
exhibited a precipitation which appeared to be a salting out 
of an initially liquid component. This phenomenon occurred 
especially at comparatively lower co-solvent 
concentrations. Long fatty acid chains appeared to reduce 
the solubility of calcium chloride at least in the DEGEE data 
subset. In addition, glyceride PEGylation led generally to a 
slight increase in solubility of the calcium ions. Among the 
complementary excipients, especially peppermint oil 
hindered salt solubilisation, which typically resulted in 
opalescent solutions or turbid suspensions. The other 
complementary excipients were able to dissolve the 
calcium chloride at the given concentration. 
 
FIGURE 4.2 – Four examples of the overlaid ternary 
phase diagrams. Each corner represents 100% of the 
component indicated. The white, light grey, and dark 
grey areas correspond to scores of 2, 1, and 0, 
respectively. 
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4.1.4.1.3 Mono-N-carboxymethyl chitosan (MCC) gelling 
Adding a co-solvent was found to be of critical importance 
for MCC gelling, regardless of the type used. A 
comparatively higher co-solvent concentration allowed the 
formation of well-defined spherical microgels without signs 
of particle interpenetration or coalescence. Conversely, a 
higher content of either glycerides or complementary 
excipients led to rather poor gelling characteristics, likely 
due to a lower extent of cross-linking. In these cases, the 
systems formed rather irregular particle shapes, had 
increased coalescence, or exhibited poor mechanical 
resistance to vortexing. In specific mixtures, even the 
absence of gelling was noted. The increase in chain length 
had a rather negative effect on the gelling properties of 
MCC. Similarly, increased hydroxyl values of the glycerides 
resulted in a relatively negative effect on MCC gelling. 
PEGylation had a positive effect on the polymer gelling for 
both subsets (Table 4.3), although it appeared to be 
significant only with ethanol as a co-solvent. 
4.1.4.1.4 Overall score 
According to the initial PLS analysis of the ternary phase 
diagrams (Table 4.3), both co-solvents had a positive effect 
on overall score. Conversely, the fraction increase of 
glycerides and complementary excipient led to poorer 
suitability of the hardening bath for prilling. The most 
advantageous glyceride characteristics for this process 
were a high hydroxyl value and PEGylation. Instead, the 
increase in fatty acid chain length was shown to reduce the 
suitability of the lipid-based hardening bath for prilling. In 
terms of interactions, the DEGEE subset revealed several 
statistically significant interactions between co-solvent 
fraction and different glyceride properties. Higher DEGEE 
fractions combined with increased glyceride chain length 
appeared to reduce the overall suitability of the formulation 
for prilling. However, the presence of PEGylated residues on 
the glycerides appeared to positively influence the 
hardening baths’ properties at high co-solvent 
concentrations. As expected, an opposite interaction was 
seen with the increase of glyceride fraction. As for the 
ethanol-containing subset, only a positive interaction 
between PEGylation and glyceride fraction proved to be 
statistically significant. This effect was opposite to the one 
found for DEGEE. This result indicates that overall effects 
had to be carefully analysed regarding factor interactions to 
obtain a more refined view on the data, as it was here 
meaningful to differentiate the ethanol and the DEGEE data 
sets. A common interaction for both datasets was between 
the co-solvent and glyceride fractions. Thus, a simultaneous 
increase of both excipient fractions meant a lower 
complementary excipient content in the formulation. The 
negative influence of this factor interaction on the overall 
score entailed that the complementary excipient played a 
critical role for obtaining a suitable hardening bath. Overall, 
the PLS regression analysis yielded models with high 
goodness of fit and cross-validation predictivity for both the 
ethanol subset (R2 = 85.3%, Q2 = 83.9%) and the DEGEE 
subset (R2 = 86.0%, Q2 = 84.4%).  
4.1.4.1.5 Capsule compatibility 
Not all hardening bath compositions were further evaluated 
regarding capsule shell compatibility. Only formulations 
with an overall score higher than unity and with a co-
solvent fraction lower that 0.35 were evaluated. As a result, 
two-piece hard gelatine capsules appeared to have higher 
compatibility with the different hardening baths and 87.5% 
of these capsules were visually compatible over the 4-week 
stability period. However, the SGC did not perform as well 
because in several cases (> 55.6%), the liquid filling showed 
signs of immediate incompatibility and started to leak out 
before the end of the first week. The two-piece 
hypromellose capsules and the starch-based soft capsules 
TABLE 4.3 – Summary of the factors’ effects on the scores in the ternary phase diagrams. Significant increase (++), non-
significant increase (+), significant decrease (--), and non-significant decrease (-) p ≤ 0.05 from PLS regression analysis. 
Factor 
Miscibility Solubility Gelling Overall 
ethanol subset / DEGEE subset 
Co-solvent fraction ++ / ++ ++ / ++ ++ / ++ ++ / ++ 
Glyceride fraction + / +  -- / ++ -- / -- -- / -- 
Chain length -- / --  - / --  - / --  - / -- 
Hydroxyl value ++ / ++ ++ / ++ -- / -  ++ / ++ 
Glyceride PEGylation ++ / ++ ++ / ++ ++ / +  ++ / ++ 
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also exhibited comparatively lower compatibility from the 
beginning, with 52.3% and 45.8% capsules that were 
deformed or clearly harmed after the first week of stability 
testing, respectively. In line with the expectation that 
hydrophilic excipients can cause shell incompatibility, it 
was found that a higher fraction of co-solvent was critical 
regarding capsule compatibility [81,455]. An increased 
amount of glycerides appeared to generally increase 
capsule compatibility. When comparing the different types 
of glycerides, there was no remarkable effect of PEGylation 
or of fatty acid chain length.  
In Table 4.4 we listed the formulations with the best 
compatibility characteristics among the ternary phase 
diagrams centre points. However, although the sample size 
was rather large, no overriding effect could be found 
because the PLS regression analysis did not result in a 
significant model. 
4.1.4.2 Prilling of the microgels 
The 60 hardening baths from the centre points of the 
different phase diagrams were selected for prilling trials 
using the vibrating nozzle equipment. While all the data are 
provided in the complementary data of this article, 
Figure 4.3 summarises the effect plots of the experimental 
factors on the individual response variables. The Q2 and the 
R2 of the PLS regression model are specified in Table 4.5. 
4.1.4.2.1 Morphological characterisation of the microgels 
According to the manufacturer, the prilled polymer 
droplets are roughly twice the size of the nozzle from which 
they were extruded. Consequently, the microgels’ median 
Waddle disk diameter ranged overall between 424.57 µm 
and 600.69 µm. Since the employed nozzle diameter of this 
study was 300 µm, the measured particle sizes were in good 
agreement with the expected size range. Ethanol and 
DEGEE were not significantly different in altering the 
particle size. Instead, the complementary excipients 
appeared to have a stronger influence on the size.  
TABLE 4.4 – Capsule compatibility characteristics of the centre point (phase diagrams) formulations. Details of score 
assignment and compatibility testing are given in the text. 
Centre point 
composition 
Overall score 
Incompatibility according to capsule type 
Licaps® Quali-V® SGC VegaGels® 
Ethanol 
Miglyol® 812 
Peppermint oil 
4 absent absent absent absent 
Ethanol 
Captex® 1000 
Peppermint oil 
8 absent absent immediate absent 
Ethanol 
Imwitor® 742 
Peppermint oil 
4 absent absent immediate absent 
DEGEE 
Imwitor® 742 
Peppermint oil 
8 absent absent immediate absent 
TABLE 4.5 – Goodness of fit (R2) and cross-validation 
predictivity (Q2) values from the partial least square 
analysis using the centre points of the phase 
diagrams. 
Response 
variable 
Goodness of 
fit, R2 
Cross-
validation 
predictivity, Q2 
Waddle disk 
diameter 
89.1 77.2 
Elongation factor 91.8 64.4 
Encapsulation 
efficiency 
96.9 87.8 
α-helix content m 82.2 57.0 
Electrophoresis 
impurities 
76.5 62.8 
m percentage of α-helix structure after deconvolution 
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FIGURE 4.3 – Effect plots of the factors used in the PLS regression for the microgel characteristics. Among the 
complementary excipients, “Pro. Carb.” stands for propylene carbonate, and “Pep. Oil” for peppermint oil. MC is 
medium chain length, whereas LC is long chain. A significant difference is represented by an asterisk (p ≤ 0.05). 
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Formulations containing PEG 600 led to smaller microgels, 
compared to propylene carbonate and peppermint oil. 
Among the glyceride properties, PEGylation appeared to 
increase the volume of the microgels. Interestingly, the 
interaction of PEGylated glycerides and PEG 600 increased 
significantly the median particle size. These results indicate 
that there was no simple explanation of overall polarity that 
improved or hindered microgel swelling. Depending on the 
individual composition, there was a specific arrangement of 
the hardening bath microstructure that eventually 
determined the final swelling (or de-swelling) of the 
microgels in the mixtures. 
The particular swelling characteristics were also 
determining the shape of the particles. This particle shape 
varied greatly among the different hardening bath 
formulations, from 1.44 to 2.52. Ethanol allowed the 
formation of more regular microgels when compared to 
DEGEE. The type of complementary excipient also appeared 
to influence the microgel shape. PEG 600, especially, 
increased the overall ellipticity of the prilled droplets. This 
effect was not as remarkable when using propylene 
carbonate or peppermint oil. The glyceride characteristics 
which affected mostly the particle shape appeared to be the 
fatty acid chain length and the PEG-substitution of the 
glycerol. A most notable and significant interaction was 
found between propylene carbonate and long chain 
glycerides that led to smaller elongation factors. 
Figure 4.4 shows different morphological characteristics of 
the microgels. Spherical microgels could be obtained 
(Figure 4.4a), although different morphologies within the 
same batch could be found (Figure 4.4b). The latter case 
occurred especially in presence of DEGEE. A particular 
 
FIGURE 4.4 – Microgel pictures taken by the XPT-C during dynamic image analysis. The microgels shown were formed 
in DEGEE, Captex®, and peppermint oil (a), DEGEE, Capmul® MCM, and propylene carbonate (b), ethanol, 
Capmul® MCM-C10, and propylene carbonate (c, f), DEGEE, Maisine™ 35-1, and peppermint oil (d), ethanol, 
Imwitor® 742, and PEG 600 (e), ethanol, Capmul® MCM-CM8, and peppermint oil (g), ethanol, Acconon® CC-6, and 
PEG 600 (h), and DEGEE, Labrafil® M2125CS, and peppermint oil (i). All hardening baths’ components were in a ratio 
of 1:1:1. Scale bar is 500 µm. 
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shape commonly found in prilling is represented in Figure 
4.4d. Here, the droplets are slightly elongated and retain a 
small “tail” on their surface. A similarly elongated shape can 
be seen in Figure 4.4g, but here the characteristic “tail” is 
strongly combined to the elongated shape of the microgel. 
Other irregular shapes can be seen in Figure 4.4e and 4.4h, 
where the microgels appeared to be mechanically deformed 
(which may have resulted from the impact on the hardening 
bath surface) and in Figures 4.4c and 4.4f, where the 
microgels have a concave geometry. Interestingly, some 
microgels were macroscopically spherical, while a complex 
rough surface was obtained as seen from the example in 
Figure 4.4i. 
4.1.4.2.2 BSA encapsulation efficiency in microgels 
The overall EE of all the formulations varied between 44.2% 
and 89.3%. Such difference among the hardening baths was 
mostly due to the different complementary excipients. PEG 
600 and propylene carbonate allowed higher EE values 
compared to formulations containing peppermint oil. 
Microgels formed with peppermint oil could not retain 
more that 63.0% of the BSA. Figure 4.3 shows further effects 
that are statistically significant but changed the EE on the 
average only slightly. Among the significant interactions, 
mixtures of ethanol and medium chain glycerides showed 
lower EE than mixtures with DEGEE. Similarly, when 
compared to DEGEE, ethanol mixed with peppermint oil 
had lower EE. 
4.1.4.3 Protein stability 
4.1.4.3.1 Circular dichroism 
From a qualitative point of view, most profiles did not differ 
from those which were recorded with BSA standard, as 
shown in Figure 4.5b. However, some formulations 
modified the secondary structure of the encapsulated BSA. 
In Figure 4.5a we present the three worst-case profiles 
which were recorded. The α-helix profile, which is typical 
for this far-UV region, was completely lost or its intensity 
was reduced [219]. This showed a modification of the 
protein’s secondary structure, which may correspond to 
denaturation. From the analysis of the deconvoluted 
circular dichroism spectra, our BSA reference had an 
α-helix fraction of 54.7%. Ethanol appeared to have a 
stronger influence than DEGEE on protein denaturation. 
Among the complementary excipients, PEG 600 and 
peppermint oil resulted as the least harmful for BSA. 
 
FIGURE 4.5 – Circular dichroism profiles of BSA. In a.: BSA reference (solid line), ethanol, propylene carbonate, and 
Maisine™ 35-1 (dotted line), ethanol, propylene carbonate, and Imwitor® 742 (short dashes), and ethanol, PEG 600, 
and Acconon® CC-6 (long dashes). In b.: BSA reference (solid line), ethanol, PEG 600, and Acconon® CC-6 (dotted 
line), DEGEE, PEG 600, and Miglyol® 812 (short dashes), and ethanol, peppermint oil, and Imwitor® 742 (long 
dashes). All hardening baths’ components were in a ratio of 1:1:1. 
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Consequently, propylene carbonate showed the strongest 
denaturing effect. The composition of the glycerides also 
influenced the protein’s secondary structure. Low hydroxyl 
values appeared to have minimal influence on the protein 
structure. Long fatty acid chains contributed to a negative 
modification of the secondary structure, whereas 
PEGylation helped to retain the three-dimensional 
arrangement of the protein. The altering effect of the chain 
length in combination with ethanol was markedly higher. 
4.1.4.3.2 Microfluidic capillary electrophoresis 
The microfluidic capillary electrophoresis was conducted 
both in reducing and non-reducing conditions to detect 
protein aggregation or protein fragments, respectively. All 
the samples which were prepared in reducing conditions 
did not show any trace of impurity. On the other hand, the 
samples prepared in non-reducing conditions revealed the 
presence of impurities up to concentrations of 19.0%. The 
only impurity found in all analysed samples was a 
compound with molecular weight between 105 and 
110 kDa, which would represent a BSA dimer (Figure 4.6). 
As a co-solvent, DEGEE appeared to prevent protein 
aggregation better than ethanol. While propylene 
carbonate had a negative influence on protein stability, no 
significant difference could be determined when compared 
to the other complementary excipients. None of the 
glycerides’ properties was found to be significantly related 
to a variation in protein aggregation. However, the 
interaction between co-solvents and complementary 
excipients with PEGylated glycerides appeared to reduce 
the possible denaturing effects of hardening baths. 
 
FIGURE 4.6 – Data evaluation of microfluidic capillary electrophoresis profiles. BSA standard band is at 66 kDa, as 
shown in lane 1. Lanes 2, 3, and 4 had the highest fraction of BSA dimer impurity (~110 kDa). Lanes 4, 5, and 6 had the 
lowest fraction. From left to right, the impurity content was 1.8, 19.0, 17.2, 15.6, 3.1, 3.0, and 2.2%. All hardening baths’ 
components were in a ratio of 1:1:1. 
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4.1.5. Discussion 
Formulating proteins without harmful manufacturing 
processes is an important task of modern pharmaceutical 
technology. An interesting recent finding was 
manufacturing protein-loaded microgels into lipid-based 
formulations by means of prilling [28]. This delivery system 
is appealing given that the components bear the potential to 
increase oral protein bioavailability. Since the formulation 
requirements depend on the therapeutic target, the current 
formulation approach may only aim for luminal protection 
or mucus penetration, or even additional uptake of the 
active macromolecule by the enterocytes. We evaluated 
systematically the influence of the hardening baths’ 
composition on the prilling process. Subsequently, the 
suitability of these systems was determined for capsule 
filling. A last step employed the centre point formulations of 
the different ternary phase diagrams as receiving baths to 
study prilling. The model protein BSA was 
microencapsulated by prilling using a vibrating nozzle 
equipment. The responses of particle morphology, 
encapsulation efficiency, BSA loading, and protein stability 
were analysed. Partial least square analysis was used to 
gain a correlative understanding from the large dataset.  
4.1.5.1 Ternary phase diagrams and capsule 
compatibility 
Commonly, the prilling technique is used to encapsulate 
APIs or living cells into polymeric microgels hardened in 
aqueous hardening baths. To represent a suitable 
alternative, compatible with pharmaceutical capsule shells, 
non-aqueous hardening baths must possess adequate 
characteristics. Miscibility of the different non-aqueous 
excipients is a first requirement for the microgel dispersion. 
Thus, a phase separation would certainly not lead to a viable 
pharmaceutical formulation. The chemical similarity among 
the glycerides explained the miscibility of several 
combinations. However, mixtures of triglycerides and PEG 
600 or propylene carbonate could not be mixed, except with 
high fractions of co-solvent added, namely above 70%. 
Mono- and diglycerides were particularly suited to achieve 
a good miscibility because of their higher polarity compared 
to triglycerides. The hardening bath polarity was important 
to dissolve salts that are necessary in ionotropic gelling. Yet, 
especially at low co-solvent fractions, the addition of 
calcium chloride led to phase separation (e.g. in 
formulations containing glyceryl tricaprate, PEG 600, and 
ethanol) and solidification (e.g. in formulations containing 
glyceryl tricaprylocaprate, propylene carbonate, and 
DEGEE). Dissolved salt was expected to interact with the 
polar moieties of the excipients, and such microstructural 
change was obviously critical for phase separation with 
some systems. While the co-solvent fraction increase 
seemed beneficial for miscibility and salt solubility, it also 
led to a higher risk of capsule incompatibility. Moreover, the 
negative interaction between the co-solvent and glyceride 
fraction indicated that the presence of the third 
complementary excipient was valuable regarding system 
suitability for prilling. While all properties contribute to the 
overall success of prilling and to the quality of the hydrogel 
dispersion, the polymeric gelling is particularly crucial to 
allow an efficient encapsulation. Many of the tested 
mixtures exhibited adequate excipient miscibility and ion 
solubility, whereas the finding of suitable polymer swelling 
was more rarely encountered. For example, formulations 
containing glyceryl monolinoleate were easily miscible with 
both co-solvents and all complementary excipients. 
However, most of these formulations were unable to 
effectively form hydrogels after the polymeric solution was 
dripped in. Concerning prilling suitability, the results 
clearly showed that the specific combination of mixture 
properties was required. This combination was difficult to 
predict theoretically so that extensive experimentation was 
pursued. 
To get an overview from the large dataset (n = 880), the PLS 
regression analysis proved to be a powerful tool. It was 
possible, for example, to statistically assess the overriding 
effect of the co-solvent component on the different mixture 
properties. Furthermore, this approach allowed to identify 
subtle effects given by the type of glyceride component. 
Since many different glycerides (and mixtures thereof) are 
available for pharmaceutical purposes, the study of 
different glyceride grades may aid the formulation 
screening for prilling. However, in this work, the glyceride 
choice was narrowed by the melting point. An increase in 
fatty acid chain length of a glyceride raises the melting 
point. In the case of triglycerides, the melting point of 
glyceryl tricaprylate, tricaprate, trilaurate, and tristearate, 
is 8.3°C, 31.5°C, 46.4°C, and 73.5°C, respectively [456]. Such 
increase in melting points occurs similarly in mono- and 
diglycerides series. Still, for use in hardening baths, 
glycerides must remain in the liquid phase at room 
temperature. Any elevated temperature required to 
maintain this single phase could harm a macromolecule 
loaded in the microgels [457]. Therefore, the long chain 
glycerides employed in this work contained linoleic acid as 
fatty acid, whose triglyceride has a melting point of -12.7°C 
[458]. Such unsaturated fatty acids are certainly chemically 
less stable than saturated fatty acids. Although no evidence 
of oxidation was found in the present work, the addition of 
antioxidants in lipid-filled capsules would have to be 
considered for a later stage of formulation development 
[459]. Our study focused on short-term capsule 
compatibility over four weeks. Harmful effects of the 
formulation on the shell material were expected especially 
at high co-solvent levels based on earlier reports in the 
literature [81,111,460]. The obtained compatibility data 
showed that formulations with a high hardening bath score 
were also promising regarding shell compatibility using 
different capsule types. The differences among the capsule 
Chapter 4. Quality aspects of lipid-based pharmaceutical formulation  72 
 
 
types, however, should not be over interpreted. Soft 
capsules may exhibit improved capsule compatibility when 
hydrophilic excipients are pre-added to the shell 
composition [88]. Such a modification of the shell 
composition would be a typical part of the drug-specific 
formulation development. Still, this was certainly beyond 
the scope of the present compatibility study, which is 
intended as a first assessment only. 
4.1.5.2 Microgel characteristics  
The presence of ethanol had been already described in the 
literature as relevant to reduce particle size [28]. However, 
an even stronger effect of PEG 600 on this reduction was an 
interesting finding in the present study. This excipient 
influence was opposite regarding the elongation factor. For 
example, PEG 600 appeared to increase the ellipticity of the 
microgels, whereas ethanol promoted sphericity. A 
mechanistic explanation of such empirical findings 
regarding particle morphology is challenging. It is likely 
that several material characteristics as well as process 
variables heavily influence the overall particle shape. While 
the relevant process factors and polymer solution 
characteristics have been studied to some extent, little 
effort has been directed to understand which of the 
hardening bath’s properties could influence the prilled 
particle morphology [27,453,461]. To the best of our 
knowledge, only the work by Buthe et al. addressed the use 
of non-aqueous hardening baths [247]. The most critical 
aspect when using non-aqueous hardening baths is the 
gelling process. The polymeric gel surface properties are 
affected by those of the surrounding medium [462]. To 
retain suitable swelling without excessive shrinking of the 
polymeric chains, the physicochemical affinity between the 
medium and the polymer has to be high [463]. When the 
affinity remains low, the surface chains undergo local 
coiling [55]. Such conformational polymer change may 
occur in a microgel zone close to the surface. Moreover, 
hydrophilic components of the hardening bath can partition 
into the microgels thereby affecting polymer swelling. 
These effects can reduce the overall size of the microgel, as 
well as alter its shape. 
The physicochemical interaction between the hardening 
bath and the polymer appeared to influence also the 
encapsulation efficiency. Different types of solvents and co-
solvents are known to affect the gel structure and stability 
[411,464]. In the present work, the EE varied widely 
depending on the given excipients. In our previous study 
[28], a mechanism explaining such high EE was proposed. 
Briefly, the formed MCC gel is generally in a “swollen” state, 
where the polymer is well expanding and network points 
include the interactions of calcium ions with MCC’s 
carboxylic groups. On the surface (or in an interfacial zone), 
there is a different environment because of the dissimilar 
polarity of the surrounding media. Thus, some polymer 
coiling on the microgel surface may contribute to 
maintaining the BSA within the gel boundaries. The 
“swollen” nature of the microgel network has previously 
shown a rather fast protein release during dissolution 
testing that entails the need for additional enteric coating 
after capsule filling [28]. In the present work, the EE for 
most formulations was above 70%. However, a significant 
EE reduction occurred in presence of peppermint oil. From 
the dynamic imaging results (Figure 4.4a, 4.4d, 4.4g, and 
4.4i), we noticed that the surface of microgels formed in 
peppermint oil was comparatively rough. A rougher surface 
is the likely result of a different arrangement of the 
polymeric chains close to the surface. Moreover, a direct 
consequence of roughness is an increase in contact surface 
between microgel and surrounding medium. Altered 
surface characteristics may explain an initial higher leakage 
of BSA from the MCC polymer network, and consequently a 
lower EE. 
4.1.5.3 Protein stability 
The formulation of proteins using potential denaturants 
appeared to be a challenging endeavour. Ethanol is a well-
known protein denaturant, which alters the α-helices and 
other tertiary structures [405,413,415]. Furthermore, 
propylene carbonate is known in literature to denature 
proteins [416], although the mechanism has not been 
investigated. The data gathered in terms of structural 
modification and protein aggregation showed that 
propylene carbonate affected BSA, especially when 
combined with ethanol. These excipients caused both a loss 
in the α-helix fraction, as well as an increase in the amount 
of dimers formed. Interestingly, the lowest α-helix fraction 
was found in the formulation composed of ethanol, 
propylene carbonate, and glyceryl monolinoleate. The latter 
excipient contains polyunsaturated fatty acid chains, which 
are prone to peroxidation [465]. This reaction is known to 
damage proteins [466], especially on its thiol-containing 
groups and lysine amino acids [418,419,467]. BSA 
possesses a free surface cysteine group (Cys-34), which 
may form disulphide-mediated BSA dimers [406]. Lysine 
has a very high α-helix propensity [420], and any 
modification may lead to an altered secondary protein 
structure. As for DEGEE, recent non-clinical trials showed 
its lack of toxicity in food, cosmetic, and pharmaceutical 
applications [468]. Moreover, there has not been a report 
on protein denaturation using DEGEE, as far as we know. 
Our data confirmed the absence of denaturing activity in the 
microgels containing DEGEE. Similarly, PEG 600 did not 
alter the protein structure. PEGs have been used to 
precipitate proteins, but they are known not to cause a 
protein denaturation due to steric exclusion from the 
protein structure [469]. Another notable finding of the 
present study is that PEGylated lipids positively influenced 
the overall BSA stability even in presence of potential 
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denaturing agents such as ethanol and propylene 
carbonate. 
Many therapeutically active proteins are formulated with 
lipids, for example as solid lipid nanoparticles, emulsions, 
or liposomes [470,471]. To the best of our knowledge, no 
denaturation effect has been related to the fatty chain 
length. However, in our work, it appeared that longer chain 
glycerides hindered the BSA α-helix structure. In this case, 
the denaturing effect may be associated with the 
polyunsaturated fatty chains of the chosen glycerides. As 
mentioned previously, glycerides with saturated long chain 
fatty acids are solid at room temperature, and the heat 
required to compound them with the other components of 
the hardening bath would have probably harmed the BSA. 
This indicates that even gentle heating during compounding 
of long fatty chain glycerides may harm the protein. Thus, 
the importance of having a manufacturing process that 
avoids heating as much as possible is further stressed. 
Finally, the free hydroxyl groups appeared to have a slight 
influence on lowering the protein stability. A possible 
explanation is here the presence of impurities in the mono- 
and diglyceride mixtures, namely glycerol, which is known 
to cause protein precipitation [472]. 
4.1.6 Conclusions 
Formulating proteins as microgels in a lipid system by 
prilling is a novel approach to avoid potentially harmful 
processing during manufacturing. The current study 
provided an extensive data set to evaluate the influence of 
several excipients on the quality of the final dispersions 
using bovine serum albumin as model protein. 
A partial least square regression analysis proved to be a 
viable tool to find overriding effects and to guide 
formulation development. The tested formulations 
included two different non-aqueous and non-toxic additives 
(ethanol and DEGEE) that were proposed as potentially 
suitable co-solvents. Both were found to improve the 
outcome of the prilling process, although some protein 
stability and capsule compatibility issues may still occur 
with ethanol especially at rather high concentrations. Three 
complementary excipients with different chemical and 
physical properties were added to the formulation. Polarity 
played a dominating role in terms of formulation stability. 
A major focus was put on the glyceride selection. These 
compounds’ chemical properties were studied, namely 
glyceride chain length, free hydroxyl groups, and 
PEGylation. The statistical analysis showed significant 
effects of all glyceride components on different aspects of 
prilling. Notably, PEGylation appeared to positively 
                                                                        
**  de Kruif JK et al. Novel Quality by Design Tools for Concentrated Drug Suspensions: Surface Energy Profiling and the 
Fractal Concept of Flocculation. Journal of Pharmaceutical Sciences, 2013, 102, 993-1007. 
influence the formulation suitability for prilling, the EE, and 
the protein stability, although it led to larger microparticles 
with less spherical morphology. The choice of the optimal 
hardening bath must consider the critical formulation and 
drug characteristics. Different suspension media 
compositions may be considered as optimal depending on 
whether protein structure is especially instable (DEGEE, 
PEGylated medium chain glyceride, and PEG 600) or 
particle morphology is paramount (ethanol, unmodified 
long chain glyceride, and propylene carbonate). This work 
should guide formulations scientists in finding suitable 
compositions when using non-aqueous hardening baths for 
subsequent capsule filling. 
The present study provided a first systematic approach to 
study microgels formed through prilling into lipid-based 
hardening baths. Much knowledge has been generated on a 
correlative level together with some mechanistic 
hypotheses. Future research should on the one hand follow-
up on such mechanistic aspects, as well as to further study 
this type of delivery system using more biopharmaceutical 
tests. Moreover, the protein integrity should be further 
investigated in the microgel lipid-based suspensions by ICH 
stability testing. Some preliminary stability and dissolution 
data exist for selected formulations of the model protein 
BSA, and results are promising. Future biopharmaceutical 
studies should include an in vitro as well as an in vivo 
assessment to better clarify the pharmaceutical potential of 
this oral delivery approach. Such potential is depending on 
the therapeutic target, and aims may range from luminal 
drug protection to the quite ambitious goal of 
macromolecule absorption. 
4.2 Novel Quality-by-Design tools 
for concentrated drug suspensions: 
surface energy profiling and the fractal 
concept of flocculation ** 
4.2.1 Summary 
Quality-by-design is an important concept, but only limited 
research has been invested in concentrated pharmaceutical 
suspensions. A need exists for novel analytical tools to 
thoroughly characterise the drug as well as its aggregated 
particle structure in suspension. This work focuses on a 
lipid-based pharmaceutical suspension for filling of 
capsules. A rheological approach, namely the fractal 
concept of flocculation, is introduced to the pharmaceutical 
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field. The model drug mebeverine hydrochloride was first 
physicochemically analysed. A special aim was to study the 
surface energy profiles using inverse gas chromatography 
as a critical characteristic for the suspension’s rheological 
behaviour. Lipid-based suspensions were manufactured in 
laboratory process equipment while applying different 
homogenisation speeds. Flow curves of the final 
suspensions were measured using a cone-and-plate 
rheometer. As a result, surface energy profiles revealed 
differences from one mebeverine lot to another. Different 
homogenisation intensities greatly affected the viscosity 
and the Mooney model was able to predict experimental 
values as a function of the drug volume fraction. The fractal 
concept of flocculation characterised mebeverine in 
suspension and a slight increase of fractal dimension was 
noted when homogenisation speed was increased. It was 
concluded that the introduced concepts have large potential 
for designing quality into concentrated pharmaceutical 
suspensions. 
4.2.2 Introduction 
Rather concentrated drug suspensions are widely used in 
pharmaceutics. They can be found as final dosage forms as 
well as intermediate bulk products; a special interest is 
their filling into capsules for oral drug delivery [105]. These 
formulations are generally lipid-based to assure adequate 
capsule compatibility. The dispersed drug is often rather 
concentrated to provide required dose strength. However, 
the suspension would have to exhibit adequate rheological 
properties for the filling of hard or soft capsules. Especially 
for the two-piece hard capsules the filling process critically 
depends on the rheology of the fill mass. Kattige et al. [473] 
showed that highly viscous suspensions can form a string at 
the dosing nozzle. A bridging from one capsule to another 
can occur depending on the process speed. A direct 
consequence is increased variability of the capsule weight, 
which is a critical quality attribute of the dosage form. An 
increased or variable viscosity can therefore be a severe 
manufacturing issue in liquid-filling of capsules. Such 
effects on critical quality attributes are important to 
understand when attempting to implement Quality by 
Design (QbD) in pharmaceutical suspensions [32]. 
The rheological influence of a suspension on the final 
capsule attributes is one important aspect, while another is 
to learn about how rheological properties are determined 
by the raw materials. Due to the complexity of particle 
interactions and structure, the science of concentrated 
suspensions is not fully understood and is still subject to 
basic research [50,474,475]. However, some important 
aspects can already be inferred from the early models of the 
mid-20th century [60,62]. The viscosity has been assumed 
to increase non-linearly with the volume fraction of the 
solid (Φ), i.e. the drug. Herein there is not a constant 
exponent in a power or exponential law assumed, but the 
exponent is characteristic for the given drug. In the case of 
the Mooney law [62], it is the crowding factor (k) that 
dictates the curve shape. Equation 4.3 displays the relative 
viscosity ηr (viscosity divided by the viscosity of the drug-
free formulation) according to the Mooney law: 
 
𝜂𝑟 = 𝑒𝑥𝑝 (
2.5 ∙ 𝛷
1 − 𝑘 ∙ 𝛷
) 4.3 
The equation was developed partially in a heuristic way, 
and the factor 2.5 was in accordance to Einstein’s first 
rheology studies of dilute dispersions [58]. The crowding 
factor was previously interpreted as reciprocal of a 
maximal packing fraction Φmax so that Equation 4.4, 
modified from 2.9, can be obtained [61,476]: 
 
𝜂 = 𝜂0𝑒𝑥𝑝(
2.5 ∙ 𝛷
1 −
𝛷
𝛷𝑚𝑎𝑥
) 4.4 
Where η holds for the suspension’s apparent (measured) 
viscosity and η0 represents the viscosity of the drug-free 
vehicle. The non-linearity of the equation as well as the non-
universal character of the exponent can be problematic 
from a practical consideration. Given that the model 
describes adequately a pharmaceutical suspension, it is 
possible that even a small effect of the solid fraction may 
greatly affect the viscosity. Rheology of a concentrated 
pharmaceutical suspension may be influenced significantly 
by rather subtle batch-to-batch differences of an active 
pharmaceutical ingredient (API) (e.g., due to impurities, 
enantiomeric excess, or particle characteristics). Thus, 
some questions arise from a QbD viewpoint. Are there 
sufficient experimental tools available to detect such subtle 
variances among different batches of a drug? What is the 
effect of a given process factor or small formulation change 
on viscosity? Is it possible to assess the evolving particle 
structure in a concentrated suspension? 
Concerning tools to analyse an API for suspensions, a 
review by Rawle et al. emphasised that powder 
characterisation proved to be critical [477]. The authors 
highlighted several methods to measure particle size 
distribution, including dynamic image analysis, which 
provides the means to additionally determine the shape of 
particles. However, the influence of surface energies was 
not taken in consideration. Especially the profiling of 
surface energies would be of interest. The standard 
technique to assess the surface energy is the contact angle 
measurement; its use, however, is problematic for samples 
in powder form [478]. For this surface energy analysis 
(SEA), a novel technique based on inverse gas 
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chromatography (iGC) has become recently available. Such 
iGC technique has been used to profile surface energy of 
powders in solid dosage forms [479–485]. However, energy 
profiling based on iGC has, to the best of our knowledge, 
never been applied to study drugs that were intended for 
pharmaceutical suspensions. A first aim of this study is to 
profile the surface energies of mebeverine hydrochloride 
using the iGC, and to correlate them with the rheological 
parameters of different batches in lipid-based suspensions. 
Another aim of this study addresses the question, whether 
or not it is possible to study the aggregation structure of a 
drug in suspension. The fractal concept of flocculation is 
therefore to be introduced to pharmaceutical suspension 
analysis [50]. This approach describes the structure of 
particle aggregation in terms of a fractal dimension [486]. 
As model drug we selected mebeverine hydrochloride, 
which is commonly used in the treatment of lower-bowel 
inflammations and diseases [487]. 
4.2.3 Materials and methods 
4.2.3.1 Materials 
Mebeverine hydrochloride ((RS)-4-(ethyl[1-(4-
methoxyphenyl)propan-2-yl]amino)butyl-3,4-
dimethoxybenzoate hydrochloride) was supplied by 
Tillotts Pharma AG (Rheinfelden, Switzerland) from two 
different batches (A and B). Lipoid PPL-600 was from 
Lipoid GmbH (Ludwigshafen, Germany). Refined peanut oil 
and fumed silica was purchased from Hänseler AG (Herisau, 
Switzerland). Isopropyl alcohol, n-hexane, and methanol 
(all branded J.T. Baker®) were purchased from Avantor 
performance materials BV (Deventer, Netherlands). 
Triethylamine, sodium chloride, and silver nitrate 0.1 M 
solution were supplied by Fluka GmbH (Buchs, Germany). 
For the surface energy measurements, high purity helium 
and methane were both supplied by BOC gases Ltd 
(Guildford, UK), whereas n-heptane, n-octane, n-nonane, n-
decane, ethanol, ethyl acetate, dichloromethane, acetone, 
and acetonitrile (all HPLC/GC grade solvents) were 
purchased from Sigma-Aldrich Ltd (Gillingham, UK). All raw 
materials were used as received. 
4.2.3.2 Methods 
4.2.3.2.1 Active pharmaceutical ingredient (API) 
characterisation 
Radwan et al. suggested a method to determine the racemic 
ratio of mebeverine hydrochloride by means of enantio-
selective high performance liquid chromatography (HPLC) 
[488]. We applied this method on an Agilent 1200 Series 
HPLC (Agilent Technologies AG, Switzerland) using the 
same column, conditions, and detector as described in the 
original article. Briefly, a mixture of n-hexane, isopropyl 
alcohol, and triethylamine (90.0:9.9:0.1, v/v/v) was used as 
a mobile phase. The calibration curve was prepared by 
dissolving the API powder directly in methanol at a 
concentration of 1 mg mL-1 and consequently diluting it to a 
concentration range from 0.5 to 20 µg mL-1 with mobile 
phase. The samples were prepared in the same way, but the 
final concentration was 10 µg mL-1. 
To assay impurities, we chemically studied the batches in 
addition to the initial release analysis that was documented 
by the certificate of analysis. We modified the 
aforementioned HPLC assay by increasing ten-fold the 
quantity of sample tested; the samples for calibration were 
treated in the same way. This procedure was intended to 
increase the signal-to-noise ratio with respect to impurity 
detection. The release analysis employed thin layer 
chromatography to analyse impurities according to the 
local Pharmacopoeia [489], and both batches were within 
the specification limits. 
Following the enantio-selective analysis, the ratio between 
free base of mebeverine and chloride salt was studied. A 
potentiometric titration was conducted using an 809 
Titrando system (Metrohm AG, Switzerland), which was 
connected to an 801 Stirrer and 800 Dosino dosing pump. 
Before analysing the sample, we plotted a calibration curve 
(R2 = 100.0%) by titrating a range from 25 to 75 mg of 
sodium chloride. The titration was carried out by diluting 
250 mg of mebeverine hydrochloride in 200 mL of water, 
and measuring the volume of silver nitrate 0.1 M solution 
used. The quantified chloride content was then converted 
to the corresponding salt concentration of mebeverine. 
Mebeverine hydrochloride batches were studied using 
differential scanning calorimetry (DSC) on a DSC 30 
(Mettler Toledo AG, Switzerland). Samples of 5 mg were 
weighed for each measurement using the XS105DualRange 
balance (Mettler Toledo AG, Switzerland) and the samples 
were subsequently sealed in individual 40 µl aluminium 
pan. A heating rate of 10°C min-1 was selected in a range 
from 10°C to 360°C using inert argon environment 
(100 mL min-1). We then determined the melting 
temperature (Tm) and the heat of fusion (ΔHf) of 
mebeverine hydrochloride from the peak maximum and the 
area under the peak, respectively. 
The X-ray powder diffraction analysis was carried out on a 
D2 Phaser diffractometer (Bruker AXS Inc., Germany) 
equipped with a LYNXEYETM detector and DIFFRACplus EVA 
software. The sample was put on a holder, which was set to 
rotate at 15 rpm. The radiation source was Co Kα at 30 kV 
and 10 mA, and the measurement range was 2 theta from 
5° to 80°. 
We investigated the true density (t) of the mebeverine 
hydrochloride batches with a helium Multipycnometer 
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MVP-1 (Quantachrome Instruments Inc., USA) on an 
average of 20.0 g of sample, which was weighed on a 
PB3002DeltaRange balance (Mettler Toledo, Switzerland). 
The particle size and shape were measured by dynamic 
image analysis using an XPT-C particle analyser 
(Prozesstechnik GmbH, Switzerland). Each sample was 
dispersed in refined peanut oil to a suitable dilution, and 
sonicated for 10 minutes in a UR1 ultrasound bath (Retsch 
GmbH, Germany). A constant magnetic stirring was 
employed during the image analysis. 
The image analysis was based on 10 000 particles, and for 
a size measure we calculated the Waddle disk diameter, 
which is the diameter of a disk having the same area as the 
projected image of the given particle. This diameter was 
analysed as median as well as 5th and 95th percentile of the 
size distribution. To describe the particle shape, we selected 
the elongation factor. This form factor is defined as the ratio 
between the maximal intercept (length of the longest 
segment in the convex hull of the particle) and mean 
intercept perpendicular (the mean length of the chords in 
the particle perpendicular to its maximal intercept). 
The particle morphology of the powder was evaluated by 
scanning electron microscopy (SEM) with an M-SEM Supra 
(Carl Zeiss AG, Switzerland). The electron high tension was 
set to 5 kV. The samples were prepared by depositing the 
mebeverine hydrochloride powder on an adhesive carbon 
plate and removing the excess material with compressed 
air. 
4.2.3.2.2 Surface energy profiling 
Gemini V BET analyser (Micromeritics Instrument Inc., 
USA) was used to determine the BET (Brunauer Emett 
Teller) specific surface area of each sample. Sample tubes 
were initially dried for 3 hours at 105°C along with the 
mebeverine hydrochloride. Then, 1 g of the sample was 
weighed and heated in the tube to 105°C under nitrogen 
overnight. The instrument ran the analysis at -196°C. 
Surface energy profiles were obtained directly from inverse 
gas chromatography Surface Energy Analyser (iGC-SEA, 
Surface Measurement Systems Ltd, Alperton, Middlesex, 
UK). Approximately 300 mg were packed into individual 
iGC silanised columns (300 mm length, 3 mm internal 
diameter) plugged at both ends by silanised glass wool. The 
specific surface area of the sample was first determined by 
measuring the octane adsorption isotherms at 30°C and 0% 
relative humidity using the iGC-SEA. As for the surface 
energy measurement, each sample column was conditioned 
in-situ for 2 hours at 30°C and 0% relative humidity in a 
10 cm3 min-1 flow of helium carrier gas. The column dead 
volume corrections were determined by using methane as 
an inert probe at an injection time of 5 seconds and an 
injection volume of 30 cm3. 
This instrument determined the total surface energy (γsT) of 
the sample, which is the sum of its polar (the specific surface 
energy, γsAB) and apolar (dispersive surface energy, γsD) 
components. The specific interactions mostly take place 
between polar groups and can be Lewis acid-base 
interactions, whereas the apolar component of surface 
energy is mainly based on Lifshitz-van der Waals 
interactions. Another thermodynamic parameter, the work 
of cohesion (Wcoh), was also considered in this work. This 
normalised work equals to twice the value of the total 
surface energy 2γsT; it represents the tendency of particles 
to adhere to each other.  
The iGC measurement principle is based on packing a 
column with the sample and allowing different probe 
vapours to flow through it; thus, the retention time of the 
probe can be measured and then the net retention volume 
(VN) is calculated (Equation 4.5) [490]. 
 
𝑉𝑁 =  
𝑗
𝑀
∙ 𝐹(𝑡𝑅 − 𝑡0) ∙
𝑇𝑠
𝑇𝑅𝑒𝑓
 4.5 
Where j is the James-Martin correction; M is the sample 
mass; F is the flow rate; tR is the probe retention time; t0 is 
the retention time of a non-interacting probe, in our case 
methane; Ts is the column temperature; TRef is the reference 
temperature for the flow rate determination.  
The obtained retention volume VN in Equation 4.5 allows 
determining the aforementioned surface energies. Hence, 
the γsD and γsAB can be determined; for the former, a set of 
alkane eluents with different carbon number (n-heptane, n-
octane, n-nonane, and n-decane) were used, whereas for the 
latter probes with different polarities were employed 
(acetone, acetonitrile, ethanol, ethyl acetate, 
dichloromethane). Using the first set of experimental 
alkane eluents, the γsD was determined according to the 
Dorris-Gray method by plotting R T ln(VN) against the 
carbon number of the alkanes [491], and then by using 
Equation 4.6. 
 
𝑅 ∙ 𝑇 ∙ ln 𝑉𝑁 = 2𝑁𝐴 ∙ √𝛾𝐶𝐻2 ∙ 𝛾𝑠
𝐷 ∙ 𝑎𝐶𝐻2  4.6 
Where NA is Avogadro’s number; γCH2 is the methylene 
surface energy; aCH2 is the molecular area of a methylene 
group; R is the universal gas constant (8.314 J mol-1 K-1); T 
the temperature in Kelvin. 
In a second step, γsAB was obtained by the polarisation 
method of Donnet et al. where R T ln(VN) is plotted against 
the molar deformation polarisation of the probes [492]. The 
difference between the measured R T ln(VN) and the ones 
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obtained with the alkane series is the free energy of 
desorption ΔGSP. By applying the van Oss concept of acid-
base surface chemistry [493], ΔGSP can be related to the acid 
and base components of γsAB (Equations 4.7 and 4.8). 
 
ΔG𝑆𝑃 = 𝑁𝐴 ∙ 𝑎𝑃 ∙ (√𝛾𝑃
+ ∙ 𝛾𝑠
− + √𝛾𝑃
− ∙ 𝛾𝑠
+) 4.7 
 
𝛾𝑠
𝐴𝐵 = 2 ∙ √𝛾𝑠
+ ∙ 𝛾𝑠
− 4.8 
Where aP is the cross sectional area of the probe; γs+ and γs- 
are the acid and base components of sample’s surface, 
respectively; γP+ and γP- are the acid and base component of 
the probe, respectively (e.g., dichloromethane and ethyl 
acetate). 
Part of the energy profiling was the study of surface 
heterogeneity by injecting different amounts of probe 
vapour, thereby creating different surface coverages as 
expressed by the ratio ni/nm. Herein, ni is the moles of probe 
injected, where nm refers to the monolayer capacity of the 
probe molecule. This monolayer capacity of the probe 
molecule is determined by the sample’s specific surface 
area and by the area occupied by each probe molecule. 
4.2.3.2.3 Suspension manufacture 
Suspensions were manufactured on a small-scale of 1000 g 
using laboratory process equipment MI-MOLTO (Krieger, 
Switzerland). The instrument uses two couples of 
counter-rotating stirring blades to mix the loaded 
ingredients; the blades are also equipped with a set of 
vertical and horizontal baffles in order to prevent material 
from sticking to the sides of the manufacturing vessel. The 
central rotor/stator element homogenises the particles of 
the suspension by disrupting particle agglomerates and 
reducing the particle size. Temperature was controlled with 
a double jacketed vessel connected to a Julabo HC5/8 water 
bath (Julabo Labortechnik GmbH, Germany). and vacuum 
was obtained with a Vacfox VGD 15 rotary vacuum pump 
(Rietschle Thomas GmbH + Co. KG, Germany). Before 
mixing the ingredients, mebeverine hydrochloride was 
sieved (1 mm opening). All needed quantities were weighed 
on a PB5001-L balance (Mettler Toledo AG, Switzerland). 
Ingredients were added directly in the following order: 
Aerosil 200 1.82% (w/w), Lipoid PPL-600 13.64% (w/w), 
and then refined peanut oil 84.55% (w/w). Aerosil 200 was 
chosen to provide an adequate stability to the 
manufactured suspension; Lipoid PPL-600, a liquid 
formulation of soybean phospholipids enriched in 
phosphatidylcholine (40%), was added to increase the 
wettability of the particles; refined peanut oil served as the 
lipid continuous phase. The drug-free formulation 
(placebo) was then placed in the homogenising vessel 
under vacuum at 40°C for 5 min, 30 rpm stirrer speed, and 
manufactured at the selected homogenisation speeds (0, 
3000, 6000, and 9000 rpm). Different drug concentrations 
were then incorporated in the placebo: 0, 15, 30, 35, 39, 43, 
45, 47, and 51% (w/w) (Table 4.6). 
For each concentration, level n = 3 individual batches were 
manufactured and the effect of homogenisation intensity 
was studied by employing a cascade of increasing 
homogenisation steps. Thus, mebeverine hydrochloride 
was first incorporated at 40°C in the placebo and premixed 
at 30 rpm; then, the dispersion was mixed thoroughly 
maintaining the same temperature at 100 rpm for 
30 minutes under vacuum. The suspension was further 
mixed for 20 minutes without homogenisation at 20 rpm 
mixing for degassing and a first sample of 50 mL sample 
was drawn. The remaining suspension was subsequently 
mixed at 100 rpm for 10 minutes and homogenised at 
3000 rpm for 2 minutes. We degassed again as previously 
described and drew another sample. The remaining 
suspension followed the same procedure of mixing, 
homogenising, degassing, and sampling twice: the first time 
at 6000 rpm and the second at 9000 rpm. All manufactured 
suspension samples were further stored for 3 hours in a 
Salvis KVTS 11 vacuum chamber (SalvisLab AG, 
Switzerland) at 45°C. 
TABLE 4.6 – Ingredients’ list of the lipid-based 
suspension at different drug fractions. Values are 
expressed as w/w %. Please note that the relative ratio 
between the excipients (i.e., refined peanut oil, Lipoid 
PPl-600, and Aerosil) remains constant. 
Mebeverine 
hydrochloride 
Refined 
peanut 
oil 
Lipoid 
PPL-
600 
Aerosil 
200 
0 84.55 13.64 1.82 
15 71.86 11.59 1.55 
30 59.18 9.55 1.27 
35 54.95 8.86 1.18 
39 51.57 8.32 1.11 
43 48.19 7.77 1.04 
45 46.50 7.50 1.00 
47 44.81 7.23 0.96 
51 41.43 6.68 0.89 
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4.2.3.2.4 Suspension analysis 
The rheology of the suspensions was studied using a Bohlin 
Gemini rheometer (Malvern Instruments Ltd, UK). The 
system was equipped with a Bohlin Peltier drive and a 
PNEUDRI MiDAS DAS-2 air bearing (Parker Domnick 
Hunter Ltd, UK). A cone-plate sensor was employed. The 
cone was truncated with a diameter of 40 mm diameter and 
4° inclination. The apparent viscosity (η) of the 
formulations was obtained at 25°C by recording a flow 
curve from 0 to 100 s-1 and using the value obtained at a 
reference shear rate (γ) of 30 s-1. This upper value was for 
all suspensions clearly below a critical shear rate for which 
a loss of homogenous force transmission limits the flow 
curve. 
We selected the Casson model [494] to describe shear 
stress (σ) as a function of applied shear and the yield stress 
(σ0) was extrapolated from the up-curve in a range of 
0 to 30 s-1 (Equation 4.9): 
 √𝜎 = √𝜎0 + √ 𝜂 ∙ 𝛾 4.9 
The viscosity of the drug-free formulation provided the 
vehicle for the different suspensions and provided the value 
η0. The ratio between η and η0 is called relative viscosity 
(ηr). The placebo density (0) was measured using a DA-
100M densitometer (Mettler Toledo AG, Switzerland) at 
25°C. 
To convert the mass fraction of API (wAPI) to the volume 
fraction (Φ) Equation 4.10 was used. 
 
Φ=
𝑤𝐴𝑃𝐼 𝜌𝑡⁄
𝑤𝐴𝑃𝐼 𝜌𝑡⁄ + (1 − 𝑤𝐴𝑃𝐼) 𝜌0⁄
 4.10 
To measure the fractal dimension (Df) of the particle 
structure in suspension, we employed the fractal concept of 
flocculation [50]. Thus, yield stress was plotted as logarithm 
against the logarithmic volume fraction of the drug. A linear 
range using the four highest concentrations (43%, 45%, 
47%, 51% w/w) was selected for regression analysis and 
determination of the slope (m). The fractal dimension Df 
was then calculated from the embedding Euclidean 
dimension d (d = 3) using the following Equation (4.11): 
 
𝐷𝑓 = 𝑑 −
2
𝑚
 4.11 
4.2.3.2.5 Data analysis 
For statistical analyses and model fitting of the Mooney 
equation (Equation 4.4), the software STATGRAPHICS 
Centurion XVI version 16.1.15 from StatPoint Technologies 
Inc. (Warrenton, USA) was used. All other calculations were 
based on Microsoft Office Excel 2010 (Microsoft Inc., 
Redmond, USA). Statistical significance was assumed with a 
p-value lower than 0.05. Results were expressed as means 
± standard deviations (from n = 3 experiments), except 
where differently specified. A Student’s t-test was 
conducted after having assured that variances were 
homogenous (by an F-test) when comparing the means 
from two groups; when more than two groups were 
analysed, an analysis of the variance (ANOVA) was used. 
4.2.4 Results 
4.2.4.1 Initial API characterisation 
Two mebeverine hydrochloride batches were used in this 
study, which were both of high purity and showed no 
difference based on their chemical certificate of analysis. 
However, since drug batch release analysis did not include 
enantiomeric purity, we studied the batches using an 
enantio-selective HPLC method. Table 4.7 displays the 
enantiomeric excess for the two batches studied. As 
expected for a racemic mixture, the enantiomeric excess 
yielded low values close to zero. There was no difference 
revealed between the batches based on a statistical 
comparison of the enantiomeric excess. 
In accordance with the certificate of analysis, our assay of 
mebeverine hydrochloride showed that both batch A and 
batch B were within specification limits as for the total of 
unknown impurities (less than or equal to 0.5% [489]). The 
method detected two peaks that did not appear in the blank 
runs, with a retention time lower than that of mebeverine 
hydrochloride’s enantiomers. The two unknown impurities 
were found at a retention time of 8.444 ± 0.089 minutes and 
9.774 ± 0.085 minutes, while the relative retention time 
(RRT) to the first API peak at 10.743 ± 0.095 minutes were 
0.785 and 0.897, respectively. The impurity amounts are 
shown in Table 4.7 and they are lower in batch A than in 
batch B. The differences were found to be significant and 
thus could theoretically contribute to technical 
batch-to-batch differences at later stages of manufacturing. 
Another kind of chemical purity analysis for mebeverine 
hydrochloride is the molar ratio of the drug truly present as 
hydrochloride salt compared to the total amount of API. The 
results of the titration analysis demonstrated for both 
batches a hydrochloride salt fraction close to unity (Table 
4.7). No significant difference was found between the 
batches in terms of the hydrochloride salt fraction and the 
high purity indicated that free base was barely present. 
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Figure 4.7 shows the overlaid DSC profiles of the two 
batches. The fusion temperature was the same and also in 
terms of the fusion enthalpy, Student’s t-test could not show 
a significant difference between the two batches. To 
complement the solid state analysis from thermal methods, 
we further conducted X-ray powder diffraction. Figure 4.8 
demonstrates that the two diffractograms reflected the 
same crystallinity of the batches. The intensity, shape, and 
position of the peaks were practically the same so that 
complete overlaying of the diffractograms was possible. It 
appeared from the distinct peaks and absence of a 
pronounced halo that both batches were highly crystalline. 
In line with this solid state analysis, it was expected that 
also the true densities of the materials would also be nearly 
the same. The results from gas pycnometry indeed 
confirmed the true densities of both batches could not be 
distinguished statistically (Table 4.8). 
A next batch comparison emphasised the size distribution 
and shape of the particles. For size distribution, the 5th, the 
50th, and the 95th percentile (or d5, d50, and d95, 
respectively) were selected and determined by means of 
dynamic image analysis. Some skewness was noted in the 
size distributions. Table 4.8 exhibits the comparison of the 
batches, and interestingly a significant difference was found 
for the d5 values. The effect was rather subtle and no 
significance was obtained when comparing the d50 or d95 
values. Image analysis could not reveal further batch-to-
batch differences. For quantitative shape analysis, the mean 
TABLE 4.7 – Enantiomeric excess, hydrochloride salt fraction, and impurity content of the mebeverine hydrochloride 
batches (mean values ± standard deviations; n = 3 experiments). 
Property Batch A Batch B Student’s t-test (p-value) 
Enantiomeric excess (%) 0.0495 ± 0.0342 0.0727 ± 0.0160 0.347 
Hydrochloride salt fraction 0.9892 ± 0.0127 0.9990 ± 0.0009 0.311 
Impurity content by relative 
retention time (%) 
  RRT = 0.785 
  RRT = 0.897 
 
 
0.0281 ± 0.0063 
0.0058 ± 0.0052 
 
 
0.0581 ± 0.0049 
0.0397 ± 0.0006 
 
 
0.003 
< 0.001 
 
FIGURE 4.7 – Overlaid DSC profiles of batch A (dotted 
line) and B (continuous line). 
 
FIGURE 4.8 – Overlaid X-ray diffractogram profiles of 
batch A (a) and B (b). 
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elongation factor was determined but both batches resulted 
in similar values (Table 4.8). The obtained shape parameter 
indicated a rather elongated habitus of mebeverine 
hydrochloride particles. Such elongated particle shape was 
also observed in the scanning electron microscopy (SEM) 
images (Figure 4.9). Moreover, a cohesive tendency was 
noted for both batches since smaller particles were 
adhering to the larger ones. 
4.2.4.2 Specific surface area measurement 
The specific surface areas assessed by BET-nitrogen 
adsorption were 0.2385 ± 0.0229 m2 g-1 for batch A and 
0.7227 ± 0.0058 m2 g-1 for batch B (p < 0.001). The 
difference was statistically significant and it was in line with 
the finding that batch B had a slightly lower d5 value of the 
fine particle fraction. This effect certainly contributed to 
higher surface area, but it may not fully explain the 
observed difference. There might have been an additional 
difference in surface roughness or in intra-particulate 
pores, although it was difficult to detect clear differences in 
the SEM images. 
4.2.4.3 Surface energy profiling 
Analysis of the dispersive surface energy γsD (Figure 4.10a) 
revealed another subtle difference between the batches. 
Batch B exhibited higher γsD compared to batch A at rather 
low surface coverage. Once the surface was more 
extensively covered, the two curves of γsD gradually 
converged to similar values. There was even a tendency that 
γsD of batch A levelled off at a slightly higher plateau. 
However, the energy change with increasing surface 
coverage was more pronounced with batch B. The extent of 
this decline in surface energy is a marker of energetic 
inhomogeneity and it shows that batch B exhibited more 
energy heterogeneity with respect to the various surface 
sites. Such a distinction of surface heterogeneity was 
previously observed for energies on the surface of an 
excipient by Ho et al. In the present study, γsD results 
pointed to another physical difference of the solid state 
using the mebeverine hydrochloride batches [482]. 
Figure 4.10b shows the specific surface energy γsAB of the 
two batches. This polar contribution to total surface energy 
γsT was evidently much smaller than the dispersive surface 
energy γsD. Given the small specific energy contribution, the 
difference between the batches was also minor. However, 
batch B demonstrated significantly higher values of γsAB 
primarily at low surface coverage. 
 
FIGURE 4.9 – Example of a scanning electron 
microscopy image of mebeverine hydrochloride 
(batch A at 4960 x magnification). 
TABLE 4.8 – Comparison of physical properties between the mebeverine hydrochloride batches (mean 
values ± standard deviations; n = 3 experiments). 
Property Batch A Batch B Student’s t-test (p-value) 
Fusion enthalpy (J g-1) 104.85 ± 0.58 104.09 ± 0.47 0.151 
Fusion temperature (°C) 136.56 ± 0.56 136.85 ± 0.38 0.499 
True density (g cm-3) 1.213 ± 0.005 1.212 ± 0.004 0.886 
Particle size distribution as 
Waddle disk diameter 
  d5 (µm) 
  d50 (µm) 
  d95 (µm) 
 
 
10.34 ± 0.15 
25.72 ± 0.85 
64.50 ± 7.71 
 
 
9.38 ± 0.20 
26.19 ± 0.87 
62.71 ± 17.36 
 
 
0.003 
0.541 
0.878 
Particle shape 
  elongation factor 
 
2.59 ± 0.03 
 
2.63 ± 0.06 
 
0.337 
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In line with the previous findings, the batch B revealed a 
higher work of cohesion Wcoh than batch A at a low surface 
coverage (Figure 4.11). The profiles were similar to those of 
the dispersive energy. Since Wcoh equals to 2γsT, the results 
confirmed the view that most of the total surface energy 
was attributed to the dispersive contribution. 
4.2.4.4 Rheological suspension analysis 
The formulation viscosity against API volume fraction (for 
batches A and B) was plotted in Figure 4.12. The viscosity 
increase at low volume fractions appeared to be nearly 
linear, whereas at higher solid concentrations the change in 
viscosity became highly nonlinear. While there was hardly 
a difference in viscosity observed for suspensions at low 
volume fractions, the concentrated systems revealed a 
batch-to-batch difference. Batch A showed lower viscosity 
compared to batch B, but this difference was statistically 
significant (p < 0.001) only at a drug concentration 
wAPI > 30%. 
The range of concentrated suspensions further revealed 
different viscosities for varying homogenisation intensities. 
Figure 4.13 exhibits the effect of homogenisation intensity 
for two selected volume fractions of the suspensions. It can 
be inferred from Figure 4.13 that homogenisation speed 
barely made a difference for the viscosity of the 30% (wAPI) 
suspension, whereas a significant trend was observed at 
wAPI of 51%. A rising homogenisation intensity decreased 
viscosity in the concentrated suspensions. This range of 
higher drug concentrations obviously not only 
demonstrated a rheological difference from batch-to-batch, 
but provided also a clear differentiation among the process 
conditions. 
 
FIGURE 4.10 – The dispersive surface energy γsD (a) 
and specific γsAB surface energy (b) vs. surface 
coverage of batch A (open circles) and batch B (black 
squares). Error bars show standard deviations (n = 3). 
 
FIGURE 4.11 – The work of cohesion Wcoh vs. surface 
coverage of batches A (open circles) and B (black 
squares). Error bars show standard deviation (n = 3). 
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The yield values σ0 of the suspensions were studied in a 
second step. Extrapolation according to Casson (Equation 
4.9) provided estimates that are depicted in Figure 4.14. 
The double- logarithmic plot of yield value (log σ0) against 
the volume fraction (log Φ) displayed two linear ranges, as 
it was expected from the rheological literature on 
concentrated dispersions [50,495]. The range of higher 
concentrations provided excellent linear regression models 
with R2 values in a range of 97.44% to 98.66%. Slopes of the 
regression lines appeared to be only slightly different but 
the effect was still found to be significant (p < 0.001). The 
different slopes were used to calculate fractal dimensions Df 
of the flocculated particles according to Equation 4.11. 
Figure 4.15 indicates that higher homogenisation speed 
increased the fractal dimension. Like in other physical 
applications of fractal geometry, the values differed only 
slightly. However, the trend was observed with both 
batches and the slopes for calculation of Df generally 
differed from batch to batch (p < 0.001). 
Finally, the flow curves were further studied by fitting the 
Mooney model in the form of Equation 4.4. The obtained 
parameters from the non-linear regression are listed in 
Table 4.9. Excellent model fits were found, with adjusted-R2 
values generally higher than 98.00%. Figure 4.16 shows 
that the models adequately described the increase in 
viscosity as a function of the drug volume fraction. Curves 
at different homogenisation level were equally well 
described by the Mooney model indicating that higher 
homogenisation intensity generally lowered the viscosity. 
Homogenisation intensity further affected both of the fitted 
parameters, i.e. the vehicle viscosity η0 as well as the 
maximal packing fraction Φmax. 
4.2.5 Discussion 
4.2.5.1 Surface energy profiling 
A better understanding of critical material properties for 
drug product performance can be deemed a cornerstone of 
QbD [32]. It has been reported that drug surface energy can 
be critical for its solid bulk properties such as particle flow 
or wetting behaviour  
of powders [496]. The present study focused on drug 
suspensions. Herein, the surface energy of a powder is 
expected to play a role in how the particles immerse in the 
formulation liquid and how a surfactant can adhere to the 
available surface sites. Surface energetics can theoretically 
make a difference in the process of dispersion as well as in 
the properties of the evolving drug suspension. 
We employed surface energy profiling by means of iGC with 
pharmaceutical suspensions. A broad spectrum of surface 
 
FIGURE 4.12 – Viscosity values η of batches A (a) and B (b) at different API volume fractions (Φ). The values are sorted 
by homogenisation intensity during manufacturing: no homogenisation (orange diamonds), 3000 rpm (red squares), 
6000 rpm (grey triangles), 9000 rpm (yellow circles). 
Chapter 4. Quality aspects of lipid-based pharmaceutical formulation  83 
 
 
analytical information was provided by this method and 
enabled a differentiation of the model batches using 
mebeverine hydrochloride. The analysis at a series of 
surface coverages was especially useful to delineate the 
surface energy heterogeneity. Most of the surface energy 
was shown to arise from dispersive interactions. At lower 
surface coverages, there were higher energy sites at the 
drug surface interacting with the different eluent gases. 
Batch B possessed significantly higher dispersive surface 
energy and thus higher work of cohesion than batch A. This 
increase in work of cohesion can correspond to an increase 
in inter-particle friction forces and in interaction between 
the particles and the vehicle of the suspension. In addition, 
batch B showed a broader distribution of energy levels at 
various surface sites. 
There are several potential sources which can lead to the 
energetic differences in the surface sites. These sources 
mainly comprise of the differences in physicochemical 
characteristics between the particle surface and the powder 
bulk. The presence on the surface of differences in terms of 
amorphous drug content, enantiomeric excess, free base 
concentration, and presence of impurities can vary the final 
product’s properties [497,498]. However, the bulk 
techniques employed for the characterisation of the 
aforementioned properties, namely XRPD, DSC, enantio-
selective HPLC, and volumetric titration, couldn’t 
discriminate between the batch-to-batch differences 
captured by inverse gas chromatography. 
 
FIGURE 4.13 – Interactions at wAPI 0.30 (a) and 0.51 (b) 
of batches A (white) and B (black). Error bars show 
standard deviation (n = 3). 
 
FIGURE 4.14 – Linear extrapolations of the yield stress 
(ln σ0) at higher API concentrations (ln Φ) for batch A. 
The measured values are the open markers 
(diamonds = no homogenisation, squares = 3000 rpm, 
triangles = 6000 rpm, circles = 9000 rpm) and 
fitted/estimated values are the dotted lines 
(orange = no homogenisation, red = 3000 rpm, 
grey = 6000 rpm, yellow = 9000 rpm). The values are 
fitted using the four higher points (Φ > 0.35, 
wAPI ≥ 0.43) and linear extrapolation provides a 
theoretical maximum packing fraction. 
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It is a common observation in pharmaceutics that, albeit 
release analysis of the API points to the same quality within 
specifications, the manufacturing process and the final 
product still exhibit a relevant batch-to-batch variability. 
From a QbD perspective, it is thus vital to learn in which 
pharmaceutical systems even small API differences can 
translate into batch-related differences, as we have 
observed with the concentrated suspensions of mebeverine 
hydrochloride. The availability of novel sensitive analytical 
tools is equally important. Based on our findings, the 
surface energy profiling proved to be highly promising for 
drug characterisation with respect to concentrated 
suspensions. 
4.2.5.2 Rheology and the fractal concept of 
flocculation 
The flow curves exhibited a different viscosity for batch A 
and B but the effect was mainly observed in the 
concentrated suspensions. For suspensions with 
 
FIGURE 4.15 – Homogenisation level-specific fractal dimension Df for batches A (a) and B (b); the black dotted line 
indicates the trend according to homogenisation level. 
TABLE 4.9 – Fitted constants (i.e., viscosity of the drug-free vehicle η0 and maximal packing fraction Φmax) of the 
Mooney model according to Equation 4.4 together with standard errors of the estimates. 
Homogenisation level Estimated η0 (Pa s) Estimated Φmax Adjusted-R2 (%) 
Batch A 
  no homogenisation 
  3000 rpm 
  6000 rpm 
  9000 rpm 
 
0.553 ± 0.032 
0.453 ± 0.022 
0.390 ± 0.020 
0.309 ± 0.014 
 
0.696 ± 0.009 
0.681 ± 0.007 
0.678 ± 0.007 
0.663 ± 0.006 
 
98.28 
98.89 
98.72 
99.14 
Batch B 
  no homogenisation 
  3000 rpm 
  6000 rpm 
  9000 rpm 
 
0.643 ± 0.059 
0.560 ± 0.039 
0.508 ± 0.038 
0.393 ± 0.025 
 
0.665 ± 0.012 
0.654 ± 0.008 
0.661 ± 0.009 
0.649 ± 0.007 
 
96.61 
98.24 
97.79 
98.51 
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wAPI > 0.30, the average viscosity difference increased 
sharply to about 30%. This was a remarkable difference in 
the drug product thinking of the only subtle 
physicochemical differences that were found between the 
API batches. The small differences in surface energy profiles 
and particle characteristics were evidently amplified in the 
dispersion process to result in notable rheological 
differences of the lipid-based suspensions. 
Another factor on suspension viscosity was the intensity of 
homogenisation. Higher homogenisation intensity can have 
several effects on a suspension depending on the type of 
particle systems and the given energy input. A recent study 
of nanoparticulate pharmaceutical vehicles demonstrated a 
similar rheological effect caused by homogenisation as in 
case of the mebeverine suspensions [499]. Thus, rising 
homogenisation intensity was generally lowering the 
viscosity under shear, as well as decreasing the yield point 
σ0. Apart from the homogenisation effects, the observed 
shear thinning in the flow curves of the lipid-based 
suspension is likely due to orientation effects of anisometric 
particles or their flocs [500,501]. 
The concentrated suspensions of mebeverine 
hydrochloride displayed in the image analysis diverse 
aggregates that can be named alternatively as flocs. Such 
flocs were earlier described by means of fractal geometry 
[502,503]. We employed the fractal concept of flocculation 
and determined the fractal dimension Df from the different 
yield points as a function of the solid volume fraction 
(Figure 4.15) [50]. Two ranges were clearly distinguished 
that represented different structures. It was expected that 
in a high concentration range, the flocs would increasingly 
inter-penetrate to form dense structures. These structures 
were characterised by the fractal dimensions in this study. 
We found different fractal dimensions for the various 
homogenisation levels. The differences were small but 
based on slopes that were statistically different (Equation 
4.11). Homogenisation intensity appeared to define the 
dimension of the inter-penetrating floc structure. This is 
interesting to compare with the findings of Maggi [504], 
who studied concentrated suspensions of kaolinite and 
showed variable fractal dimensions depending on shear 
and flocculation kinematics. Different systems are certainly 
not always directly comparable as they differ in primary 
particle size, floc structure and on how strongly the 
particles were aggregated. However, the changes in the 
fractal structure depending on API batch and process 
conditions were an important finding. It was shown that 
small differences in the raw materials, for example surface 
energy profiles of the drug, were generating different 
structures in the concentrated suspensions, which in turn 
resulted in quite different viscosity values. 
Since the fractal dimensions were extrapolated from yield 
points, they primarily characterised the particle structure 
at rest. To learn more about the particle packing under flow, 
we fitted the Mooney model (Equation 4.4) to the flow 
curves. As already suggested by Krieger [61], this version of 
the Mooney model (i.e., including the maximal packing 
fraction) was particularly suited to describe concentrated 
suspensions. The obtained maximal packing fractions were 
in a reasonable range of 0.66 to 0.70 (Table 4.9) [50]. 
However, some care is needed with detailed interpretation 
of these fitted values. It was interestingly observed that 
values of Φmax slightly decreased with rising 
homogenisation speed. Since higher homogenisation was 
leading to an increased fractal dimension, it was notable 
that the effective maximal packing under flow conditions 
was supposed to be comparatively smaller than from 
suspensions where less homogenisation was applied. This 
consideration is in agreement with the experimental 
finding that higher homogenisation speed produced 
suspensions with comparatively higher yield point and 
lower viscosity under shear. It seems that in complex 
flocculated systems Φmax can be viewed as an apparent 
value for the packing of floc structures that evolve in a shear 
field. 
 
FIGURE 4.16 – Mooney model fitted to the viscosity 
values η of batch A vs. volume fraction Φ, sorted by 
homogenisation intensity. The measured values are 
the open points (diamonds = no homogenisation, 
squares = 3000 rpm, triangles = 6000 rpm, 
circles = 9000 rpm) and fitted values are the lines 
(orange continuous = no homogenisation, red long 
dash = 3000 rpm, grey short dash = 6000 rpm, yellow 
medium dash = 9000 rpm). 
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An apparent fitting constant was also η0. Some care is 
needed when interpreting this value as a constant viscosity 
of the vehicle. In case of simple oil, η0 would indeed be 
constant. However, in the complex pharmaceutical model 
suspensions, the drug-free vehicle contained a small 
amount of colloidal silicon dioxide. The volume fraction of 
these particles was almost negligible compared to the 
amount of drug in suspension (average Φ of colloidal silicon 
dioxide less than 1.8%), but it may explain why obtained 
values of η0 were not constant. 
In summary, the fractal concept of flocculation was found to 
be a useful tool to study the particle structures in the 
concentrated mebeverine hydrochloride suspensions. In 
this respect, the effects of the API batch as well as of the 
homogenisation conditions were described in a range of 
comparatively high drug loads. This concentrated range 
exhibited a substantial non-linearity of the rheological 
properties, which was also supported by the analysis of the 
viscosity values with the Mooney model. The fractal concept 
of flocculation as well as the viscosity fitting according to 
Mooney can be termed as semi-empirical models. Such a 
model is different from a purely correlative model as it is 
obtained from any statistical design. Even though statistical 
designs are useful and widely employed in pharmaceutics 
these days, they can a priori only correlate data. We should 
not forget that a main idea of QbD is to target an improved 
process and product understanding. To this end, the applied 
semi-empirical models provided advanced tools to analyse 
the mebeverine hydrochloride suspensions. 
4.2.6 Conclusion 
The rheological properties of a suspension are generally 
critical to pharmaceutical quality. However, it seems to be 
difficult to design robust drug suspensions, when 
formulating at comparatively high concentrations. 
Especially at such drug concentrations, smallest differences 
in raw materials can greatly affect the suspension rheology. 
Moreover, the effect of homogenisation intensities was 
highly relevant for the resulting dispersion viscosity. 
The fractal concept of flocculation was introduced to this 
field of pharmaceutics and it demonstrated a change of 
aggregated particle structure depending on process 
conditions as well as on the batch used. This was 
particularly remarkable, since the model batches hardly 
revealed differences in a first physicochemical testing. 
However, differences were observed using a novel method 
of iGC that allowed a surface energy profiling. Some inter-
batch variability was demonstrated regarding the extent 
and heterogeneity of surface energies. Thus, iGC-SEA 
proved to be a useful QbD technique for characterisation of 
mebeverine hydrochloride in concentrated suspensions. 
More research is needed to optimally apply the novel tools 
in the future development and manufacture of concentrated 
drug suspensions. For example, the Mooney law could be 
used to simulate the viscosity of a suspension in 
formulation development. An early anticipation of the 
realistic variability is crucial for rational specification 
setting and hence for avoidance of manufacturing failures.
 
 
 Chapter 5 
Final remarks and outlook 
Oral protein delivery represents a major challenge of 
modern pharmaceutics. While systemic exposure is a 
particularly ambitious goal, the local delivery of a 
therapeutic macromolecule to the GI tract as site of action 
is a more realistic target. Lipid-based (LB) systems have 
shown much promise in this regard [3]. Still, many 
formulation and manufacturing aspects, apart from the 
biopharmaceutical performance, must be considered to 
achieve a stable drug product and, eventually, successful 
delivery. The present thesis focused on the manufacturing 
and Quality-by-Design (QbD) aspects of LB dispersions. A 
particular aim was to introduce novel lipid-based drug 
delivery architectures and to adapt the production thereof 
for oral (local) protein administration by encapsulation 
while ensuring adequate pharmaceutical quality. 
Manufacturing of protein-loaded microgels was 
successfully achieved by means of prilling directly into 
lipid-based hardening baths. These lipid-based dispersions 
exhibited potential for direct capsule filling. The model 
protein remained stable throughout the entire process, thus 
showing great promise to be formulated through this 
microencapsulation technology. The proposed polymer, 
mono-N-carboxymethyl chitosan, did 
 not interact with the protein structure, and its 
polyfunctional characteristics, namely bioadhesion and 
permeation enhancement, may prove useful at later stages 
of pharmaceutical development. Ionotropic gelling, a non-
toxic method of polymeric cross-linking, was achieved even 
in non-aqueous media. This technique allowed high protein 
encapsulation efficiency, yet did not hinder protein release 
during in vitro testing. Moreover, by avoiding the standard 
aqueous hardening bath, a water removal process that 
could otherwise harm a therapeutic protein was avoided. 
The further advancement of this system by adding an extra 
nanotubular compartment in the microgel was technically 
demonstrated. This hierarchical multi-compartmental drug 
delivery system (DDS) took the advantages of the 
previously introduced protein-loaded microgels, but in 
addition it modified protein release and limited enzymatic 
digestion in vitro. The nanotubular clay used, halloysite 
(HNT), is a non-toxic, natural, and cost-effective material, 
which has already been successfully suggested as drug 
carrier. While this Nanotubes-in-Microgel Oral System was 
intended primarily for local administration to the 
gastrointestinal tract, this DDS theoretically even holds 
potential for systemic action. The microgel polymer has 
previously shown mucoadhesiveness, the HNT therein 
contained has a suitable particle size to penetrate the 
mucus layer, and the lipids from dispersing media have 
been reported to possess permeation enhancing properties. 
LB dispersions have shown their potential as DDS and they 
display an especially high flexibility in terms of formulation. 
LB dispersions can be loaded both with small active 
pharmaceutical ingredients (API) as well as with 
macromolecular drugs. A thorough experimental design 
allowed identifying the significant factors of lipid 
composition that influence the microgel LB dispersion. 
Lipid’s chemical properties such as glyceride chain length 
or PEG-modification were found to have statistical 
influence on process parameters, microgel morphological 
properties, encapsulated protein stability and quantity, and 
overall dispersion characteristics. These systematic 
evaluations are typical of the Quality-by-Design (QbD) 
initiative, which aims to increase understanding of 
pharmaceutical development steps to embed quality 
directly in the dosage form design. The application of this 
approach is not only challenging with the novel microgel 
dispersions in lipids, but is also a current topic for 
concentrated dispersions of drugs with low molecular 
weight. The latter model systems were employed to 
demonstrate the suitability of novel QbD tools and it was 
possible to more mechanistically interpret the behaviour of 
these systems. Specific surface energy profiling was 
employed to analyse batch-to-batch differences, which 
represent a common pitfall in formulation and process 
control. Mathematical model fitting allowed preliminary 
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prediction of LB suspension’s viscosity at high 
concentrations. Finally, the introduction of a fractal analysis 
based on rheological data was found valuable in the 
dispersion characterisation and with regard to its stability 
The present thesis introduced novel possibilities in terms of 
design, production, characterisation, and control of LB 
formulations. While this work embraces different aspects of 
pharmaceutical development, it also leads to further 
research opportunities and options. The protein-loaded 
microgel LB dispersion and the Nanotubes-in-Microgel Oral 
System can be further studied in terms of in vivo 
characterisation, since both systems have been thoroughly 
characterised in vitro. For instance, in vivo performance can 
be assessed according to the intended site of action, i.e., 
local or systemic. Furthermore, the proposed model 
protein, bovine serum albumin, can be substituted with 
more therapeutically relevant macromolecules, such as 
enzymes or antibodies. Technical improvements may be 
implemented, for instance enteric coating of the final 
dosage form after capsule filling. This coating can ensure 
additional protection from enzymatic degradation and it 
may lead to increased oral exposure where this is targeted. 
For local delivery, the protection should ensure suitable 
local drug availability. The latter application may limit or 
prevent systemic exposure that could otherwise lead to 
undesired drug effects.  
In terms of quality, an experimental design can be carried 
out on the multi-compartmental DDS to find optimal 
process settings and define critical aspects of formulation. 
Further research can also address formulation optimisation 
of the hereby introduced DDS based on prilling. A more 
mechanistic understanding of the complex prilling process 
could integrate the preliminary DoE findings to provide 
additional control over the prilling process. Additionally, a 
systematic study could complement the proposed QbD tools 
for highly concentrated LB suspensions, with the ultimate 
goal of creating robust formulation from these systems. 
This work proposed significant advances in terms of novel 
architectures applied to LB dispersion design, as well as 
formulation of proteins for oral administration with these 
DDS. This thesis addresses aspects of formulation 
development within a QbD framework, thus implementing 
technically innovative approaches with emphasis on 
feasibility and final drug product quality. The findings 
indicated the potential of LB systems and 
microencapsulation for oral (local) delivery of 
therapeutically active proteins. A technical and quality 
oriented advancement has been obtained in the field of 
pharmaceutical lipid-based dispersions. 
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List of abbreviations 
ANOVA analysis of variance 
API active pharmaceutical ingredient 
APS ammonium persulphate 
APTES γ-aminopropyltriethoxysilane 
BCA bicinchoninic acid 
BCS biopharmaceutics classification system 
BET Brunauer, Emett, Teller 
BSA bovine serum albumin 
CD circular dichroism 
CFA critical formulation attributes 
CMA critical material attributes 
COST changing one single variable at a time 
CPP Critical Process Parameter 
CQA Critical Quality Attribute 
DDS drug delivery system 
DEGEE diethylene glycol monoethyl ether (or ethoxydiglycol) 
DLS dynamic light scattering 
DLVO Derjaguin, Landau, Verwey, Overbeek 
DoE Design of Experiments 
DSC differential scanning calorimetry 
DTT dithiothreitol 
EE encapsulation efficiency 
ELISA enzyme-linked immunosorbent assay 
EtOH ethanol-based hardening bath 
FbD Formulation-by-Design 
FDA Food and Drug Administration 
FFA free fatty acid 
FMEA failure mode and effect analysis 
FTIR Fourier transform infrared spectroscopy 
GI gastrointestinal 
HBA lipid-based hardening bath containing ethoxydiglycol 
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HBB lipid-based hardening bath containing ethoxydiglycol, glyceryl caprylocaprate, and propylene carbonate 
HBC lipid-based hardening bath containing ethoxydiglycol, glyceryl monocaprylate, and propylene carbonate 
HBD lipid-based hardening bath containing ethoxydiglycol, glyceryl monocaprylocaprate, and PEG 600 
HBE lipid-based hardening bath containing ethoxydiglycol, macrogol-6 glycerides, and peppermint oil 
HBW water-based hardening bath 
HGC hard gelatine capsule 
HNT halloysite nanotubes 
HPMC hydroxypropyl methylcellulose 
HRP horseradish peroxidase 
HVO Hesselink, Vrij, Overbeek 
IEC ion exchange chromatography 
IEF isoelectric focussing 
iGC inverse gas chromatography 
LB lipid-based 
MCC mono-N-carboxymethyl chitosan 
MLR multiple linear regression 
MOPS 3-(N-morpholino)propanesulphonic acid 
MS mass spectrometry 
NBE new biological entity 
NCE new chemical entity 
NiE nanoparticles-in-emulsions 
NiMOS nanoparticles-in-microsphere oral system 
NLC nanostructured lipid carriers 
NMR nuclear magnetic resonance 
OFAT one factor at a time 
OLS ordinary least square 
OVAT one variable at a time 
PCA principal component analysis 
PCL poly(ε-caprolactone) 
PCR principal component regression 
PEG polyethylene glycol 
PLGA poly(lactic-co-glycolic acid) 
PLS partial least squares 
PLS-DA partial least squares discriminant analysis 
PRESS predicted residual sum of squares 
PVA polyvinyl alcohol 
QbD Quality-by-Design 
QbT Quality-by-Testing 
QTPP Quality Target Product Profile 
SANS small angle neutron scattering 
SAXS small angle X-ray scattering 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEA surface energy analysis 
SEC size exclusion chromatography 
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SGC soft gelatine capsule 
SEM scanning electron microscopy 
siRNA small interfering RNA 
SLN solid lipid nanoparticles 
SLS static light scattering 
SMES self-microemulsifying system 
SNEDDS self-nanoemulsifying drug delivery system 
S-PVA starch-polyvinyl alcohol 
TEMED tetramethylethylenediamine 
TGA thermogravimetric analysis 
TMC N,N,N-trimethyl chitosan 
TRIS tris(hydroxymethyl)aminomethane 
UV ultraviolet 
XRPD X-ray powder diffraction 
 
  
List of symbols 
aP cross-sectional area of the probe 
c sample concentration 
d10 10th percentile 
d50 median value 
d90 90th percentile 
d Euclidean dimension 
dd drop diameter 
dj jet diameter 
dn nozzle diameter 
dp particle diameter 
f  frequency 
fi predicted data point 
fi,-i predicted values 
g gravitational acceleration 
h shortest distance between two particles 
j James-Martin correction 
k crowding factor 
kB Boltzmann constant 
l optical path length 
m regression slope 
n number of amino acids 
n2  number of polymer or surfactant chains per unit area 
ni probe moles injected 
nm monolayer capacity of the probe molecule 
r particle radius 
t0 non-interacting probe retention time 
tR retention time 
vj jet velocity 
vs settling velocity 
wAPI API mass fraction 
ӯ mean of observed data 
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yi measured datapoint 
 
A Hamaker constant 
Df fractal dimension 
F volumetric flow 
Ga van der Waals attraction energy 
Gcon elastic repulsion energy (loss of conformational entropy) 
Gmix polymer free mixing energy 
Gr electrostatic repulsion energy 
Gt sum of interaction energies 
M sample mass 
NA Avogadro’s number 
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